Access Genetics Pty. Ltd.

Contact: Phone: Email: Address: Mr Donald Coles, Managing Director +61 3 5797 6203 Fax: +61 3 5797 6307

ACN 43 091 834 972

dcoles@valleyseeds.com
295 Maroondah Link Highway Alexandra, VIC, 3714 Australia In March 2000, the proprietor of Valley Seeds Proprietary Limited, Mr Donald Coles, formed a new spin-off company, Access Genetics Pty. Ltd., to specialise in generating cereal grain varieties using new breeding techniques. Strategic alliances have been established with US and European breeders to introduce elite varieties to the breeding program. Access Genetics has licensed to leading German life sciences and chemical company BASF AG a key technology that was developed by the University of Melbourne - a genetic mechanism (male gamete specific promoter) for expressing key genes in specific parts of the plant. Access Genetics is using this technology and others in a research project at the University of Melbourne, with aims including the production of special purpose wheat varieties for use in healthfoods such as lowcalorie breakfast cereal and biscuits. [See separate entry for Valley Seeds].

Profile:

Acrux Limited
Contact: Phone: Email: Internet: Address: Dr Igor Gonda, Chief Executive Officer/Managing director +61 3 8379 0100 Fax: +61 3 8379 0101

ACN 72 082 001 152

info@acrux.com.au www.acrux.com.au
103-113 Stanley Street West Melbourne, VIC, 3003 Australia Acrux Limited is developing and commercializing a new, superior generation of transdermal, skin and healthcare products based on technology initially discovered at Monash University, Melbourne, Australia. The portfolio is developed through investments by Acrux and partnerships with pharmaceutical and healthcare companies. The Company has a diversified pipeline that includes a Phase 3 program with estradiol, Phase 2b study on the treatment of low libido associated with low androgen levels in women, Phase 2 trial on pain management with fentanyl plus numerous other products at an earlier stage of development. The technology combines widely used GRAS (generally recognised as safe) status compounds to aid delivery of drugs topically and across the skin into the bloodstream with an applicator designed to spray a rapid-drying, metered dose of drug onto the skin. Acrux Ltd licensed the patented technology from Monash University. Acrux’s technology has a number of features that are expected to provide an improved form of therapy to patients, including: • convenience of use (compared with injections, and tablets, patches or gels) • no skin irritation • cosmetic acceptability (quick-drying, non-occlusive spray) • dosage flexibility • ease of manufacture • low cost of goods • control of drug levels within the blood that minimisze potentially toxic peaks or ineffective troughs; and • reduction in the frequency of drug administration (resulting from the slow release of the drug through the skin). Further research and development (preclinical screening) will be conducted in the company’s dedicated laboratories. Manufacturing, clinical and regulatory services will be contracted to local and international contract research organisations. Acrux personnel will manage the delivery of these services. Acrux is organised as a Pooled Development Fund.

Profile:

Adipogen Pty Ltd

ACN 102 901 397

Contact: Phone: Email: Internet: Address:

Dr Mark Harvey, Group Manager +61 7 3365 4037

m.harvey@uniquest.com.au www.uniquest.com.au
Melbourne University Carlton, VIC, 3053 Australia Postal Address: Edith Cavell Building Royal Brisbane Hospital Herston, Queensland, 4029 Australia

Profile:

Adipogen was formed in 2002 by UniQuest, The University of Queensland’s technology commercialisation company. UniQuest has licensed the intellectual property associated with the development of the new drug to Adipogen, which has attracted seed funding from Uniseed Pty Ltd, the $20 million pre-seed fund formed in 2001 by the UQ and Melbourne University.

Advanced Laboratory Solutions Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Peter Robert, Executive Director +61 3 9686 5022 Fax: +61 3 9686 5033

ACN 74 082 016 626

peter@advancedlabs.com.au www.advancedlabs.com.au
182 -184 Ferrars Street South Melbourne, VIC, 3205 Australia Advanced Laboratory Solutions Pty. Ltd., trading as Advanced Labs, offers ‘next generation’ platform technology to the Australian scientific and medical research community. Their goal is to offer this technology in a timely manner so as to maximize the Australian scientific community's ability to remain globally competitive. Advanced Labs’ core industry focus is genomics, proteomics, bioinformatics, drug discovery, pharmaceutical manufacturing, and biotechnology. The company invests significant resources in the Australian and USA markets, in order to rapidly transfer knowledge from centers of research excellence (such as Stanford and Harvard Universities and the National Institutes of Health - NIH) to Australian customers. The company is successfully transferring the skills developed in this market to other customers within the Pacific Rim. Advanced Labs’ goal is to be a successful, respected, ‘Technology Partner’ to its target market. Core components of this vision are a global support network, an educated and dynamic Sales & Marketing Department, a responsive customer service team, and factory-trained service engineers. As an example, Advanced Labs in conjunction with the Peter MacCallum Cancer Institute entered into a joint 'Technology Evaluation Program' in 1999. The outcome of this relationship was the rapid integration and knowledge transfer of microarray manufacturing to Australian scientists, the selection of the most appropriate platform technology for the Australian market, and the subsequent decision by four additional core research precincts to adopt identical technology, thus aiding and accelerating Australia's push into the international business of medical genomics.

Profile:

Advent Pharmaceuticals Pty Ltd
Contact: Phone: Email: Address: Dr Jill Snell, General Manager +61 3 8562 2235 Fax: +61 3 8562 2288

ACN 43 095 494 563

jsnell@advent-pharma.com
Monash Enterprise Centre 5a Harnett Close Mulgrave, VIC, 3170 Australia Advent Pharmaceuticals is a technology development company specialising in the development of novel dry powder inhalation delivery platforms. The focus of Advent’s product development is directed initially at novel platforms for the management of asthma and chronic obstructive pulmonary disease, with future therapeutic applications in new pulmonary delivered medications. Established in January 2001, Advent Pharmaceuticals is an Australian-registered, privately owned company. Advent’s product design, development and preclinical testings are presently conducted in Victoria, Australia. Clinical, regulatory and manufacturing will be outsourced to local and international contract organisations. ACN 16 099 612 423 AgGenomics Pty. Ltd. Dr Glenn Tong, Managing Director +61 3 8412 7066 Fax: +61 3 9417 4076

Profile:

Contact: Phone: Email: Internet: Address:

glenn.tong@aggenomics.com.au www.aggenomics.com.au
60-66 Hanover Street Fitzroy, VIC, 3065 Australia Postal Address: P. O. Box 115 Fitzroy, VIC, 3065 Australia

Profile:

AgGenomics Pty. Ltd. was formed in March 2002 as a joint venture between Genetic Technologies Limited (ASX-GTG) and Agriculture Victoria Services Pty Ltd (the commercial arm of the Victorian Government's Department of Natural Resources and Environment). This joint venture, the first ultra high throughput genomics facility in Australasia, will dramatically improve the efficiency of traditional plant and animal breeding programs via the use of ultra high throughput genomics technologies. AgGenomics has unique enabling technologies, expertise and extensive experience in the identification of genetic markers linked to commercially important traits in a wide variety of plant species. The same technology is also applicable to animal species. The development of genetic markers such as SNPs, microsatellites (SSRs) and AFLPs and the application of these markers in marker assisted selection (MAS) is AgGenomics’ key strength and primary business activity. AgGenomics has extremely high throughput capabilities, with a capacity of well over 20,000 genotype analyses per day using a suite of state-of-the-art automated technology platforms. These capabilities allow plant and animal breeders to deliver improved varieties to the market quicker and more economically through the use of MAS. AgGenomics also has expertise and experience in cultivar identification, eg for Plant Breeders’ Rights and transgene detection. AgGenomics primarily operates on a fee-for-service basis, with no participation in the sharing of intellectual property. In certain circumstances, such as genetic marker discovery programs which are linked to a marker assisted selection program requiring ultra high throughput genotyping, AgGenomics may also enter into collaborative R&D programs on a cost and IP sharing basis.

Agri-Gene Pty. Ltd.
Contact: Phone: Email: Internet: Address: Mr Albert McIlroy, CEO +61 3 5722 2666 Fax: +61 3 5722 2777

ACN 28 006 665 381

info@agrigene.com.au www.agrigene.com.au
123-125 Tone Road Wangaratta, VIC, 3677 Australia Agri-Gene is a privately owned artificial breeding and merchandise company based at Wangaratta in North-East Victoria. Agri-Gene imports and exports bovine artificial breeding semen and embryos for all beef and dairy cattle breeds. Product is distributed Australia-wide through a network of over 150 resellers and merchandise outlets, and exported globally. The company has been operating since 1986 as a separate identity, and of its 14 staff, some have over 25 years’ experience in the cattle genetics industry. Agri-Gene provides, selects and markets breeding programs and genetics. Agri-Gene is the Australian representative for Sersia France, the exporter for the French Artificial Breeding CoOperatives. Agri-Gene also represents Ag-Link from the USA for coloured breeds and Holsteins, and Jersey Island Genetics from Jersey Island. Approximately 40% of Agri-Gene’s business is in beef semen, with suppliers being World Wide Sires, Select Sires, Accelerated Genetics, and Sersia France. Agri-Gene also has a merchandise division which distributes products such as KAMAR Heat Detectors, Taylor Wharton LN2 Tanks and a full range of BIO-VET artificial insemination requisites from France. Agri-Gene is also a licensed veterinary wholesaler specialising in synchronization and reproduction in both dairy and beef. ACN 006 598 198 Agriculture Victoria Services Pty Ltd

Profile:

Contact: Phone: Email: Address:

Mr Bruce Lang, Company Secretary +61 3 9217 4139 Fax: +61 3 9217 4161

bruce.lang@nre.vic.gov.au
475 Mickleham Road Attwood, VIC, 3049 Australia Agriculture Victoria Services Pty Ltd (AVS) commercialises agricultural and natural resource management R&D from the Victorian Department of Natural Resources and Environment primary industries(DPI). AVS also provides contract R&D for commercial organisations, performed by NRE scientists, in areas such as plant and animal improvement; animal and plant production; animal nutrition; health and welfare; functional foods; disease diagnosis for animals and plants; integrated farm systems; soil, water and plant analysis; food safety; land suitability assessment; management and mapping; and pest and weed control; groundwater salinity investigations; waste management; organic and inorganic analytical chemistry. AVS has specialist expertise in contract management, marketing and business development and intellectual property. Biotechnology research and application fields include: Dairy: applying genomics and marker assisted selection technologies to produce improved dairy genetics and milk products. Crops and Pastures: engineering forages and grains that offer disease resistance, drought resistance, longer-lived plants, better tolerance to soil stress, and herbicide resistance as well as fingerprints and molecular markers to identify elite plants. Functional Foods: developing plants with amplified levels of bioactive therapeutic compounds; evaluating and testing active plant-derived molecules; optimising agronomic practices to elevate levels of actives in plants; extraction and post-harvest protocols; trials and commercialisation of ‘healthy plants’. In September 2001, AVS was awarded a Biotechnology Innovation Fund grant to help commercialise, via a spin off company, Phytogene Pty Ltd, a method for the manipulation of senescence in plants. AVS has, together with Genetic Technologies Ltd, also established a joint venture company, AgGenomics Pty Ltd, which offers a unique service for plant genomics. See separate entries.

Profile:

AgSeed Research, a Division of Monsanto Australia
Contact: Phone: Email: Internet: Address: Mr David Hudson, Canola Business Manager +61 3 9522 7122 Fax: +61 3 9525 2253

ACN 61 086 442 435

david.j.hudson@monsanto.com www.monsanto.com.au
Level 12 600 St Kilda Road Melbourne, VIC, 3000 Australia AgSeed Research is a division of Monsanto Australia Limited. The business unit is focused on the breeding and development of elite canola varieties for commercialization in Australia. The developed products include conventional canola, triazine-tolerant canola, and canola varieties incorporating tolerance to Roundup herbicide. The business develops both open-pollinated and hybrid canola varities. AgSeed owns a significant collection of canola germplasm adapted to Australian conditions. The business undertakes a full breeding program for its products and includes full glasshouse and field nursery and trials capacity. Monsanto is investing additional resources to build AgSeed's capabilities and facilities at Horsham in Western Victoria, to meet the needs of the growing canola market. The business has access to the global resources of the US based Monsanto Company, in particular to the Brassica breeding activities in Canada and Europe. ACN 79 000 248 304 AGT Biosciences Ltd Prof Greg Collier, Managing Director, CEO AGT +61 3 9234 1188 Fax: +61 3 9234 1244

Profile:

Contact: ASX: Phone: Email: Internet: Address:

autogen@autogenlimited.com.au www.autogenlimited.com.au
Pigdon’s Road Waurn Ponds, VIC, 3205 Australia Postal Address: PO Box 1069 Grovedale, VIC, 3216 Australia

Profile:

AGT BioSciences (formerly Autogen) is an Australian biotechnology company specializing in the use of gene discovery approaches to identify novel therapeutic targets for the treatment of prevalent human diseases. The company's vision is to translate its discoveries into new drug therapies through partnering with pharmaceutical companies. AGT Bioscience's diabetes and obesity gene discovery program has been highly successful, with over 40 novel genes in various stages of patent protection. The company’s first major target, Beacon, has been granted full patent protection in the US and several other major jurisdictions. AGT Bioscience's major new initiative in depression and anxiety is progressing well, with an application for patent protection of an animal model for the disease, and a significant number of target genes being identified. The company’s Center for Human Statistical Genetics is leading a program aimed at identifying disease genes in human populations with high prevalence disease rates. AGT Bioscience has launched the eXpress Technology Platform as a commercially available offering for gene discovery and validation. This has attracted significant interest from biotechnology companies in the US, Europe and Australia. AGT Bioscience's largest alliance to date is the obesity and gene discovery program with French pharmaceutical company Merck-Santé, a subsidiary of Merck KGaA. This is a successful longterm relationship that has been extended through contract until 2006. This partnership has provided in excess of US$16 million as research funding, milestone payments and equity purchase. In addition, AGT Bioscience will receive royalties and profit sharing on any drugs developed from the program. AGT Bioscience has partnered with Sequenom, giving Sequenom access to AGT Bioscience's eXpress Technology Platform, resources and expertise to validate and functionally characterize a number of their selected gene targets.

Albright & Wilson (Australia) Ltd
Contact: Phone: Email: Internet: Address: Dr Richard Thwaites, Manager, Special Projects +61 3 9396 8777 (switch), +61 3 9396 8749 (direct)

ACN 36 004 234 137

Fax: +61 3 9396 8729

rthwaites@albright.com.au www.albright.com.au
295 Whitehall Street Yarraville, VIC, 3013 Australia Postal Address: PO Box 20 Yarraville, VIC, 3013 Australia

Profile:

In 1994, Albright & Wilson (Australia) Ltd, a large chemical manufacturer, formed a partnership with Tridan Limited, a small R&D investment company, to establish a state-of-the-art biotech fermentation scale-up facility at Yarraville and together with the University of Melbourne and Food Science Australia, became core participants in what has now become the CRC for Bioproducts. The three groups have an equal share in the intellectual property. The CRC for Bioproducts has a focus on developing commercially valuable materials produced by plants and other living organisms - such as natural colours, nutraceuticals including the active components in herbal remedies, pharmaceutical intermediates, and biopolymers. It aims to establish new industries based on these novel bioproducts and bioprocesses, and also use the skills developed by the Centre to improve the efficiency and profitability of existing industries involved in the production and use of bioproducts. The research program has three facets: cell culture and fermentation of novel plant cell lines; extraction of novel and useful compounds from agricultural waste, seaweed and other biomass sources, including the extraction of pectin from citrus peel; and applied physico-chemical studies of macromolecules in solutions and gels, relevant to products in a range of industries. The resources of the Centre include a pilot scale fermentation facility (up to 10,000 litres) used primarily for production of materials from plant cells, laboratories equipped for functional testing of biopolymers and food ingredients, and state-of-the-art facilities for carbohydrate chemistry and plant molecular biology. Albright & Wilson Australia's core business comprises phosphates and surfactants, used in a variety of industrial applications including detergents, personal care products, food ingredients, water treatment, mining & minerals processing, and the building & construction industry. ACN 68 088 526 229 Alpharma Animal Health Pty Ltd

Contact: Phone: Email: Internet: Address:

Dr Colin Peel, Managing Director +61 3 9826 4777 Fax: +61 3 9826 4822

colin.peel@alpharma.com.au www.alpharma.com.au
Level 10, Trak Centre 443-449 Toorak Road Toorak, VIC, 3142 Australia Alpharma Animal Health Pty Ltd specialises in commercial-scale manufacture of recombinant porcine somatotropin (growth hormone), Reporcin, used to aid in the production of leaner pork. A subsidiary of US biopharmaceutical company Alpharma, Inc., Alpharma Animal Health has a purpose-built fermentation plant for Reporcin production located within the CSL precinct in Parkville, Melbourne. The plant has the capacity to supply the Australian market and countries in Asia and South America as registrations are received. US-based Alpharma Inc. established its Asia Pacific headquarters in Melbourne in mid-2000, along with plans to expand its existing manufacturing plant and operations at Parkville. Alpharma, presently active in more than 60 countries, is the largest manufacturer of generic liquid and topical pharmaceuticals in the USA, and is a major producer of antibiotics, vaccines for farmed fish, and animal health feed additives. Alpharma acquired Southern Cross Biotech Pty Ltd, developer and manufacturer of Reporcin, to form Alpharma Animal Health Pty. Ltd. in September 1999.

Profile:

AMGEN Australia Pty Limited (Scientific Affairs Office)
Contact: Phone: Email: Internet: Address: Mr Russell Edwards, Regional Director, South East Asia +61 2 9870 1333 Fax: +61 2 9870 1344

ACN 31 051 057 428

redwards@amgen.com www.amgen.com
Level 7, 123 Epping Road North Ryde, NSW, 2113 Australia Amgen Australia is a subsidiary of Amgen Inc, based in Thousand Oaks, California USA. Amgen, the world's largest biotechnology company, uses science and innovation in an effort to dramatically improve people's lives. Amgen aspires to be the world's best human therapeutics company. With its head office in Sydney, Amgen Australia was established in 1991. Amgen Australia markets the products of Amgen Inc. and contributes to the global product development program of the company, through collaborations with Australia's laboratory and clinical researchers. Amgen Australia's mission is to become Australia's leading biopharmaceutical company, based on the application of cellular and molecular biology. Amgen Australia's positioning is as pioneers in biotherapy, committed to bringing the benefits of science to the patient. Melbourne is home to the Scientific Affairs office of Amgen Australia Pty Limited. Based at Hawthorn, the Scientific Affairs Office is the principal site for research and development activities for Amgen Australia. These activities include a large clinical research and registration program. The clinical research programs involve all of the major hospitals around Australia. The research and product development programs of Amgen aim to help patients in four critical areas: cancer and complications of cancer, kidney diseases, inflammatory and bone diseases, and neurological and endocrine diseases.

Profile:

AMRAD Corporation Limited
Contact: ASX: Phone: Email: Internet: Address: Mr Bob Moses, CEO (Interim) AML +61 3 9208 4302 Fax: +61 3 9208 4352

ACN 37 006 614 375

amrad@amrad.com.au www.amrad.com.au
576 Swan Street Richmond, VIC, 3121 Australia Amrad Corporation Limited is an Australian drug discovery and development based biotechnology company. Amrad's in-house pharmaceutical R&D expertise is focused on five priority status projects in the areas of allergy and inflammation, anti-infectives and neurological indications. Amrad is dedicated towards delivering candidate products into clinical development for serious chronic human diseases, focused on early commercial returns. Amrad continues to expand its intellectual property either through in-house research programs or with collaborations with Australian research institutes. Amrad currently has five key projects in preclinical and clinical development. Amrad's strategy is to add significant value to its portfolio of candidate pharmaceutical products, to the point where they can be licensed to international pharmaceutical companies. Amrad aims to progress projects through either collaborations or licensing agreements with appropriate development partners. Amrad receives returns from its research and development expenditure from agreements with these project partners. Amrad’s key competitive advantages are: • Drug discovery and development capabilities in virology, oncology, neurology and allergy/inflammation • Access to enabling technologies of medicinal and protein chemistry and antibodies • Validated science with pharma and biotechnology partners • World wide patent protection. Amrad's core competencies are in the therapeutic areas of infectious diseases (viral, chronic), neurology (neuro-protection) and allergy/inflammation (asthma, rheumatoid arthritis) and based on the following enabling technologies – medicinal chemistry, therapeutic proteins and monoclonal antibodies. Amrad currently has five key projects in preclinical and clinical development. The lead clinical projects include AM336 for the treatment of chronic severe pain (Phase I/II completed) and emfilermin for the treatment of reproductive health in collaboration with Serono (Proof of concept completed). Preclinical projects include AM132 and AM133 for the treatment of cardiovascular disease in collaboration with Gencell Inc. (a wholly owned subsidiary of Aventis) and Edwards Lifesciences respectively; AM36 for the treatment of stroke. Drug discovery activities are focused on the following targets :- IL-13 receptor, GM-CSF receptor (with Cambridge Antibody Technology), Hepatitis B virus, HIV integrase and the suppressors of cytokine signalling (SOCS).

Profile:

Anadis Limited
Contact: ASX: Phone: Email: Internet: Address: Mr Steven Skorobogaty, General Manager ANX +61 3 9358 6388 Fax: +61 3 9358 6399

ACN 80 063 114 045

steven.s@anadis.com.au www.anadis.com.au
No. 4 Capital Link Drive Campbellfield, VIC, 3061 Australia Anadis Limited is a research, development and production company specialising in innovative biopharmaceutical products and related technologies. Applications are therapeutic, primarily in humans. Anadis listed on the Australian Stock Exchange in 1999. Since 1994, Anadis has developed several products containing antibodies and bioactive factors derived from bovine colostrum. Taken orally, specific hyperimmune colostral antibodies, coupled with a key proprietary delivery systems, confer passive immunity to the recipient. This principle underlies two of the four lead products in development (Travelan & Pyloran). Key advantages include an excellent association with the dairy industry in Australia and the predominantly disease-free status of the cattle, as the source of high quality colostrum. Anadis has in place Standard Operating Procedures for OTC grade products for human use. Anadis opened its new Melbourne office and manufacturing facility in May 2001. During 2001, Anadis expanded into three areas: Development of natural bioactive substances from animal and plant sources, acquisition of new technology for active immunity & vaccine development and contract packaging & blending of food grade products. Phase II clinical trials of Travelan, a preventative tablet against traveller’s diarrhoea, were successfully completed during 2000-2001, and Phase III trials are in consideration for pharmaceutical level claims. Travelan will be launched as an OTC in 2003. Osteoporon, a bioactive casein derivative for treatment & prevention of Osteoporosis, is currently undergoing 2 x Phase II clinical trials at Monash University & Austin Hospital. Phase II trials are underway for Pyloran, an antibody based therapeutic to deal with Helicobacter pylori, the bacteria which causes gastritis and gastric ulcers. Anadis is also working in and developing the following area’s; A “bioshielding” technology which protects, vaccines, probiotics, enzymes and other delicate proteins to pass through the harsh stomach environment and into the small intestine intact. Respiratory protection against airborne viruses. Current work is in the short term protection of military personnel and emergency workers. Enterovirus 71 – a joint research & commercial development project with the Taiwanese government's Development Centre for Biotechnolgy against this important and emerging disease.

Profile:

Angiostar Ltd
Contact: Phone: Internet: Address: Dr John Raff, CEO (03) 8532 2700 Fax: (03) 9510 5955

ACN 080 492 404

www.starpharma.com
Level 6 Baker Heart Research Building Commercial Road Melbourne, VIC, 3004 Australia Postal Address: PO Box 6535 ST KILDA ROAD CENTRAL, VIC, 8008 Australia

Animal Reproduction Company Pty Ltd
Contact: Phone: Email: Internet: Address: Dr Richard Fry, CEO +61 3 9397 7144 Fax: +61 3 9397 7944

ACN 11 080 648 291

animalreproductionco@bigpond.com www.animalreproductionco.com
c/- Victorian Institute of Animal Science Sneydes Road Werribee, VIC, 3030 Australia Postal Address: PO Box 544 Newport, VIC, 3015 Australia

Profile:

The Animal Reproduction Company was formed by Dr Richard Fry and Dr Colin Earl to commercialise in vitro fertilisation (IVF) technology in the cattle and sheep industries. The ARC is principally an R&D company that has developed IVF for very young calves and lambs where the resulting embryos are implanted into recipient mothers. This has resulted in the rapid multiplication of elite seedstock and the ability to halve the generation interval. The ARC is currently developing the use of sex-sorted sperm in IVF to preselect the sex of offspring. In addition, the ARC has recently been awarded an AusIndustry R&D START grant to develop cryopreservation of these elite IVF embryos to facilitate their storage and shipment world wide.

Antisense Therapeutics Limited
Contact: ASX: Phone: Email: Internet: Address: Mr Mark Diamond, Chief Executive Officer and Managing Director ANP +61 3 9827 8999 Fax: +61 3 9827 1166

ACN 41 095 060 745

mark.diamond@antisense.com.au www.antisense.com.au
Level 1 10 Wallace Avenue Toorak, VIC, 3142 Australia A new Australian company entering the gene-directed therapeutics field is Antisense Therapeutics Limited (ATL), incorporated on 13 November 2000 and listed on the Australian Stock Exchange in December 2001. ATL’s mission is to create, develop and commercialise novel antisense pharmaceuticals for large unmet markets. The company plans to develop several antisense drugs, with its two most advanced projects targeting multiple sclerosis (ATL 1102) and psoriasis (ATL 1101). The company’s access to these projects is derived from its technology and research collaborations with Isis Pharmaceuticals Inc. and the Murdoch Children’s Research Institute. Californian based Isis is the world leader in antisense technology. Through its relationship with Isis, ATL has access to a broad range of intellectual property which will allow it to develop a substantial product pipeline. ATL plans to commercialise its pipeline via licensing agreements with larger biotechnology and pharmaceutical companies. Antisense drugs work by entering cells and blocking the protein-producing activity of specific genes. Most current drugs act on proteins directly. Antisense compounds work at an earlier stage, preventing production of disease-causing proteins. Compared to conventional drugs, antisense aims to provide more efficient and predictable drug discovery, based on increased specificity of action and uniformity of methods of manufacture, formulation and delivery. Antisense drugs should also have advantages as medicines as they can be designed to be more selective than traditional therapy, resulting in more effective and potentially less toxic drugs. The technology available to ATL under its agreement with Isis also allows them to develop antisense drugs for a very broad range of diseases and with more convenient dosing regimens and potentially more acceptable routes of administration. Antisense Therapeutics has achieved a number of key milestones in a timely manner since listing in December 2001. ATL’s primary focus is to progress its two lead compounds, ATL1102 for multiple sclerosis and ATL1101 for psoriasis, through development into human efficacy trials (Phase IIa) and then on success look to license the compounds to larger pharmaceutical companies. However, the company may license out earlier if commercially attractive. The following key development milestones are expected to be achieved over the next 6-12 months: • The commencement of Phase I human trial in mid-2003 which is expected to be completed in the first half of 2004. A Phase IIa trial in multiple sclerosis patients is expected to start in the second half of 2004; • On the psoriasis project, pre-clinical efficacy testing is expected to be completed by the end of this year and the animal toxicology studies commenced in 2004; • An additional six lead compounds for other disease targets including viral, skin, growth and inflammatory disorders are in the pipeline. Several of these compounds will be tested in pilot animal efficacy studies with results expected throughout the period.

Profile:

AorTech Biomaterials Pty Ltd
Contact: Phone: Email: Internet: Address: Dr Ian Griffiths, Business Unit Director +61 3 9562 2669 Fax: +61 3 9562 2977

ACN 17 079 265 286

iang@aortechbio.com www.aortechbio.com
677 Springvale Road Mulgrave, VIC, 3170 Australia AorTech Biomaterials Pty Ltd was formed in Australia in 1997 to commercialise innovative polymer technology developed by the Cooperative Research Centre (CRC) for Cardiac Technology. The polymers are a series of novel polyurethanes that incorporate high levels of silicone in the molecular structure. The major advance is the discovery that through novel raw materials and a complex proprietary synthetic process, polymers are produced that retain flexibility and processability while exhibiting biostability, biocompatability and outstanding mechanical and physical properties. The technology is covered by a family of 7 patents (granted or pending). The company offers a family of formulations (Elast-Eons) that span grades from quite flexible to rigid. It also offers customisation and product/component development services using its capabilities in the processing of polymers. Recently the company has made the decision to commercially supply a new grade, Elast-Eon HF. This material combines all of the advantages of Elast-Eon technology with unparalleled fatigue performance in demanding environments. This allows new device opportunities for flexible materials, such as replacement heart valves and components in the next generation of cardiac assist technologies. AorTech Biomaterials' parent company is AorTech International plc, based in Scotland. AorTech Biomaterials Pty Ltd has its headquarters in Melbourne, and is specialised in stabilization of biomaterials technologies and pilot scale manufacturing. The Melbourne facility was launched by the Minister for State and Regional Development, John Brumby, in 2001. The main objectives for the business are to realize the full commercial potential for the technologies, while stabilizing new biomaterials inventions from partner organizations. ACN 89 004 669 863 Applied Biosystems Pty Ltd Dr Nick Samaras, General Manager +61 3 9730 8600 Fax: +61 3 9730 8799

Profile:

Contact: Phone: Email: Internet: Address:

abozsales@appliedbiosystems.com www.appliedbiosystems.com.au
52 Rocco Drive Scoresby, VIC, 3179 Australia Applied Biosystems provides state-of-the-art instrumentation, reagents, consumables and bioinformatic solutions to life science researchers. These systems enable scientists to realise new research possibilities in basic research, pharmaceutical research and development, diagnostics, forensics and food and environmental testing. The company’s broad portfolio of technologies are crucial for applications such as DNA sequencing, the polymerase chain reaction (PCR), real-time PCR, DNA and peptide synthesis, chemiluminescence, mass spectrometry, chromatography and data management. Serving over 30,000 laboratories in more than 150 countries, and with over 5,000 employees worldwide (50 in Australia), Applied Biosystems has had a broad impact on the evolution of biology over the last 20 years, including the unraveling of the human genome sequence. The company’s commitment to innovation and investment in research continues to fuel the development of advanced technologies for the life sciences. Whatever the vision for discovery, Applied Biosystems is building a scalable integrated applications infrastructure to support it - infrastructure that will enable scientists to discover the secrets of life and apply this knowledge to improve the human condition. Applied Biosystems Pty Ltd commenced activity in Melbourne in the mid-1980s, and the Group headquarters is in Foster City, California.

Profile:

Applied Biotechnologies Pty Ltd
Contact: Phone: Email: Internet: Address: Miss Linton Staples, Managing Director +61 3 9305 2653 Fax: +61 3 9308 9622

ACN 006 669 414

appbiotech@bigpond.com www.animalcontrol.com.au
46-50 Freight Drive Somerton, VIC, 3062 Australia Postal Address: P O Box 379 Somerton, Vic, 3062 Australia ACN 96 082 810 973

Applied Chemicals Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Ed Dwyer, Managing Director (Australia) +61 3 8542 5111 Fax: +61 3 8542 5188

edward.dwyer@appliedchemicals.com; applied.aus@appliedchemicals.com www.appliedchemicals.com
92 Fairbank Road Clayton South, VIC, 3169 Australia Applied Chemicals Pty Ltd is a specialist supplier of high quality chemicals products and services that are technically innovative and environmentally sound. The company’s focus is to improve process efficiencies and environmental hygiene. Founded in Australia in 1942 and established in the UK ten years later, Applied Chemicals’ technically innovative and environmentally sound products are used in over 35 countries. Applied Chemicals manufactures and develops chemical products for use in the metal processing, non-road transport (ie aviation and shipping), food and mining sectors. Their chemicals are used in a wide range of products, such as sanitisers and toilet disinfectants, and in the specific treatment of metals. Applied Chemicals also supplies imported biotech products to Australian industry, such as petrochemical products, enzyme products used for cleaning in the dairy industry, and dry concentrated bacteria used for mining remediation. Applied Chemicals also produces an automotive product range, which is available through retail outlets. Applied has recently announced the launch of its new E-commerce web site and is leading the market in providing comprehensive E-commerce facilities to its global customer base.

Profile:

Arkopharma
Contact: Phone: Email: Internet: Address: Mr Alistair Cumming, Managing Director +61 3 5973 4888 Fax: +61 3 5973 4188

ACN 23 081 455 094

info@nutrasense-australia.com www.arkopharma.com
Unit 30 1140 Nepean Highway Mornington, VIC, 3931 Australia Postal Address: PO Box 324 Mt Eliza, VIC, 3931 Australia

Profile:

Nutrasense Australia Pty Ltd, formed in 1998, is now part of the Arkopharma Laboratories nutraceuticals group, based in Europe. Nutrasense Australia has its head office based on Victoria's Mornington Peninsula. Currently, Nutrasense Australia manufactures and markets a range of arthritis and osteoarthritis treatments, including ARTHRO-AID™ Capsules, for temporary relief from painful flare ups in the hand, knee, ankle or hip joints, back, or any other localised area of the body; and ARTHRO-AID DIRECT™ Arthritis Cream, using the Fusome™ delivery system for enhanced transfer of nutrients through the dermal layer. ARTHRO-AID DIRECT contains glucosamine, a vital, naturally occurring building block of normal cartilage, and shark cartilage, a naturally occurring source of glycosaminoglycans. Now, as part of the Arkopharma group, Nutrasense Australia will be expanding its product range. It is through Arkopharma’s mission to provide a comprehensive approach to health and well-being that Nutrasense Australia aims to grow and become a leader in the field of complementary medicine. New products of natural origin are planned for a range of conditions, including menopause, weight control, headache and stress, and skin disorders. Products recently launched in Australia include Phyto Soya (for menopause) based on soy bean, and Exolise (slimming) based on green tea extract, AR25® Catechol. ACN 15 088 417 403 Arrow Laboratories Limited Dr Stewart Cheng, Technical Director +61 3 9737 4300 Fax: +61 3 9737 4399

Contact: Phone: Email: Internet: Address:

scheng@arrowlabs.com www.arrowpharma.com
110 Merrindale Drive Croydon, VIC, 3136 Australia Arrow Pharmaceuticals Ltd was established in January 2000 with Head Office in Sydney and a Research and Development Centre in Melbourne. The company's business strategy involves the development of a portfolio of products spanning three separate, but interrelated, segments of the pharmaceutical market. 1. Non-PBS or Private Prescription Products Arrow has developed a portfolio of licences to distribute some private prescription products on a non-exclusive basis. In general, Arrow's unique distribution and promotional program adds value to both the manufacturers and the pharmacists by eliminating many of the costs that are currently involved in the private prescription market. 2. Generic Products Arrow has licensed a number of generic (or patent expired) products from other companies, both within Australia and internationally. It has also implemented its own product development program at its R&D facility (Arrow Laboratories) in Melbourne. This facility currently employs over 30 scientists and is equipped with state of the art instruments and machinery. 3. Branded Products Arrow has acquired a range of both new and existing patented ('branded') products that it promotes to doctors. This involves the traditional medical detailing in promoting the product's qualities to doctors in order to generate prescriptions for the brand.

Profile:

Arthron Limited
Contact: Phone: Email: Internet: Address: Mr Marcus Clark, interim CEO and Director +61 3 9287 0637 Fax: +61 3 9287 0639

ACN 92 093 947 294

mclark@primabiomed.com.au www.primabiomed.com.au
Kronheimer Building A&RMC Studley Road Heidelberg, VIC, 3084 Australia Postal Address: Kronheimer Building A&RMCStudley Road Heidelberg, VIC, 3084 Australia

Profile:

A leading Melbourne research organisation, the Austin Research Institute, together with the former Biomolecular Research Institute, in July 2000 established a new company, Arthron Limited, to develop new biopharmaceuticals to combat the inflammation accompanying devastating autoimmune diseases. Arthron is using drug design to target a key molecule found on the surface of blood cells involved in the inflammatory response - neutrophils, monocytes and platelets. The autoimmune diseases being targeted include rheumatoid arthritis and a severe bleeding disorder, immune thrombocytopenia purpura (ITP). The strategy is to block certain receptors, found on most inflammatory white blood cells, and that are involved in key inflammatory pathways. The target is compounds to control autoimmune disease by blocking these "Fc" receptors, thereby inhibiting the release of inflammatory chemicals. In mid-2001, the Austin Research Institute entered into an agreement with ASX-listed company Prima Biomed Limited [see separate entry] to fund the product development in return for a majority shareholding in Arthron.

ATO Engineering Services
Contact: Phone: Email: Internet: Address: Mr Kerrin Chin, Technical Service and Marketing Manager (03) 9580 5511 Fax: (03) 9587 6361

ACN 006 151 202

kchin@rosecorp.com.au www.atoturbines.com
Hangar 59 Bundorra Parade Moorabbin Airport, Victoria, 3194 Australia Postal Address: PO Box 46 Mentone, Victoria, 3194 Australia

Profile:

ATO Engineering Services provides Precision Machining and Welding of High Performance materials such as Titanium, Stainless Steel, Magnesium, Nickel, Aluminium, and Cobalt alloys, and High Strength Low Alloy Steels. ATO Engineering Services also has Thermal Spray equipment (Wire Spray, Powder Spray and Plasma Spray)capable of coating substrates with metallic or ceramic coatings to impart specialised properties such as corrosion resistance, wear resistance,etc. Examples of coatings are: Yttria-stabilised Zirconia, Chromium Oxide, Tungsten Carbide, Aluminium, Zinc, Bronze, Nickel/Aluminium Manufacturer of prototypes, single units or small runs.

Aus Bio Limited
Contact: Phone: Email: Internet: Address: Dr Peter Jenkins, Executive Director +61 3 9905 9831 Fax: +61 3 9905 5528

ACN 64 091 858 114

ausbio@bigpond.com www.ausbio.com.au (reserved)
P.O. Box 13 D Department of Biochemistry and Molecular Biology Monash University, VIC, 3800 Australia Aus Bio is a highly focussed, Start Up Biotechnology Company which has identified a number of areas of clinical need, and as a consequence the research programme is currently centered around 4 projects in the areas of: 1. Lower limb ulcer and wound healing 2. Diabetes and insulin resistance 3. Anti-infective agents including novel anti-virals against Hepatitis B & C 4. In the agreibusiness area, the development of non absorbable “Growth Promoters” The Company has been granted a US patent on the novel small molecule wound healing compounds . Preclinical studies indicate no toxicity, and the company is planning clinical trials during 2003. Aus Bio is also involved in early-phase development of antiviral agents for hepatitis C and B. The company has now recruited a strong scientific R & D team and has recently raised capital to progress pre-clinical and clinical projects. Further strategic alliance, partnership, and joint venture opportunities exist and are being sought. The company's move to the Department of Biochemistry and Molecular Biology at Monash University has resulted in a number of scientific and preclinical relationships being developed which will expedite Aus Bio's R&D program.

Profile:

Ausgenics Pty Ltd
Contact: Phone: Email: Internet: Address: Ms Ann Cronin +61 3 8341 6200 Fax: +61 3 9348 1391 cronin@cryptic.rch.unimelb.

ACN 096 588 395

http://murdoch.rch.unimelb.edu.au/pages/lab/chromosome_research/overview.html
Murdoch Childrens Research Institute Royal Children's Hospital Flemington Road Parkville, VIC, 3052 Australia Postal Address: Murdoch Childrens Research Institute PO Box 1100 Parkville, VIC, 3052 Australia

Profile:

Ausgenics Pty Ltd is a subsidiary company of the Murdoch Childrens Research Institute established during 2001 to commercialise a novel gene therapy delivery system.

Auspep Pty. Ltd.
Contact: Phone: Email: Internet: Address: Mr Stuart Banks, Buisiness Manager +61 3 9328 1211 Fax: +61 3 9326 8810

ACN 86 006 673 347

auspep@auspep.com.au www.auspep.com.au
115 Ireland Street West Melbourne, VIC, 3003 Australia Postal Address: PO Box 806 Parkville, VIC, 3052 Australia

Profile:

Auspep Pty. Ltd. is a manufacturer of biologically active peptides supplying the research and pharmaceutical communities worldwide. For over a decade, Auspep has supplied peptide-based products to researchers worldwide. Auspep has built up a high degree of technical expertise in both the protein and DNA areas, enabling technical enquiries to be responded to immediately by either customer service personnel or by Auspep’s team of scientific staff. In 1996, as testament to its ongoing commitment to high achievement and continual improvement in all facets of operation, Auspep was certified to an ISO9002 quality system. This has taken Auspep to new levels of customer service and product consistency and quality.

Austin Research Institute
Contact: Phone: Email: Internet: Address: Prof Mark Hogarth, Professor/Director +61 3 9287 0666 Fax: +61 3 9287 0601

pm.hogarth@ari.unimelb.edu.au www.ari.unimelb.edu.au
Kronheimer Building Austin & Repatriation Medical Centre Studley Road Heidelberg, VIC, 3084 Australia The AUSTIN RESEARCH INSTITUTE (ARI) is a world leader in developing vaccines for cancer, improving organ transplantation and understanding the nature of inflammatory diseases. The ARI also now has a major commitment to develop vaccines for infectious diseases. Established in 1991, the Austin Research Institute (ARI) is located in the grounds of the Austin and Repatriation Medical Centre (A&RMC) Heidelberg, Melbourne Victoria. It grew from the Research Centre for Cancer and Transplantation, a “Centre of Excellence” funded by the Federal Government and established at The University of Melbourne in 1982. Both the ARI and the Research Centre were formed around research groups established by Professor Ian McKenzie upon his return to Australia in 1974 from the USA, where he worked at the Massachusetts General Hospital, the Harvard Medical School and at the Jackson Laboratories with Nobel Laureate, Dr George Snell. Under the direction of Professor Ian McKenzie, the ARI has assembled a world-recognised team of researchers. The Austin Research Institute is a centre of excellence and has the status of a world-class research institute. ARI has a major mission to develop new therapeutics for the treatment of diseases including autoimmunity, rheumatoid arthritis, lupus, breast cancer, transplantation rejection and infectious diseases such as malaria. This is evident from over 128 patents (14 families) that encompass a broad range of platform and specific technologies. These include immunoconjugates (drug: antibody) for cancer and transplantation and structure based design of inflammatory drugs; targeted vaccines for infection and cancer, mucosal vaccines; transgenic pigs, gene discovery, complement regulation. In addition, many cutting edge technologies are used i.e. gene discovery, X-ray crystallography, combinatorial chemistry, animal transgenesis.

Profile:

Australian Animal Health Laboratory - CSIRO
Contact: Phone: Email: Internet: Address: Dr Jack Malecki, Commercial Manager +61 3 5227 5000 Fax: +61 3 5227 5555

Jack.Malecki@csiro.au www.csiro.au/aahl
5 Portarlington Road Geelong, VIC, 3220 Australia Postal Address: Private Bag 24 Geelong, VIC, 3220 Australia

Profile:

The Australian Animal Health Laboratory (AAHL) opened in 1985 and is one of the most sophisticated laboratories in the world for the safe handling and containment of exotic animal diseases. The Australian Animal Health Laboratory (AAHL) plays a vital role in maintaining Australia's capability to quickly diagnose exotic (foreign) and emerging animal diseases. This is achieved through ongoing research programs to develop the most sensitive, accurate and timely diagnostic tests, which are critical to the success of any eradication campaign in the event of a disease outbreak. AAHL also undertakes research to develop new diagnostic tests, vaccines and therapeutics for endemic and emergency animal diseases of national importance. Major diseases of livestock, aquaculture animals, and wildlife, are studied.

Australian Botanical Products Pty. Ltd.
Contact: Phone: Email: Internet: Address: Mr Tim Smith, Chief Operating Officer +61 3 9796 4833 Fax: +61 3 9796 4966

ACN 45 006 782 529

ausbot@ozemail.com.au www.essentialoils.com.au
39 Melverton Drive Hallam, VIC, 3803 Australia Australian Botanical Products (ABP), together with its subsidiary company Auroma, was established in 1982 and offers an extensive range of essential oils, fragrance oils, perfumes, cosmetics, and raw materials for use in the flavour, fragrance, pharmaceutical, and cosmetic industry. ABP’s research and development facility is one of the most sophisticated private laboratories of its kind in Australia. Using the latest gas chromatography and mass spectrometry equipment in conjunction with an on-line computer that has the largest essential oil database in Australia, ABP can accurately analyse essential oils, identify their constituent parts and confirm their purity and origin. The laboratory is staffed with expert pharmacologists and chemists who are dedicated to quality assurance. The Australian Federal Government regulates the handling of essential oils through the Therapeutic Goods Administration (TGA). ABP has been granted a TGA licence to manufacture and contract pack essential oils and other related products. ABP was the first essential oil company in Australia to set up an in-house analysis facility comprising GC-MS and multi-dimensional chiral chromatography. The company has also established Australia's most extensive private collection of essential oils and their components, their mass spectra and retention indices, physico-chemical and organoleptic properties. ABP is in the process of establishing an Australian distillation facility for the production of essential oils from local and imported materials; refining and fractionation for the production of natural isolates and molecules. The company is seeking to establish agencies for international raw material suppliers into the cosmetic and pharmaceutical industries.

Profile:

Australian Genome Research Facility
Contact: Phone: Email: Internet: Address: Dr Susan Forrest, Director 03 9345 2449 Fax: 03 9345 2678

sue.forrest@agrf.org.au www.agrf.org.au
7th Floor, Walter & Eliza Hall Institute of Medical Research 1G Royal Parade Parkville, VIC, 3050 Australia The Australian Genome Research Facility, funded by a Major National Research Facility grant, is an established well managed and effective fee for service genomics facility that serves hundreds of researchers all around Victoria and Australia. The facility has over 40 staff who are all well trained in high throughput genomics services. The core services that the AGRF supplies include DNA sequencing, genotyping and microarray production. The AGRF has contributed to large microbial, plant, animal and human genome as well as EST sequencing projects, and large gene mapping projects throughout Australia with a documented level of quality and satisfaction by its many users. AGRF is highly recognised and well appreciated both nationally and internationally, for its quality and throughput. The facility has nodes in Brisbane, Melbourne and Adelaide to access its suite of genomics technologies. We also support an active research and technology group, the major aim of which is to introduce new cost-effective genetic tools to enhance the scientific discoveries of the research community. Collaborative efforts when developing and trialling such methods is encouraged.

Profile:

Australian Mint Oils Pty Ltd
Contact: Phone: Email: Address: Mr Leo Cahill, Managing Director +61 3 9310 3271 Fax: +61 3 9310 3432

cahillhl@ocean.com.au
5 Ovata Drive Tullamarine, VIC, 3043 Australia Australian Mint Oils Pty Ltd grows peppermint, and processes it into peppermint oil at its Tullamarine facility. The product is customised as an ingredient for manufacturers of toothpaste, confectionery, and oral hygiene products.

Profile:

Australian Starter Culture Research Centre Limited
Contact: Phone: Email: Internet: Address: Dr Guy Limsowtin, CEO +61 3 9974 8900 Fax: +61 3 9742 4233

ACN 69 053 927 003

admin@ascrc.com.au www.ascrc.com.au
180 Princes Highway Werribee, VIC, 3030 Australia Australian Starter Culture Research Centre Limited is a non-profit research and development organization supported by subscriptions from Australian dairy processing companies. ASCRC subscriber companies are among Australia's leading dairy processors, manufacturers and exporters. This special relationship with the Australian dairy industry puts ASCRC in a unique position to introduce its subscribers to the fruits of basic and applied research, to foster the adoption of new technologies, to provide assistance in microbiological aspects of process and product development, and to provide starter-related products and services. The ASCRC laboratories are located within the Werribee Agriculture and Food Technology Precinct. Werribee is on the western suburban fringe of Melbourne, in the southern Australian state of Victoria. An additional link between subscriber cheese manufacturers and ASCRC's primary research and development functions is provided by the ASCRC Commercial Business Unit (CBU). The goal of the CBU is to facilitate transfer of starter strains and other technologies that have been developed from ASCRC to its subscriber companies, primarily via reliable supply of frozen cultures derived and characterized by ASCRC. After nearly two years of laboratory development and trials, the CBU and its production facility were established at ASCRC to make frozen bulk-set cheese starters available to subscribers on a commercial basis. ASCRC CBU is certified to HACCP-9000 for quality management. This certification covers all aspects of production, microbiological quality control, performance testing and supply.

Profile:

Axon Instruments, Inc.
Contact: ASX: Phone: Email: Internet: Address: Dr Alan Finkel, Chief Executive Officer AXN +61 3 9804 6800

ACN 59 090 106 844

maryannk@axonet.com.au www.axon.com
405 Tooronga Road Hawthorn East, VIC, 3123 Australia Axon Instruments, Inc. is the world's pre-eminent manufacturer of hardware and software products for cellular neurosciences and biophysical research. Axon was founded by Victorian, Dr Alan Finkel, in 1983 in Silicon Valley, California. Much of Axon’s software engineering development is done in Melbourne by its wholly owned subsidiary Axon Research Pty. Ltd. US parent Axon Instruments, Inc. listed on the Australian Stock Exchange in March 2000. Axon's corporate goal is to produce a range of superior yet affordable products for drug discovery and diagnostics, aimed at the pharmaceutical industry, biotechnology companies and academic researchers. Axon has long been a world leader in the design and manufacture of instrumentation and software for analysing electrical impulses within and between cells. One important new application of its core technology is in high throughput drug screening systems using the methods of cellular electrophysiology to screen an important class of pharmaceutical drug targets known as ion channels. Another of Axon’s new high throughput screening systems for drug discovery is based on fluorescence visualisation of the effects of drugs on cell shape, protein trafficking from the cell membrane to the nucleus, neurite outgrowth, changes in adhesion and other cellular changes. Axon is collaborating with CSIRO Mathematical & Information Sciences to write the complex imaging algorithms required. Axon is an important world supplier of instrumentation and software for genomics and proteomics. The company has a range of instruments for scanning content from DNA and protein microarrays. Axon’s software for genomics and proteomics ranges from image processing software to extract information from gene and protein chips, through to bioinformatics software to store, analyse and visualize the massive amounts of data generated in microarray studies. Uses include investigation of the complex relationships between genetic makeup, disease susceptibilities, and differing responses to drugs. Such devices may improve disease diagnosis and permit individually tailored medical treatments.

Profile:

Baker Medical Research Institute / Baker Heart Research Institute
Contact: Phone: Email: Internet: Address: Ms Louisa Garone, Commercialisation Manager +61 3 8532 1111 Fax: +61 3 8532 1100

louisa.garone@baker.edu.au www.baker.edu.au
Commercial Road Melbourne, VIC, 3004 Australia Postal Address: PO Box 6492 St. Kilda Road Central Melbourne, Victoria, 8008 Australia

Profile:

The Baker Medical Research Institute was founded in 1926 by Thomas Baker and has developed into one of the world’s leading cardiovascular research centres. The Baker Institute has made a series of internationally recognised contributions to understanding the causes of high blood pressure and atherosclerosis. This research has helped establish the Alfred Hospital as a major world centre for the care of heart patients. The Institute is affiliated with both Monash University (since 1965) and the Alfred Hospital. The Baker Institute - Alfred partnership started the first clinic in Australia for the treatment of hypertension and established open heart surgery in Australia. The Institute is principally funded by both the Commonwealth and State Governments, through its own ability to contract research activities, commercialise intellectual property and through various donor support mechanisms. The Baker has also been a World Health Organisation collaborating centre since 1989. The current Director is Professor Garry Jennings and he has led one of the major research groups in the world studying the translation of basic research findings to clinical practice in cardiology. The Institute has in excess of 240 staff members, including 34 postgraduate research students and 24 research fellows. The Institute relocated in November 2001 into a new state of the art research facility enabling enhanced development of core research capabilities and increased opportunity for external collaboration.

BALTECH Pty Ltd
Contact: Phone: Email: Address: Mr Peter Moon, CEO +61 3 5330 3552 Fax: +61 3 5330 2542

ACN 29 071 789 850

baltech@baltel.com.au
Suite 16. ICV Ballarat GHEC Technology Park UoB University Drive Mt Helen, VIC, 3353 Australia Postal Address: PO Box 57W Ballarat West Post Office, VIC, 3350 Australia

Profile:

Ballarat-based BALTECH Pty Ltd and its business partner Animated BioMedical Products of Sydney have procured full access to a significant US technology that has been under development by Dynoverse Corporation. Dynoverse has agreed to transfer the total business opportunity and technology to Australia. The technology is called Virtual Interactive Anatomy (VIA), which integrates the precise structure and functionality of any individual with advanced devices to collect those data, and innovative technologies to visualise and analyse them. The technology is based on, and a significant extension of, the outcomes of the US National Library of Medicine's “Visible Human Project”. This VIA methodology will impact on/in sectors including defence, medicine, road safety health care, rehabilitation, sports fitness, education and entertainment, to name a few. BALTECH and Animated BioMedical Products plan to develop a range of biomedical and defence simulation and visualisation outcomes, applications and products. The VIA technology offers the creation of design, engineering and production simulations in which unique people react, interact and interface with their environment. In healthcare, this affords for the first time individualised analyses of patient diagnosis, therapy and outcomes. The VIA Technology is intended to be multisensory, creating a highly realistic interactive experience. In addition, the VIA Technology allows simulation of abnormalities and challenges to the body from its surroundings. Lacerate the skin and the body bleeds; suture the virtual skin and close the wound; produce a spinal cord lesion that removes nerve supply to a body segment; then evaluate what mobility would remain and how best to rehabilitate the patient. The partners are pursuing a total body approach, combined with tissue level resolution, physiologic, biomechanical and biophysical realism, tactile interaction with the models, and extensive provision for customization.

Baxter Laboratories Pty. Ltd.
Contact: Phone: Email: Internet: Address: Mr Brent Baxter, Director +61 3 9763 3711 Fax: +61 3 9763 3722

ACN 42 093 625 435

bbaxter@baxterlaboratories.com www.baxterlaboratories.com
22 Kingsley Close Rowville, VIC, 3178 Australia Baxter Laboratories Pty. Ltd. is a family-based Australian-owned contract manufacturer, specialising in the development, manufacturing and packaging of cosmetic and therapeutic products, with a particular emphasis on short to medium-sized production runs. Established in 1995, Baxter Laboratories has grown quickly to become a market leader in low volume quality products. Goods manufactured by Baxter Laboratories are sold in all corners of the globe, including Asia, Europe, USA and the Middle East. Over 65% of the products Baxter Laboratories manufactures are exported to these markets. All manufacturing and packaging is conducted within cleanroom environments. The company is registered with the Therapeutic Goods Administration and the National Registration Authority, and its quality systems ensure full traceability. Baxter Laboratories is based at Rowville, Melbourne.

Profile:

Bayer Australia Ltd (Healthcare Operations Centre)
Contact: Phone: Email: Internet: Address: Dr Karl-Hine Timer, Operations Manager +61 3 9263 2222 Fax: +61 3 9263 2200

ACN 22 000 138 714

george.nearchou.gn@bayer-ag.de www.bayer.com.au
500 Wellington Road Mulgave, VIC, 0 Australia Postal Address: PO Box 158 Ferntree Gully, VIC, 3156 Australia

Profile:

Bayer Australia Ltd, the Australian arm of German-based multinational pharmaceutical company Bayer AG, has several important functions based in Victoria. The Bayer Healthcare Operations Centre in Wellington Road, Mulgrave, is the manufacturing site for several Bayer pharmaceutical and "over-the-counter" products. It also provides warehousing and distribution functions for these products, as well as those imported, for both domestic and international destinations in the Australia-Pacific region. The Diagnostics Business Group activities of Bayer in Australian and New Zealand are headquartered in the Scoresby facility. Management, marketing, sales and distribution are coordinated from this location. Bayer Australia is a provider of a broad range of biotechnology and pharmaceutical products for markets including pharmacy, crop protection, and veterinary. Human diagnostics cover a broad range, including laboratory diagnostics and automation solutions; amplification products for viral serology, especially hepatitis and retroviruses; "near patient testing" diagnostics solutions, especially for blood gas, electrolytes, diabetes and urinalysis; and "self testing" diagnostics solutions, especially for diabetes and renal disease.

Bayer CropScience Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Olivier Duroni, CEO +61 3 9248 6888 Fax: +61 3 9248 6800

ACN 87 000 226 022

max.cowie@aventis.com www.bayercropscience.com.au
391-393 Tooronga Road East Hawthorn, VIC, 3123 Australia Bayer CropScience (formerly Aventis CropScience) is a major crop protection and crop production company which is also involved in top-ranking environmental and public health activities. Committed to developing sustainable agriculture worldwide, Bayer CropScience focuses on researching, developing and marketing innovative solutions that meet the needs of today's farming - healthy crops, increased yields, improved crop and food quality - whilst constantly striving to meet the needs of the environment. Bayer CropScience devotes a significant proportion of its turnover to the research and development of new chemicals, biotechnology and plant varieties. Bayer CropScience's Australian headquarters are located in Melbourne, Victoria, and the company has over 200 employees Australia-wide. Biotechnology research and development and seed breeding activities are coordinated from regional offices in Horsham (Victoria), Mount Gambier (SA), Wagga Wagga (NSW), Canberra (ACT) and Toowomba (Qld).

Profile:

Bernard O'Brien Institute of Microsurgery
Contact: Phone: Email: Internet: Address: Prof Wayne Morrison, Director +61 3 9288 4018 Fax: +61 3 9416 0926

morriswa@svhm.org.au www.bobim.org
42 Fitzroy Street Fitzroy, VIC, 3065 Australia The Bernard O’Brien Institute of Microsurgery is a surgical research centre with general surgical interests but with a special focus on reconstructive plastic surgery, in particular the management of soft tissue and limb trauma. The Director of the Institute, Wayne Morrison, is also the University of Melbourne Professor of Surgery and Head of Department of Surgery at St Vincent’s Hospital Melbourne. The Institute has many collaborations within the hospital and university and with other institutes, including overseas, and has full affiliation with the University of Melbourne. The Bernard O’Brien Institute of Microsurgery has been instrumental in its team of surgeons and scientists developing some innovative procedures over the last decade, particularly in microsurgery, hand surgery and tissue engineering. Our mission is to undertake clinical and experimental research in the field of reconstructive surgery, and especially microsurgery, for the betterment of the health of those afflicted by injury, disease or abnormality. The Institute has not only pioneered reconstructive microsurgery in this country but has been responsible for the great majority of microsurgery research in Australia. The Institute has made striking advances in replantation surgery and the transfer by microsurgical techniques of skin, fat, bone, tendon, joint, nerve and muscle. It is working actively in the field of foetal microsurgery. The staff of the Institute consists of a core of clinical microsurgeons as well as a group of international research fellows. At any one time the Institute supports several postgraduate students from surgical disciplines and basic science. They average five microsurgical fellows each year. They learn to assist consultant surgeons and treat all age groups covering: trauma (motor vehicle, farm and industrial); limb and digit replantation; cancer (skin, breast, face, neck, etc); nerve and muscle; vascular biology and pain management. In addition to the clinical staff and research fellows, there is a strong presence of multidisciplinary scientists including the Director of Research, Associate Professor Erik Thompson, who brings a career of connective tissue/matrix biology research in cancer to the Institute. The Director of the Institute, Professor Wayne Morrison, is the Professor of Surgery of the University of Melbourne, the first occasion on which a plastic surgeon has been appointed to the Chair of Surgery in Australia. This is recognition of the excellence of microsurgery research and its clinical applications. Clinically, the Bernard O’Brien Institute of Microsurgery has established itself as a world leader in the delivery of care to patients suffering complex trauma or disfigurement. New reconstructive techniques involving transfer of tissue, facial reanimation and the treatment of lymphoedema, have been pioneered. Recently the Institute has done new work in the fundamental processes of wound healing, new vessel growth, the effect of injury on tissues and the transplantation of tissues between species. The Institute has begun pioneering work in the development of tissue banks whereby donated tissue can be stored for future use in microsurgical transfers and will begin to interface with cancer research issues brought to the Institute by the new Director of Research. Also, since breast cancer is a major focus, an emphasis on mammary gland reconstruction is being developed. A novel method for producing vascularised tissues and organs has been recently patented and the commercial consequences of this development are now being explored.

Profile:

Biacore International Limited
Contact: Phone: Email: Internet: Address: Mr Rick Filonzi, Branch Office Manager +61 3 9897 4900 Fax: +61 3 9897 4944 rfilonzi@ozemail.com.

ACN 103 121 731

www.biacore.com
3/ 26 Rutland Road Box Hill, VIC, 3128 Australia Biacore International Limited is the world leader in SPR-based technology. Biacore develops, manufactures and markets innovative and unique products using Surface Plasmon Resonance (SPR) to detect and monitor biomolecular binding. Biacore® systems are used in the drug discovery industry, life science and food analysis markets. The company pioneered the development of the SPR-based technology underlying all Biacore's products, introducing the first Biacore® system in 1990. Continuous improvements have established Biacore® systems as the most advanced, easy to use, systems of their kind, with the highest performance standards. Highly successful promotion and sales, through its own marketing companies in the United States, Europe, Japan, New Zealand and distributors in Asia-Pacific, have established Biacore as the clear market leader in this field. In the last few years Biacore has further demonstrated its commitment to the Australian market, by establishing a Biacore International Limited Branch Office in Melbourne to handle all aspects of sales, marketing and service for the Biacore Range of instruments. The company’s headquarters is in Uppsala, Sweden. Biacore is concentrating on the life science research, pharmaceutical and biotechnology markets in order to capitalize on SPR technology’s ability to improve the economics of drug discovery and developments. The company has also been extending its franchise with leading life science laboratories around the globe by highlighting the ability of its systems to solve research problems in the increasingly important fields of proteomics, cancer and neuroscience. The company has also signed several collaboration agreements with companies in the drug discovery and development industry, such as Millennium Pharmaceuticals Inc. The aim is to develop new instrumentation targeted specifically towards solving problems for this customer group.

Profile:

BigPharma Limited
Contact: Phone: Email: Address: Mr Patrick Volpe, Chairman and Executive Director +61 3 9854 6138 Fax: +61 3 9817 7137

ACN 102 456 048

cardia@bigpond.com.au
Level 1 89 High Street Kew, VIC, 3101 Australia Cardia Technologies Limited has wrapped its medical biotechnology projects into a new whollyowned subsidiary company, BigPharma Limited, focused on diabetes and obesity. BigPharma will take on Cardia's diabetes projects. One is a type 1 diabetes project focused on food toxins, and the other is a type 2 diabetes collaboration, testing a compound called ISF402, with the International Diabetes Institute and Monash University. Cardia, which will subscribe to shares in Big Pharma, expects the result to be an autonomous, fully-focused medical biotechnology company with the power to attract specialist board members, raise capital outside Cardia, and explore new R&D options. Cardia [see separate entry] plans to list the new company on the Australian Stock Exchange (ASX) in 2003.

Profile:

Bio 21 Australia Limited
Contact: Phone: Email: Internet: Address: Dr Stella Clark, Chief Executive Officer +61 3 8344 1937 Fax: +61 3 9347 9823

ACN 096 058 025

stella.clark@unimelb.edu.au www.bio21.com.au
157 Barry Street Carlton, VIC, 3053 Australia Bio21 Australia Ltd is a company, limited by guarantee, founded by Melbourne Health, The University of Melbourne and The Walter and Eliza Hall Institute of Medical Research (Founding Members). It is the governing body of a collaborative cluster of vigorous research institutions. Its purpose is to develop and enhance the reputation of Victoria as a leading academic centre for the advancement of knowledge in fundamental areas of biology, medicine, science and technology. A number of other leading research organisations have joined Bio21 as Members. Bio21 Australia Ltd is committed to the advancement of, basic biomedical science, translational clinical research and biotechnology; training in research of the highest order; science communication and education and; commercialisation of biotechnology discoveries.

Profile:

Bio Electronics Pty. Limited
Contact: Phone: Email: Internet: Address: Mr William J (Jim) Lamers, Managing Director +61 3 9370 6729 Fax: +61 3 9370 0619

j.lamers@bioelectronics.com.au www.bioelectronics.com.au or www.EziStim.com
964a Mt Alexander Road Essendon, VIC, 3040 Australia Postal Address: PO Box 87 Essendon, VIC, 3040 Australia

Profile:

Bio Electronics Pty. Limited manufactures and supplies a range of electrical nerve and muscle stimulators. The BIOSTIM® ,EziStim™ and PainEze plus™ ranges are designed for personal use electrotherapy, and incorporate unique pulse generation circuitry to provide equal stimulation at every electrode. These products are used to control chronic pain, provide relief from stress, stimulate healing after physical injury, and promote the rehabilitation of weakened muscles. BIOSTIM® is listed with Australia's Therapeutic Goods Administration (Therapeutic Devices Branch). The products have been used by Australian athletes at every Olympic Games since 1976 (excluding Moscow) and at dozens of other international sporting events. Other users include physiotherapists, masseurs, doctors, pain specialists and individuals.

Bio Nova International Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Hugh McCormack, Chief Executive Officer +61 3 9326 6955 Fax: +61 3 9329 8071

ACN 29 068 699 338

bni@bionova.com.au www.bionova.com.au
36 Munster Terrace North Melbourne, VIC, 3051 Australia Postal Address: PO Box 359 North Melbourne, VIC, 3051 Australia

Profile:

Bio Nova International Pty Ltd produces implantable tissue structures for the treatment of defective tissues and organs. A world leader and pioneer in tissue engineering, Bio Nova has developed methods to grow tissue structures in animals and safely transplant the engineered structures into humans. The technology is already used to produce replacement blood vessels that are exported to many European, Middle Eastern and Asian countries. Current research is targeted at developing a patient-specific coronary artery bypass graft. Other applications, which are at various stages from concept through to initial prototypes, include heart valves, stents, ligaments, hernia repair patches, nerve regeneration tubes, dural patches, bioartificial skin, wound dressings, endovascular grafts, bone grafting materials, surgical sealant, and other constructs to enable grafting of pancreatic islet cells for the treatment of diabetes. Bio Nova’s patented technology for engineering tissues combines synthetic materials with animal and human tissue and cells, and is expected to provide the basis for generating spare parts for many future surgical and therapeutic treatments. Bio Nova has Good Manufacturing Practice (GMP) manufacturing facilities and laboratories and ISO 9001 accreditation.

Bio-Rad Laboratories Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Glen Costin, Manager +1800 224 354 Fax: + 61 3 9899 1121

glen_costin@bio-rad.com www.bio-rad.com
10 Arcade Road Box Hill North, VIC, 3129 Australia Postal Address: PO BOX 210 Regents Park NSW 2143 Australia

Profile:

Bio-Rad Laboratories has remained at the center of scientific discovery for more than 50 years by providing a broad range of innovative tools and services to the clinical diagnostics and life science research markets. The company is world renowned among hospitals, universities, major research institutions, biotechnology and pharmaceutical firms for its commitment to quality and customer service. It has built strong customer relationships that advance research and development efforts and support the commercialization of new technology, especially in the high-growth fields of genomics, proteomics, biopharmaceutical discovery, food safety and biotechnology education. Throughout the past four decades, the company's product portfolio has increased substantially, as has its expanding customer base and global reach. Bio-Rad now manufactures and distributes thousands of products that incorporate a wide range of technologies including electrophoresis, imaging, immunoassay, chromatography, microbiology, bioinformatics, and transfection. By capitalizing on its expertise and quality reputation, Bio-Rad Laboratories will continue to strengthen its leading roles in both existing and niche markets, and maintain its position at the center of scientific discovery. BusinessWeek USA recently ranked Bio-Rad as one of the top 100 Growth Companies in the USA.

Biocomm Services Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Lawrence Bremner, COO +61 3 9660 2400 Fax: +61 3 9660 2444

ACN 17 094 476 212

info@biocomm.com.au www.biocomm.com.au
1 Collins Street Melbourne, VIC, 3000 Australia Biocomm is a biotechnology business development company based in Melbourne, Australia, providing commercialization services. Biocomm has direct relationships with Australian research institutions, and assists in developing international connectivity and commercialization of research for its members and clients. Biocomm has assembled a team of international and Australian science and business professionals to develop or bring biotechnology opportunities to commercial reality. Biocomm provides its services for business company development and licensing outcomes. New company formation is assisted by sector specific seed capital from Biocomm’s capital pool. ACN 20 096 845 993 Biodiem Ltd Mr Tom Williams, Managing Director +61 3 9613 4100 Fax: +61 3 9613 4111

Profile:

Contact: Phone: Email: Internet: Address:

info@biodiem.com www.biodiem.com
Level 10 Atrium Building 459 Collins Street Melbourne, VIC, 3000 Australia Biodiem Ltd is an Australian unlisted company based in Melbourne, with an international focus on finding, adding value and commercializing world-class research for vaccines, infectious diseases and other therapeutic areas. The company’s strategy is to accelerate development of new technologies through collaborations and sponsored research programs with university medical departments, research companies, and institutions like the Institute of Experimental Medicine (IEM) in St. Petersburg, Russia. BioDiem has three projects currently underway: (i) Live Attenuated Influenza Vaccine (LAIV) (ii) Animal Growth Promoter (BDM-I) (iii) Post Myocardial Infarction Treatment (BDM-K). Biodiem is also in late stage negotiations for a new product aimed at treating retinal eye diseases, in particular diabetic retinopathy and macular degeneration, which are leading causes of blindness in people over 50. In addition, BioDiem has an early stage program, based on a potential platform technology for developing other vaccines, for which the first target is a malaria vaccine. Live Attenuated Influenza Vaccine. BioDiem has a licence from the IEM to commercialise the LAIV technology outside of Russia and the Commonwealth of Independent States (CIS). The LAIV has been approved for public use in Russia and the CIS and has been used to vaccinate tens of millions of people over the past decade. Biodiem considers that the live attenuated influenza vaccine has several characteristics, which make it appealing: 1. It is delivered by a single dose, intranasal spray rather than hypodermic syringe as the current “killed” vaccine is. 2. As approved and used in Russia, and according to published clinical trials, it has been shown to be safe and effective in children, adults and the elderly. 3. No evidence of a tendency to induce asthma has been seen in clinical trials in Russia of healthy children as young as one year old. 4. It has been shown in clinical trials to be 93% effective against influenza in children after a single dose delivered by nasal spray. It is also significantly effective in reducing the incidence of all acute respiratory diseases. 5. Clinical trials in 33 schools in Russia demonstrated what is known as “herd immunity” wherein

Profile:

the use of the live flu vaccine in more than 40% of a school population led to markedly reduced levels of flu in the unvaccinated control group of children, thereby reducing the spread of flu through the group. Retinal eye diseases (BDM-E). Biodiem is currently in late stage commercial negotiations for another promising project with evidence of success. This particular project involves a novel synthetic compound relating to the treatment of age-related retinal eye diseases. The lead indications in this case are age-related macular degeneration and diabetic retinopathy, some of the leading causes of loss of vision in people over 55, and for both of which there is currently a significant unmet medical need. The market for such a compound is estimated to be in excess of US$2 billion per year. In early stage human studies in Russia in 63 patients with macular degeneration, 88% of patients showed an improved ophthalmoscopic picture of the eye fundus, and 85% of patients had some improvement in visual acuity. Animal Growth Promoter (BDM-I). Laboratory in vitro preliminary testing has revealed an important feature of the antimicrobial characteristics of BDM-I. In systems where major existing antibiotics show the development of resistance by bacteria, no resistance has so far developed with BDM-I. Potential animal growth promoter. The apparent lack of developed resistance (in tests to date) and the low oral absorption properties of BDM-I from the gut have suggested a potentially valuable area of use for BDM-I as a medicated feed additive, particularly for use in the poultry and swine intensive growing industries, to replace the existing use of antibiotics that have lead to concerns about the spread of antibiotic resistance. In early stage trials at a Melbourne university, BDM-I produced significant weight gain in chicks, relative to control groups. Further studies are continuing to define the potential for BDM-I as an effective growth promoter in poultry, to replace the increasingly proscribed use of antibiotic growth promoters. Post Myocardial Infarction Treatment (BDM-K). BDM-K is a tissue resolution agent that has also been acquired from the St Petersburg Institute of Experimental Medicine (IEM). It will be aimed at assisting the recovery of cardiac function after a heart attack. In early human studies, conducted in four Russian cardiac clinics, BDM-K has shown the potential to be useful in assisting the restoration of the contractile function of cardiac muscle, with 3 weeks oral treatment beginning a week after a heart attack. For patients treated with BDM-K, decreases were reported in shortness of breath, tachycardia, and oedema in the lower extremities associated with the cardiac insufficiency. BDM-K also had a positive effect on the contractile function of myocardium, as shown by a significant increase in the ejection fraction. BDM-K has the potential to assist the quality and speed of restoring some types of damaged tissue to an improved state, structure and function, with less scarring.

Bioglobal Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Pat Volpe, Chairman +61 3 9854 6138 Fax: +61 3 9854 6399

ACN 94 091 488 505

ken.i@bioglobal.com.au
bioglobal.com.au 437 Joseph Street Ballarat, VIC, 3350 Australia Postal Address: Level 1, 89 High Street, Kew. Victoria 3101. P.O.Box 361, Corinda. 4075 Kew, Victoria, 3101 Australia

Profile:

Bioglobal has been established to develop and market green, naturally based chemical products for the annual $100 billion agricultural, animal health and environmental insecticide market. Over the past two decades research has confirmed that many “hard” agricultural and pest management chemicals, from DDT and CCA to organophosphates, cause major environmental and health damage. This research has substantiated strong consumer concerns about serious chemical contamination of the environment and the food we eat. Also fuelling this drive for clean and green products is the fact that agricultural producers face substantial production problems because crop and livestock pests develop chemical resistance i.e. they become immune to the “hard” broad-spectrum chemicals used. The Business Model. The objective of Bioglobal is to create environmentally safe agricultural, animal health and environmental insecticides from the commercialisation of intellectual property either generated by its research and development programmes, or by acquisition. The company then seeks to penetrate these global market segments through strategic partnerships with major agro-chemical companies who already have the appropriate marketing and distribution infrastructure in place. Product Development Strategy. Bioglobal’s product development involves projects with short, medium and long-term timelines to balance the need for revenue generation with research and development of major category products that require longer timeframes. The product selection criteria are as follows: 1. Products are biorational – which means they use green chemicals and/or natural ingredients that are GRAS (generally recognised as safe) or tier 1 toxicology only. 2. Unique intellectual property can be developed, owned and/or acquired by Bioglobal to provide a competitive advantage (patent, trademark, PVR and copywrite protection strategy). 3. The products must have global market potential to attract large agro-chemical companies to partner Bioglobal in commercialisation, marketing and distribution arrangements with significant commercial returns. In most instances, Biorational products may not be required to undergo long-term toxicology trials. This reduces the product lead-time to market, with obvious benefits for capital deployed and revenue generated.Bioglobal’s Product Portfolio. The portfolio contains a mix of products, some of which are market-ready, and others still under development. The major products fall into three market segments of the insecticide industry: crop protection, animal health and environmental. 1. Crop protection a. attract and kill technology for moths in cotton, legumes and vegetables b. attract and kill technology for corn-root worm (major pest in corn and soy beans in the mid-west of the U.S.A. 2. Animal Health a. Lucilure trap and lure for blowflies for both sheep and landfill markets b. extension of the Lucilure technology to screw-worm fly (old and new world). 3. Environmental a. natural killing agents for termites b. wood preservative treatment to replace CCA c. fire-ant bomb: green fumigant and colony control agent d. rodent repellant (for domestic and commercial plastic cabling).

Biogreen Ltd
Contact: Phone: Email: Internet: Address: Mr Brent Davey, General Manager +61 3 9866 2305 Fax: +61 3 9866 2306

ACN 37 066 056 620

Brent.Davey@biogreen.info www.biogreen.info
Level 6 499 St Kilda Road Melbourne, VIC, 3004 Australia Biogreen Ltd is a public, unlisted company with over 1000 shareholders and three operating subsidiaries - Peat Operations Pty Limited, BioRemediation Pty Ltd and Grotech Australia Pty Ltd. The group’s focus is to deliver intelligent solutions for the environment in the areas of soil restoration, fertiliser and insecticide delivery, and environmental containment and protection. This is achieved by active research and development into the properties and applications of reedsedge peat harvested by Peat Operations from the group’s resource at Swan Marsh, near Colac in south-western Victoria. Biogreen peat is a stable, 100% organic pest-free material that binds water, nutrients and pollutants, and sustains a vigorous flora of beneficial micro-organisms. The group’s marketing arm (Biogreen Products) sells substrates that have widespread application in agriculture, horticulture, broad-acre farming, viticulture, mushroom growing and commercial and domestic gardening, as soil improvers, potting and growing media, and natural plant growth stimulants, for improving crop yield and plant vigour, and for minimising water and fertiliser consumption. BioRemediation develops and markets biofilters and other products for wastewater treatment, stormwater management, contamination remediation and environmental protection, while Grotech is developing and marketing worldwide a radical new technology for the controlled delivery and targeted release of pesticides and fertilisers.

Profile:

Biological Therapies
Contact: Phone: Email: Internet: Address: Dr Ian Dettman, CEO +61 3 9587 3948 Fax: +61 3 9587 1720

ACN 99 006 897 856

biol@biol.com.au www.biologicaltherapies.com
Unit 5 20-30 Malcolm Road Braeside, VIC, 3195 Australia Biological Therapies is an Australian owned company licensed with the Australian Therapeutic Goods Administration to manufacture a comprehensive range of sterile injectable and non sterile oral nutritional supplements. Biological Therapies occupies a total of 1,000 square metres of factory space which includes separate sterile and non sterile manufacturing facilities, chemical, microbiological and research and development laboratories, dispatch area, warehousing and administration offices. The company currently employs around 20 staff. The early history of Biological Therapies dates back to 1972, when its founder commenced manufacture of injectable vitamins in his pathology premises. This was followed by a range of injectable vitamin products, along with several patents concerning their production. In 1988, the manufacturing facilities were substantially expanded for sterile manufacture of a range of injectable nutritional supplements and also manufacture of oral powders, tablets and liquids. Biological Therapies produces a range of sterile and non sterile products including:·vitamin C products for injection; vitamin B products for injection; disodium edetate products for injection; oral nutritional products including tablets, powders and liquids; a range of test strips; and a range of herbal products. Biological Therapies also specialises in contract manufacturing.

Profile:

Biomedtech Australia Pty. Ltd.

ACN 65 081 459 770

Contact: Phone: Email: Internet: Address:

Ms Juliette Moran, Marketing Assistant +61 3 9553 7200 Fax: +61 3 9553 7299

info@go2altitude.com www.go2altitude.com
17 Roberna Street Moorabbin, VIC, 3189 Australia Biomedtech Australia Pty. Ltd. specialises in development, manufacturing and distribution of equipment for hypoxic stimulation (high altitude conditioning). Biomedtech’s trademarks are GO2Altitude® and AltiPower®.

Profile:

BioMelbourne Network
Contact: Phone: Email: Internet: Address: Mr Tim Murphy, Executive Director +61 3 9650 8800 Fax: +61 3 9650 6066

tmurphy@biomelbourne.org www.biomelbourne.org
Level 2 25 Flinders Lane Melbourne, VIC, 3000 Australia BioMelbourne Network is an industry development and promotion organisation representing the leaders of research institutions, biotech companies and service providers in Melbourne – the leading biotechnology centre in the Asia Pacific. The Network is the first point of contact for local and international companies looking to do business in Melbourne and Victoria. BioMelbourne Network offers access to research and business specialists in Victoria’s health care, agricultural, industrial and environmental biotechnology sectors. The Network’s activities include: •national and international marketing of Victoria’s biotechnology capabilities, •high level State and Federal lobbying, and •industry development and education support programs. More than 250 organisations and over 750 individuals participate in the Network’s initiatives to position Melbourne as the key biotechnology centre for the Asia Pacific region. The Network benefits its members by •Exclusively focusing on growing the Victorian biotechnology industry •Representing leaders in the science and business community •Linking business, science and government •Providing access across all sectors of the Victorian industry •Providing access to international business links

Profile:

Bionic Ear Institute
Contact: Phone: Email: Internet: Address: Mr John Huigen, General Manager and Associate Director +61 3 9667 7500 Fax: +61 3 9667 7505

j.huigen@unimelb.edu.au www.bionicearinstitute.com.au
384-388 Albert St East Melbourne, VIC, 3002 Australia Neurophysiological investigation of the hearing system; safety studies of auditory prostheses, including biocompatibility studies; electroneural interface design, development and testing; in vitro and in vivo testing of the affect of trophic factors on the auditory system; psychophysical evaluation of acoustic and electric stimulation; mathematical modelling of neural activity; signal processing; development of speech processing algorithms; design, development and construction of digital signal processor (DSP)-based portable speech processors (electric and acoustic); clinical evaluation of aids to hearing. ACN 49 007 303 728 Bioproperties (Australia) Pty. Ltd. Mr David Tinworth, Managing Director +61 3 9879 0039 Fax: +61 3 9879 0713

Profile:

Contact: Phone: Email: Internet: Address:

david.tinworth@bioproperties.com.au www.bioproperties.com.au
36 Charter St Ringwood North, VIC, 3134 Australia Postal Address: Level 28 200 Queen St Melbourne, VIC, 3000 Australia

Profile:

Bioproperties (Australia) Pty. Ltd. focuses on R&D, scale up and large scale GMP manufacture of live viral, bacterial and protozoal veterinary vaccines for intensively farmed food animals. It is also involved in a JV company Nippon Medical Research developing a novel human antibiotic for resistant Staphylococci and Mycobacterium. During the past ten years Bioproperties has developed and introduced four Victorian-developed veterinary live vaccines for the poultry industry, both in Australia and globally, to combat various infectious diseases caused by two Mycoplasma strains (MG and MS), Salmonella, and the protozoan Eimeria (coccidiosis). The company also manufactures and markets high-potency vaccines that have controlled Marek’s Disease in Australia. Two other chicken vaccines (Pasturella and IBDV) are in late-stage development, with further vaccines for the cattle (Salmonella and toxigenic E.coli) and pig industries (M. hyopneumoniae) in the pipeline. Most of this work has been done in conjunction with the University of Melbourne and RMIT University, with contributions also by Monash University and Sydney University. Bioproperties, together with joint venture partner Nippon Medical Research, has also identified a new class of narrow-spectrum peptide antibiotic to kill Staphylococcus and Mycobacteria, currently completed its preclinical stage and entering Phase 1 clinicals in the USA. Bioproperties has established a multi-million dollar GMP Category 1 biological manufacturing facility in Glenorie, NSW. The facility has large-scale capabilities in egg and cell culture based viral production, bacterial fermentation, large-scale sterile filling and freeze drying downstream capacities. A new laboratory for large-scale production of Eimeria vaccines is also being established on the site.

BioRevive Pty Ltd
Contact: Phone: Email: Internet: Address: Mr William Crothers, Chief Executive Officer +61 3 8416 0399 Fax: +61 3 8416 0355

ACN 58 097 360 417

biorevive@pacificmedical.com.au www.biorevive.biz
Level 1 263 Mary Street Richmond, VIC, 3121 Australia BioRevive Pty Ltd (bioRevive) was established in 2001 in Victoria to manufacture and distribute natural targeted therapeutic products for people with metabolic imbalances to enable longer and healthier lives. The product range is 100 % natural and includes individually customised amino acids, Alcodol – a hangover preventation and treatment capsule, Orul – an aphthous ulcer treatment capsule, Probiotics - Anaerobic and Facultative microorganisms and other products targeted at specific cellular and GIT imbalances. The head office is in Melbourne, with distribution channels currently being established globally. Research and clinical trials are being conducted at several hospitals in Australia and overseas. ACN 69 066 120 796 Bioscreen Pty Ltd Mr William Crothers, Chief Executive Officer +61 3 9899 4900 Fax: +61 3 9899 4988

Profile:

Contact: Phone: Email: Internet: Address:

Bioscreen@bioscreen.com.au www.bioscreen.com.au
Level 1 263 Mary Street Richmond, VIC, 3121 Australia Postal Address: Level 1 901 White Horse Road Box Hill, VIC, 3128 Australia

Profile:

Bioscreen Pty Ltd is a Melbourne-based biotechnology company dedicated to the analysis, diagnosis and prescription of therapeutics for people with metabolic imbalances and cellular malnutrition. Its main focus is diagnosing imbalances due to both metabolic and pathogen associated mechanisms. Cellular malnutrition as a result of both cytokine and pathogen associated changes can cause chronic illness. Bioscreen was established by the Collaborative Pain Research Unit (CPRU) and the tests arose as a result of their research into the pathogen and immune responses resulting in the development of chronic fatigue and chronic pain disorders. The tests highlight changes in both metabolic and pathogen-associated mechanisms, and offer the health professional a focus for designating management and treatment programmes. Bioscreen's approach challenges some traditional approaches as they are purely evidence based and not driven by the existing clinical paradigms. Bioscreen believes that many chronic illnesses and developmental disorders are treatable diseases, based on distinct biochemical anomalies. Bioscreen has examined many thousands of patients with a wide range of symptoms; however, they have had a particular research interest in chronic pain and fatigue associated disorders, autism, attention deficit disorder, irritable bowel syndrome and gastrointestinal disorders. The role of the tests is to determine whether there is an organic basis to a patient's illness, and to compare the patient's metabolic patterns with those observed in Bioscreen's studies of over 13,000 patients with various chronic diseases imbalances.

Biota Holdings Limited
Contact: ASX: Phone: Email: Internet: Address: Mr Peter Molloy, CEO & Managing Director BTA +61 3 9529 2311 Fax: +61 3 9529 2261

ACN 28 006 479 081

info@biota.com.au www.biota-inc.com
Level 4 616 St. Kilda Road Melbourne, VIC, 3004 Australia Biota Holdings Limited is an Australian, publicly listed, biotech company engaged in R&D of new pharmaceuticals, with a focus on respiratory infectious diseases. Biota has developed two products marketed worldwide: Relenza, an antiviral treatment for influenza; and FLU OIA, a rapid point-of-care influenza A/B diagnostic kit. Biota’s US subsidiary Biota Inc, based in Carlsbad, California, is focused on improving existing nucleotide drugs to treat important viral, bacterial and fungal diseases, and cancer. Biota has two fully operational R&D facilities in Australia and the USA, with strong virology, medicinal chemistry and structural biology competencies in Australia, and strong nucleoside chemistry skills in the US. The Biota Group has three drug discovery platforms. In Australian R&D, Biota utilises its MUCO (multivalent coupling) technology and structure based drug design. MUCO is aimed at developing higher potency therapies against diseases such as influenza, bacterial infections and inflammation. In the US, Biota Inc uses novel N-MAX technology developed by Biota Inc’s Chief Scientific Officer, Dr P Dan Cook. N-MAX is aimed at improving existing nucleoside drugs with a superior side effect profile. Biota has key management in place with outstanding industry experience and commercial partnering skills. Peter Molloy (CEO) and Sterling Johnson (VP, Business Development) are based in the US to optimise and capture greater value from business development activities.

Profile:

Biotech Ventures Pty Ltd
Contact: Phone: Address: Mr Michael Furzer, Director +61 3 9866 7511 Fax: +61 3 9867 1219 Suite 2, Level 4 450 St Kilda Road Melbourne, VIC, 3004 Australia

ACN 61 094 171 007

Profile:

Biotech Ventures Pty Ltd funds research and development into the use of micro-organisms for the control of pathogens. Biotech Ventures was established in Melbourne in 2000.

Biotechnic Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Nick Sestito, Managing Director +61 3 5277 0910 Fax: +61 3 5277 1061

ACN 26 853 050 837

biotechnic@datafast.net.au www.biotechnic.com.au (under construction)
Unit 3 2a Backwell Street North Geelong, VIC, 3215 Australia Postal Address: PO Box 1215 Geelong, VIC, 3220 Australia

Profile:

Biotechnic is a designer and manufacturer of sanitary equipment for the biopharmaceutical industry. Biotechnic manufactures equipment that meets the most stringent requirements of the US Food and Drug Administration (FDA) and the ASME BPE (biopharmaceutical engineering) standard. Currently, Biotechnic supplies the biopharmaceutical market with USP Class VI compliant hoses and sanitary fittings. They have designed and manufactured fittings for several US companies, and at present export revenue represents 80% of total sales. Included among other items that Biotechnic manufactures are Bioports, which are sanitary access hatch assemblies. These are machined from Gr 316L stainless steel forgings and can be supplied in materials such as 904L and Hastelloy. These hatches comply with AS 1210 ( Australian pressure vessel code) as well as ASME VIII Div. 1. The company believes these to be the most sanitary in the world as there are no crevices in the seal due to the unique design. Currently, Biotechnic exports them to New Zealand, Singapore and the USA. Other items which the company will be manufacturing in the near future are polysulfone flow indicators, stainless steel filter housings and sanitary check valves. Biotechnic is continually researching and manufacturing new items that meet the requirements of the rapidly expanding biotech industry, and have the latest computer numeric control (CNC) equipment to ensure quality in manufacture. New products can be viewed in the future on the company's web site, currently under construction.

BMG Labtechnologies Pty Ltd
Contact: Phone: Email: Internet: Address: Mr James Balmer, Managing Director +61 3 5973 4744 Fax: +61 3 5973 4711

ACN 91 081 087 201

australia@bmglabtech.com www.bmglabtech.com
2/24 Carbine Way Mornington, VIC, 3931 Australia Postal Address: PO Box 469 Mount Eliza, VIC, 3930 Australia

Profile:

BMG Labtechnologies GmbH is a manufacturing company based in Germany specialising in all aspects of analysis of samples in microplate formats. BMG Labtechnologies Pty Ltd is the regional office covering Australia, New Zealand and the Pacific region for the sales and support of the equipment. Instruments are available to read fluorescence, polarised fluorescence, luminescence, UV-VIS absorbance and nephelometric analysis. BMG Labtechnologies is a specialist in this field and strives towards excellence in supporting its customers. Customer types include those involved in drug discovery, biotechnology, medical research, clinical diagnostics, food, forensics, environmental technologies, and toxicology.

Bonlac Foods Limited
Contact: ASX: Phone: Email: Internet: Address: Mr Peter Myers, Managing Director & CEO BFL +61 3 9270 0922 Fax: +61 3 9270 0911

ACN 52 006 483 665

Peter.myers@bonlac.com.au www.bonlacfoods.com
Level 7 636 St Kilda Road Melbourne, VIC, 3004 Australia Postal Address: PO Box 4313 Melbourne, VIC, 3001 Australia

Profile:

Bonlac Foods Limited is an Australian-based manufacturer of quality dairy products and speciality dairy ingredients. It produces butter, cheese and milk powder at factories in Victoria, Tasmania and New South Wales. Bonlac's leading consumer brands, including Western Star, Allowrie and Girgar spreads, Bodalla and Perfect Italiano cheeses and Diploma milk powder, are marketed through its 50%-owned joint venture company Bonland Dairies Pty Ltd. Its dairy ingredients products are exported to more than 50 countries. Through its Bioscience Division, Bonlac Foods is leading the way in developing specialist health care products from cows’ milk. The first of these new generation products to be launched on the market is Recaldent™, a revolutionary additive that can help to prevent early stages of tooth decay. This new and exciting remineralisation technology is a complex of casein phosphopeptides and amorphous calcium phosphate (CPP - ACP) which was identified and patented by the University of Melbourne and developed through collaboration between the University and Bonlac Foods. The phosphopeptides are derived from the casein protein naturally found in milk. When used as an ingredient in oral care products, Recaldent promotes the remineralisation, or repair, of tooth enamel. Sugarless chewing gum containing Recaldent™ is now on sale in the United States, Europe and Japan. New markets and other products containing Recaldent are planned for the future. The Bioscience Division has ongoing research into the identification of components of milk with biological activity, with a view to isolation, purification and commercialisation. Bonlac Foods was formed in 1986 through the amalgamation of several dairy enterprises with cooperative histories dating back to the 1880s. Bonlac Foods is 75% owned by its dairy farmer suppliers and 25% by New Zealand’s Fonterra Cooperative Group, and has its headquarters in Melbourne. Bonlac’s Perpetual Notes were listed on the ASX (BFL) in 1998.

Boron Molecular Pty Ltd
Contact: Phone: Email: Internet: Address: Dr Phil Reece, Managing Director, CEO +61 3 8558 8000 Fax: +61 3 8558 8004

ACN 76 092 480 674

info@boronmolecular.com www.boronmolecular.com
500 Princes Highway Noble Park, VIC, 3174 Australia Postal Address: PO Box 756 Noble Park, VIC, 3174 Australia

Profile:

Boron Molecular Pty Ltd (BM) is a research, development and manufacturing company, servicing the world’s pharmaceutical and other industries through the supply of specialist chemical products and services. BM’s core expertise is based on its staff’s knowledge of medicinal chemistry and the making of organoborons and related compounds as reflected in patents and patent applications licensed to BM. The technology is designed to achieve substantial cost reductions and technical improvements in the drug development process as well as the ability to explore novel compounds. BM is currently the only Australian owned and operated fine chemical manufacturer in this area and develops and produces a range of innovative organoboron and related products on both small and large scales for use across a broad range of markets including thepharmaceutical, agricultural, veterinary, food, cosmetic and the electronics industries. The advantage of the technology over the prior art is that it allows the production of complex and novel organoboron compounds that were either too difficult or too expensive to make when synthesized by other methodologies. Through R&D, BM will expand the compounds presently available and develop higher value-added products and technical services to the industry. ACN 60 082 909 653 Boulevarde Nurseries Mildura Pty Ltd

Contact: Phone: Email: Internet: Address:

Mr Paul Croxton, Joint Managing Director +61 3 5024 6312 Fax: +61 3 5024 6692

info@boulevarde.com.au www.boulevarde.com.au
Lot 18 Newton Avenue Irymple, VIC, 3498 Australia Postal Address: PO Box 816 Irymple, VIC, 3498 Australia

Profile:

In north-western Victoria, Boulevarde Nurseries Mildura Pty Ltd uses a synergistic combination of technologies to short-circuit the process of generating new plant varieties by up to two years, and to produce healthier plants. The main focus at present is new varieties of table and wine grapes, and the sophisticated technologies used include licensed internationally patented micrografting technology; micropropagation in tissue culture; and "embryo rescue", to allow the use of seedless varieties in the breeding program. Recently, Boulevarde Nurseries Mildura has developed a local and global export market in hybrid Zantedeschia (Calla Lily), for both cut flowers and rhizomes. Boulevarde Nurseries Mildura is a large wholesale plant nursery, and is one of the leading enterprises in the Sunraysia district. Facilities include a sophisticated tissue culture laboratory, hydroponics systems for gowing grapevines, and AQIS approved premises for performance of quarantine for medium risk crops. Through the implementation of quality systems and utilisation of leading edge technology, the nursery has attained growth in the excess of 500% over the past four years. It is Boulevarde Nurseries' aim to achieve solid growth, further establishing itself as a limited category specialist in the areas of viticulture and commercial crops such as grafted citrus and avocadoes, olives, passion fruit, kiwi fruit, and ornamental lines including Zantedeschia, Daphne, Ornithogalum, chrysanthemums, and others.

Bovogen Biologicals Pty. Ltd.
Contact: Phone: Email: Internet: Address: Mr Rick Clements, Managing Director +61 3 9336 3622 Fax: +61 3 9336 3644

ACN 16 096 634 927

info@bovogen.com www.bovogen.com
71 Ogilvie Street Essendon, VIC, 3040 Australia Bovogen Biologicals is an Australian bio-processing company manufacturing highly purified animal derived biologicals, including bulk quantities of bovine serum albumin. Bovogen Biologicals can also supply various animal sera and organs in addition to large quantities of bovine plasma as a raw material for the pharmaceutical and biotechnology industries. Bovogen Biologicals’ manufacturing premises are located in Keilor East, Melbourne, at 12 Williams Avenue.

Profile:

Brain Research Institute
Contact: Phone: Email: Internet: Address: Ms Jewell Gardner, Research Administrative Officer +61 3 9496 4076 Fax: +61 3 9496 2980

bri@brain.org.au www.brain.org.au
Neurosciences Building Austin & Repatriation Medical Centre Banksia Street Heidelberg West, VIC, 3081 Australia The Brain Research Institute (BRI) was established at the Austin and Repatriation Medical Centre, Melbourne, Australia in 1996. The Institute was created as a platform of high-standard brain research. The targeted research topics were the brain function in health and disease. The BRI first dedicated major energy into fundraising efforts towards the acquisition and commissioning of a world-class Magnetic Resonance Imaging (MRI) System. The installation of a cutting-edge 3 Tesla GE MRI system took place in early 2000. Software development, hardware designing and validation studies were priorities during the first year after the installment of the new scanner. Simultaneously, brain research started and has created some stunning results, which are about to be published. The BRI has brought together a growing group of researchers with the enthusiasm, vision and talent to tackle and overcome difficult clinical questions in brain disorders. Amongst them are neurologists, neurophysiologists, physicists, radiographers, radiologists, neuropsychologists, psychiatrists and scientists from Australia and overseas. The BRI employs over 40 researchers full time and part time on staff and 25 visiting honorary staff. BRI is an affiliated institution of the University of Melbourne and an administering institution of the National Health and Medical Research Council.

Profile:

Brain Sciences Institute
Contact: Phone: Email: Internet: Address: Assoc Prof David Crewther, Director +61 3 9214 8822 Fax: +61 3 9214 5525

dcrewther@bsi.swin.edu.au www.bsi.swin.edu.au
Swinburne University of Technology 400 Burwood Road Hawthorn, VIC, 3122 Australia Postal Address: Swinburne University of Technology PO Box 218 Hawthorn, Victoria, 3122 Australia

Profile:

The Brain Sciences Institute is a major research and postgraduate teaching facility within Swinburne University. Its primary purpose is to facilitate research into the relationship between human behavioural states and measured brain activity to understand the neural basis of cognition and emotion in the normal and disordered brain. BSI also undertakes contract research in areas consistent with its primary purpose. ACN 33 004 333 322 Bristol-Myers Squibb Australia Pty Ltd Mr John Kilborn, Managing Director +61 3 9213 4000 Fax: +61 3 9701 1526

Contact: Phone: Internet: Address:

www.bms.com
556 Princes Highway Noble Park, VIC, 3174 Australia Postal Address: PO Box 39 Noble Park, VIC, 3174 Australia

Profile:

Bristol-Myers Squibb Australia Pty Ltd is the Australian division of the Bristol-Myers Squibb Company - a global leader in the research, development, manufacturing and marketing of innovative ethical medicines. The company, which has a mission to extend and enhance human life, has a history of excellence in Australia. Preceding a major global merger in 1989, the BristolMyers Company and ER Squibb and Sons had operated in Australia since 1930 and 1955 respectively. Today, Bristol-Myers Squibb is among Australia’s leading producers of ethical pharmaceutical products. Based at Noble Park in Victoria, the Australian division manufactures and markets medicines in a number of therapeutic areas, including cancer, cardiovascular disease and infectious diseases. Australia is one of the top 10 international markets for the global corporation, representing a strategic manufacturing location, an important research and development site and a key employer of highly skilled people. In Australia, the company is able to draw upon its global strengths to achieve local benefits - both in terms of the new and innovative products it brings to market, as well as local employment and training opportunities. Bristol-Myers Squibb’s commitment to Australia has been acknowledged by the Australian Government, which selected the company as one of only nine to receive grants under the Pharmaceutical Industry Investment Program. As a grant recipient, Bristol-Myers Squibb has committed to increasing R&D and manufacturing levels in Australia over a period of five years from 1999.

Burnet Institute
Contact: Phone: Email: Internet: Address: Mr Stephan Swadzba, PR and development +61 3 9282 2135 Fax: +61 3 9282 2100

stephan@burnet.edu.au www.burnet.edu.au
Alfred Medical Research and Education Precinct (AMREP) Commercial Road Prahan, VIC, 3181 Australia Postal Address: GPO Box 2284 Melbourne, Victoria, 3001 Australia

Profile:

The Macfarlane Burnet Institute for Medical Research and Public Health (Burnet Institute) was established in 1986 as a research arm of the Virology Department of the former Fairfield Infectious Diseases Hospital in Melbourne. Incorporated as an independent entity in 1989, the Burnet Institute has grown rapidly into an internationally-recognised and influential communicable diseases research institute, distinguished by its broad, multi-disciplinary approach to diseases of national and global importance, with a major focus on HIV/AIDS, viral hepatitis and infectious respiratory diseases. The Burnet Institute's overall focus is directed at controlling the spread of serious infectious diseases and at reducing both direct and indirect harm caused to individuals and communities by these diseases. Its strategy encompasses two major, complementary approaches: discovery and development of new vaccines and drugs to combat infectious diseases; and interventions to implement changes in policy, management and behaviour to reduce the risks of disease and to deal more effectively and equitably with the consequences of disease. Approximately half of the Burnet Institute’s 120 staff and research students are engaged in laboratory-based experimental virology research programs, the other half are engaged in Institute’s innovative field-based research and public health programs in Australia and in many developing nations, particularly in the Asia-Pacific region. In July 2002, the Burnet Institute will relocate from its present research facilities on the campus of the former Fairfield Hospital, which was closed in 1996, to become one of the founding partners in the Alfred Medical Research and Education Precinct (AMREP) which is currently being constructed on the campus of the Alfred Hospital in Prahran in inner-suburban Melbourne. The Burnet Institute will occupy new, state-of-the-art purpose-built facilities within this new research complex in which more than A$90 M will have been invested by the end of 2001. The Burnet Institute’s partners in this development are the Alfred Hospital, Monash University, and the Baker Medical Research Institute.

Calibre Biotechnology Pty Limited
Contact: Phone: Email: Address: Dr Tony Hughes, Director +61 3 8344 8604 Fax: +61 3 8344 0241

ACN 51 101 665 945

rahughes@unimelb.edu.au
215 Grattan Street Parkville, VIC, 3052 Australia Calibre Biotechnology is a drug development company based on designing candidate therapeutic molecules which mimic the action of naturally occurring agents. Its initial development program is aimed at mimics of brain-derived neurotrophic factor (BDNF), for the treatment of major neurodegenerative diseases such as Parkinson’s and motor neurone disease. The design techniques also have wider application as a platform technology for the future development of drug targets across a range of therapeutic areas. ACN 64 096 859 513 Cancer Vac Limited

Profile:

Contact: Phone: Email: Internet: Address:

Mr Mark Clark, CEO +61 3 9287 0637 Fax: +61 3 9287 0639

mclark@primabiomed.com.au www.primabiomed.com.au
Kronheimer Building A&RMC Studley Road Heidelberg, VIC, 3084 Australia Formed in mid-2001 by Prima Biomed Ltd and Ilexus Pty. Ltd., Cancer Vac Limited is continuing the development of a therapeutic process for treating solid tumours. The Austin Research Institute research has discovered that stimulation of cells "ex vivo" (temporarily removed from the patient) may generate potent immune responses that will eliminate, arrest or retard the growth of tumours. The cell type of interest is the dendritic cell. Reintroduction of primed dendritic cells into the body may lead to the eradication of tumours through killing of tumour cells by cytotoxic T cells. Cancer Vac’s process involves (a) isolation of the immune system cells (dendritic cells) from the blood of a cancer patient; (b) stimulation of those dendritic cells by hormones (cytokines) of the immune system to activate the dendritic cells; (c) exposure of the dendritic cells to the immunostimulant combined with the tumour antigen to generate antigen-specific dendritic cells; and (d) introduction of these antigen-specific dendritic cells into the cancer patient to activate cancer-specific killer cells. The killer cells then seek out and eradicate the cancer cells they have been primed to recognise. The cancers being targeted for this type of therapy are breast, colon, lung, prostate, ovarian and pancreatic. A phase I clinical trial in cancer patients is in progress, with patient recruitment expected to be complete by the end of June 2002. Cancer Vac’s technology originated at the Austin Research Institute, and was exclusively sublicensed worldwide to Cancer Vac by Ilexus.

Profile:

CancerProbe Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Graeme Kaufman, Managing Director +61 3 9826 0399 Fax: +61 3 9824 0083

ACN 83 095 341 183

graeme.kaufman@circadian.com.au www.circadian.com.au/cancerprobe.htm
Level 1 10 Wallace Avenue Toorak, VIC, 3142 Australia Postal Address: PO Box 23 Toorak, VIC, 3142 Australia

Profile:

CancerProbe Pty Ltd, formed in December 2000, is developing applications of a novel method for rapid identification and detection of cancer-specific antigens. The methodology may have applications for a broad range of cancers, including breast, ovarian, colorectal and prostate cancers. CancerProbe holds the rights to the early stage research and development, and a provisional patent application covering the technology has been lodged. Researchers have been appointed for the development of new blood tests for cancer detection, which may also have potential for new therapeutic products. Circadian Technologies Limited, an Australian Stock Exchange (ASX)-listed company [see separate profile], holds a 30% interest in CancerProbe. ACN 89 064 755 237 Cardia Technologies Limited Mr Patrick Volpe, Executive Chairman CNN 0412 088 858 Fax: +61 3 9620 3452

Contact: ASX: Phone: Email: Address:

cardia@bigpond.com
Level 1 89 High Street Kew, VIC, 3101 Australia Cardia Technologies Limited is a diversified biotechnology company with interests in medical biotechnology, agricultural biotechnology and natural pharmaceuticals. Cardia is funding a diabetes type 2 research and development project with the International Diabetes Institute in Caulfield, Victoria. From this research, it is hoped that a new drug treatment programme for diabetes type 2 will be developed, and preliminary work to date is encouraging. Cardia has a further 18 months of the project to run before final animal model testing, toxicology studies and efficacy data are complete.

Profile:

Carlton and United Breweries Limited
Contact: Phone: Email: Address: Dr Peter Rogers, Manager, Manager New Technology +61 3 9420 6522 Fax: +61 3 9420 6932

ACN 76 004 056 106

peter.rogers@fostersgroup.com
4-6 Southampton Crescent Abbotsford, VIC, 3067 Australia Postal Address: GPO Box 753F Melbourne, VIC, 3001 Australia

Profile:

Carlton and United Breweries (CUB) maintains a strong technical capability in all aspects of the brewing process, and carries out strategic work in raw material science - including hop and malt chemistry and processing, yeast management and physiology, chemosensory science, packaging engineering, and alcoholic and non alcoholic beverage development. CUB is involved in value adding end-products from brewing. CUB pioneered the application of liquid carbon dioxide extraction of hop acids and the use of isomerised hop acid extracts for brewing; it was the first brewing company to introduce sterile membrane filtration of beer. The company produces tailored yeast for the food industry; various malt extracts, brewer's grain products for the diary industry, and markets a glucan immunostimulant for aquaculture and the health and wholesomeness marketplacem. CUB is expert in large scale fermentations, and the management of secondary or attenuated pathways in yeasts. This includes the analysis of brewing yeast gene expression. The company supports the Malting Barley Quality Improvement program for the developmentof new barley varieties, is a member of the Malting Barley Quality Improvement Technical Committee, and also the Western Australian Malting Quality Committee. The company is a member of the Australian Association of Brewers, which supports medical research in Australia and is a member of the subscription research organisation Brewing Research International. Several projects with Universities are supported by Australian Research Council funding. CUB commissioned a new laboratory, pilot brewery and large scale plant at the Abbotsford site in 2000, which provides over 1000 square metres of floor space for experimental work. ACN 15 100 285 916 Cell Therapies Pty Ltd

Contact: Phone: Email: Address:

Mr Ray Wood, Managing Director +61 3 8665 5270 Fax: +61 3 9639 8255

rayjwood@bigpond.com
Level 4 257 Collins Street Melbourne, VIC, 3000 Australia Cell Therapies provides clinical trials and TGA licensed contract cell manipulation services to organisations developing new treatments based on advanced stem cell (autologous) therapies for a range of disorders, including cancer.

Profile:

Cellestis Limited
Contact: ASX: Phone: Email: Internet: Address: Dr Anthony Radford, CEO CST +61 3 9571 3500 Fax: +61 3 9571 3544

ACN 86 094 962 133

quantiferon@cellestis.com www.cellestis.com
Level 1 1046a Dandenong Road Carnegie, VIC, 3163 Australia Postal Address: 1046A Dandenong Road Carnegie, VIC, 3163 Australia

Profile:

Cellestis Limited manufactures and markets QuantiFERON products for medical diagnosis and scientific research. The QuantiFERON technology is a patented whole blood method for detecting cell-mediated immune responses using whole blood samples. Cellestis currently manufactures and markets two QuantiFERON products, QuantiFERON-CMI and QuantiFERON-TB. Cellestis' platform technology, the QuantiFERON system, is applicable to monitoring a number of infectious diseases and medical conditions, and other products are under development. Cellestis licensed the Quantiferon technology from Australia's largest biotechnology company, CSL Limited, in December 2000. CSL was focusing its activities and no longer saw the Quantiferon diagnostic technology as core to its business strategy. Cellestis subsequently listed on the Australian Stock Exchange on 24 April 2001. Cellestis specializes in TB diagnosis and has developed a new and highly sensitive TB diagnostic, with high specificity as it is immune to cross-reactive effects from BCG vaccination or other kindred mycobacteria.

Centre for Animal Biotechnology
Contact: Phone: Email: Internet: Address: Dr Els Meeusen, Director +61 3 8344 7345 Fax: +61 3 9347 4083

e.meeusen@unimelb.edu.au www.cab.unimelb.edu.au
School of Veterinary Science, The University of Melbourne Cnr Flemington Road and Park Drive Parkville, VIC, 3010 Australia The Centre for Animal Biotechnology (CAB) is an international Centre of excellence for basic and applied immunology and molecular biology research in sheep. The major goal of CAB is to promote and conduct high quality research in large animal species that will contribute significantly to the development of improved methods for livestock management and disease control as well as serving as useful models for human disease processes.

Profile:

Centre for Developmental Cancer Therapeutics Inc.
Contact: Phone: Email: Internet: Address: Assoc Prof Mark Rosenthal, Director +61 3 9342 7306 Fax: +61 3 9347 7508

mark.rosenthal@mh.org.au www.cdct.org
Royal Melbourne Hospital Grattan Street Parkville, VIC, 3052 Australia Postal Address: Level 6, CCB Post Office Royal Melbourne Hospital Parkville, Victoria, 3052 Australia

Profile:

The Centre for Developmental Cancer Therapeutics (CDCT) is a cooperative venture of six Melbourne institutions with international reputations for first class cancer research and treatment. The aim of the CDCT collaboration is to improve cancer treatment through clinical and scientific research. The group has a strong focus on early drug development in oncology and haematology, with a particular emphasis on strategy to proof of concept. The CDCT also places great importance on the integration of biological endpoints to clinical trials.

Centre for Environmental Stress and Adaptation Research
Contact: Phone: Email: Internet: Address: Mr Ary Hoffmann, Director +61 3 9479 2769 Fax: +61 3 9479 2361

A.Hoffmann@latrobe.edu.au www.latrobe.edu.au/cesar
La Trobe University Bundoora, VIC, 3086 Australia The Centre for Environmental Stress Adaptation Research (CESAR) was established in 2000 with funding from the Australian Research Council via its Special Research Centre scheme. CESAR operates across nodes at La Trobe, Melbourne and Monash Universities and has a number of connections to agricultural industries. There are now more than 50 postdocs, research assistants, postgraduate students and other CESAR personnel located across the three nodes. The main aim of CESAR is to understand the main issues and mechanisms involved with adaptation of organisms to stress using experimental model systems, and to disseminate this information to industry and the community. The Centre has a major program in developing methods for predicting and minimizing the development of resistance to chemical pesticides. The Centre also has a large program in assessing the impact of stressful inputs on organisms in natural environments.

Profile:

Centre for Equine Virology
Contact: Phone: Email: Internet: Address: Prof Michael Studdert, Director +61 3 8344 7373 Fax: +61 3 8344 7374

m.studdert@unimelb.edu.au www.vet.unimelb.edu.au/research/CEV.html
School of Veterinary Science The University of Melbourne Cnr Flemington Road and Park Drive Parkville, VIC, 3050 Australia Postal Address: School of Veterinary Science The University of Melbourne Parkville, Victoria, 3010 Australia

Profile:

The Centre for Equine Virology was established by a decision of University Council in 1991. The major purposes of the CEV are: (i) to conduct research into virus diseases of horses, (ii) to provide diagnostic services to industry and (iii) to develop and provide policy advice to various industry and government agencies. The CEV and its antecedent, the Virus Laboratory, have made many notable contributions to equine virus disease research including the development of a combined inactivated vaccine for the control of respiratory disease and abortion caused by equine herpesvirus 1 (EHV1) and EHV4 and the development of a blood test to differentiate antibodies to EHV1 and EHV4. Other herpesviruses including, EHV2, EHV5 and EHV3 as well as equine adenoviruses and equine rhinoviruses are also subjects of research. A major theme of the research effort is concerned with improved diagnosis and control of viruses that cause respiratory disease in horses. The CEV provides diagnostic services nationally for all endemic equine virus diseases for which fees are charged. Policy advice is provided to many individuals, to commercial companies and to various state and federal governmental agencies. Funding for the CEV comes from a significant grant from Racing Victoria, from competitive grants currently including Rural Industries Research and Development Corporation and the Australian Research Council and from other industry bodies.

Cerylid Biosciences Ltd
Contact: Phone: Email: Internet: Address: Dr Jackie Fairley, Chief Executive Officer +61 3 9208 4444 Fax: +61 3 9208 4030

ACN 95 090 898 025

info@cerylid.com.au www.cerylid.com.au
576 Swan Street Richmond, VIC, 3121 Australia Cerylid Biosciences Ltd (Cerylid) was founded in January 2000 by a consortium of venture capital investors and has become one of Australia's leading unlisted public Australian biotechnology companies. Cerylid is focused on the discovery and development of novel small molecule pharmaceuticals from naturally occurring compounds which, historically, have provided the chemical foundation for over 40% of the drugs in the market and have been the origin of almost all therapeutic breakthroughs. Cerylid has assembled one of the world's largest collections of biotic samples for drug discovery; containing over 600,000 natural product extracts from over 60,000 samples of plants, marine organisms and microbes from the Australasian region. Cerylid has built a high-throughput screening (HTS) capability that incorporates several proprietary systems: a miniaturised, semi-automated dereplication process for identifying lead compounds, and disease discovery libraries that are enriched for therapeutically important bioactive compounds. Cerylid’s internal discovery program primarily focuses on anticancer drugs. The lead molecule, CBL316, is in preclinical development at the National Cancer Institute (USA) and appears to have a new mechanism of action. In addition, Cerylid has a further three exploratory leads, has identified over 2,800 natural product sample extracts which demonstrate anticancer bioactivity, and has developed a series of screens for the identification of new anticancer lead molecules. Partnerships, including with Aventis, Anadys Pharmaceuticals, Chiron and Chugai Pharmaceuticals, currently generate annual revenues of over A$5 m. Cerylid's Head Office and research laboratories are located in Melbourne, Australia where it employs over 35 staff including an established highly experienced team of research scientists with expertise in all aspects of natural products drug discovery and chemistry.

Profile:

Chem Eng Contracts Pty Ltd
Contact: Phone: Email: Internet: Address: Mr George Wild, Sales and Marketing Manager +61 3 9553 3788 Fax: +61 3 9555 7951

sales@chemeng.com.au www.chemeng.com.au
8 Simpson Street Moorabbin, VIC, 3189 Australia Chem Eng Contracts (CEC) has extensive experience and capabilities in the pharmaceutical and biotech industries. CEC has worked for over 30 different companies in this sector. CEC experience and capabilities includes: -Process scale up -Pilot Plants -Materials handling -GMP facilities -Plant Services -Process problem solving -Concept development -Project construction and management

Profile:

Chemicon Australia Pty Ltd
Contact: Phone: Email: Internet: Address: Ms Tina Sansotta, Operations Manager +61 3 9839 2000 Fax: +61 3 9887 3912

ACN 95 090 655 824

custserv@chemicon.com.au www.chemicon.com.au
34 Wadhurst Drive Boronia, VIC, 3155 Australia Chemicon Australia supplies high quality immunological reagents and molecular biology to the life science research and diagnostic industries. Based on previous experience as a manufacturer of quality research and diagnostic products, Chemicon offers a contract manufacturing service, including the manufacture, purification and conjugation of monoclonal and polyclonal antibodies. Other services available include diagnostic kit production and recombinant protein expression and bulk purification. The Chemicon site in Melbourne is approved under the Australian Therapeutic Goods Act, 1989, for the manufacture of in vitro diagnostic reagents and kits and is ISO9001 quality accredited. The Chemicon Australia product range (known as the SILENUS® range) forms an integral part of their manufactured products portfolio. The range includes monoclonal antibodies to human tissue antigens, human receptors, and miscellaneous antigens; and polyclonal antibodies to human immunoglobulins, animal immunoglobulins, human serum proteins and miscellaneous antigens. Miscellaneous products include flow cytometry products, gastroenterology products, and assay development. Other focus areas are cell biology, molecular biology, epitope tagging, and contract manufacturing. Chemicon Australia distributes and supports a range of imported agency lines to the domestic market, which are complementary and synergistic to their core product range. Chemicon Australia was formerly known as Silenus Labs Pty Ltd and Amrad Biotech. Silenus Labs Pty Ltd became a subsidiary of Chemicon International, Inc. in 1999, and began trading as Chemicon Australia Pty Ltd in May 2001.

Profile:

Chirogen Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Justus Hombuirg, CEO and President +61 405 499 905 Fax: +61 3 5227 1040

ACN 36 094 253 531

j.homburg@chirogen.com www.chirogen.com.au
215 Grattan St Parkville, VIC, 3052 Australia Chiral compounds are key ingredients for many chemical syntheses, including pharmaceuticals, plastics, fine chemicals and veterinary drugs. Chirality is the property of a compound in which a percentage of molecules are chemically identical but differ in the orientation of some key atomic groups. The chemical and biological properties of these two types of molecules are often profoundly different, necessitating separation of the two chiral isomers during production to ensure quality and minimum toxicity. Chirogen is developing technology that offers a breakthrough method of designing and synthesising chiral compounds of very high purity. The approach uses catalysts and other processes to directly produce a single chiral isomer, eliminating the requirement for a costly separation step. This offers the potential to yield larger quantities of pure chiral compounds at a much reduced cost with the potential to eliminate toxic side effects inherent in current technologies.

Profile:

Chr. Hansen Proprietary Limited
Contact: Phone: Email: Internet: Address: Mr Roy Con Foo, Chief Executive Officer +61 3 9762 9600 Fax: +61 3 9762 9700

ACN 33 007 624 811

Roy.ConFoo@au.chr-hansen.com www.chr-hansen.com
49 Barry Street Bayswater, VIC, 3153 Australia Postal Address: PO Box 591 Bayswater, VIC, 3153 Australia

Profile:

Chr. Hansen Proprietary Limited, with headquarters located in Bayswater, Victoria, is the Australian arm of a large Danish multinational group Chr. Hansen Holding A/S, one of the world's leading suppliers of natural ingredients for cheese, yoghurts, beverages, snacks, processed meats, confectionery, wine, and probiotics for human and animal health. Chr. Hansen's operations in Australia began in 1951 in Adelaide, South Australia, where the company's enzyme factory is situated. The Australian operations employ 43 highly qualified personnel in production, sales, administration, warehousing and customer service. The headquarters also supports the New Zealand office located in Hamilton. Australian-manufactured products include calf rennet and animal lipases. To promote human health, Chr. Hansen's large range of probiotics, imported from its production site in Denmark, are used in yoghurts, infant formulas and over-the-counter (OTC) capsules. An animal probiotic range is also available, and the natural feed additive BioPlus 2B was the first probiotic to achieve European Union (EU) approval. Its growth promotant properties have been well documented. Other products supplied include: cheese coagulants; lipase; cultures for dairy products; cultures for processed meats and wine; natural colours; flavours; spices and oleoresins; anti-oxidants; functional ingredients and growth promoters for animal nutrition.

Circadian Technologies Limited
Contact: ASX: Phone: Internet: Address: Mr Leon Serry, Managing Director CIR +61 3 9826 0399 Fax: +61 3 9824 0083

ACN 006 340 567

www.circadian.com.au
10 Wallace Avenue Toorak, VIC, 3142 Australia Provides funding and management expertise in biotechnology research and development.

Profile:

Clean TeQ Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Greg Toll, Director +61 3 9706 4122 Fax: +61 3 9706 4050

ACN 36 089 076 022

info@cleanteq.com www.cleanteq.com
38 Kimberly Road Dandenong South, VIC, 3175 Australia Over the past ten years, Victorian-based Clean TeQ Pty Ltd has established itself globally as a leading company in the environmental engineering and biotechnology sector. Using the latest scientific and engineering principles, it provides innovative solutions in air pollution control, water treatment, wastewater treatment and resource recovery and provides solutions for a number of diverse industry sectors, such as the mining, food, petrochemical, plastics and printing industries. The company’s focus is on biological treatment (live organisms) for odour control, wastewater treatment and remediation and advanced separation technology. Clean TeQ has developed technology based on the use of naturally occurring bacteria for the treatment of air, water and wastewater, and in resource recovery schemes for waste processing and mining. The Clean TeQ approach is to use the inherent ability of natural bacteria to provide cost-effective, environmentally sound solutions in the processing industries. Clean TeQ has designed, manufactured and installed over forty bioreactors (biological air and water pollution control systems) for the sewage treatment industry to reduce odour and toxic emissions, for the pharmaceutical and printing industries to reduce emissions of volatile organic compounds, and for the food industry to reduce odour emissions. Clean TeQ’s current focus is the use of biological augmentation to provide solutions for wastewater treatment and mining applications (when coupled to the Clean-iX® Advanced Separation Process, valuable resources can be separated and value-added products produced).

Profile:

Clear Cut Solutions Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Ian Mellier, Analyst +61 3 9787 6456 Fax: +61 3 9787 6567

ACN 24 070 758 244

ianm@clearcut.com.au www.clearcut.com.au
PO Box 865 Mount Eliza, VIC, 3930 Australia Clear Cut Solutions Pty. Ltd. provides tests and testing services for alcohol and drugs of dependency. Clear Cut Solutions offers a variety of drug-testing methods. Tests are available for analysing alcohol - passive and active breathalysers - and drugs of dependence - hair-based tests for detecting long-term or past drug use, and urine-based immunodiagnostic tests. Hair analysis for drugs of dependency is carried out by Clear Cut Solutions' US partner American Medical Laboratories, with Clear Cut Solutions providing a confidential link to that service. Unlike urine testing, hair testing can detect drug use for months or years, depending on the length of the sample. Clearcut Solutions can detect drug use in the previous 60-90 days. Hair testing has a major advantage arising from the fact that hair becomes a permanent record of drug use, whereas urine is quickly excreted from the body. Urine tests cover amphetamines, opiates (heroin), cocaine, THC (marijuana), methadone, and benzodiazepines. Saliva tests will be available soon.

Profile:

Clone International Pty Ltd
Contact: Phone: Email: Internet: Address: Dr Richard Fry, Chief Executive Officer +61 3 9397 7144 Fax: +61 3 9397 7944

ACN 81 091 414 283

rfry@cloneinter.com.au www.cloneinternational.com.au
c/- Victorian Institute of Animal Science Sneydes Road Werribee, VIC, 3030 Australia Postal Address: PO Box 544 Newport, VIC, 3015 Australia

Profile:

Clone International was founded by Dr Mal Brandon and Dr Richard Fry in 2000 to commercialise nuclear transfer or "cloning" technology in the Australasian livestock industry. Clone International has been granted the world's first licence from the USA-based Geron Corporation to use the "Dolly" nuclear transfer technology; the licence is to commercially produce cloned cattle and sheep for agricultural purposes in Australia, New Zealand and China. Clone International also has the rights to clone horses in Australia and New Zealand and to genetically modify cattle and sheep for agricultural application.

CobaltNiche Design
Contact: Phone: Email: Internet: Address: Mr Steve Martinuzzo, Managing Director +61 3 93263277 Fax: +61 3 93264399

ACN 074 499 371

steve@cobaltniche.com www.cobaltniche.com
114 Capel St North Melbourne, VIC, 3051 Australia CobaltNiche is a product development group operating across a range of industry sectors including biotech, scientific & medical instruments as well as IT electronics, transport, and consumer products. The group also offers manufacturing where required, especially for highquality, low volume quantities. The group is made up of consultant industrial designers and engineers using leading computer aided design (CAD) systems and unique creative thinking techniques. Our process ensures innovative designs and technically precise specifications or parts. Technologies and tools include: CAD systems (Pro/Engineer, Pro/Engineer Surfaces, Solidworks, CDRS) Rapid prototyping (incl. SLS, SLA, LOM) management, assembly and testing Finite Element Analysis (Strand7) Unique, ‘Lateral-3D’ creative thinking process

Profile:

Cognis Australia Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Tony Popper, Managing Director +61 3 9301 9900 Fax: +61 3 9309 9492

ACN 87 006 374 456

tony.popper@cognis.com www.cognis.com
83 Maffra Street Broadmeadows, VIC, 3042 Australia Cognis Australia Pty Ltd produces natural beta carotene from a salt water alga and markets a range of betacarotene formulations for sale to the food supplement and food colour and specialty chemicals for a variety of industries. As an independent firm in specialty chemicals, Cognis will continue to expand the core businesses and make targeted investments in new markets. Cognis products draw on the powers of nature. The Oleochemicals business offers the largest and most complete spectrum of chemical products made from natural raw materials to customers all over the world. Cognis Oleochemicals are the environmentally friendly alternative to many other chemicals still being used in industry and are based upon oils from coconut, palm, palm kernel, and soybean. The oleochemicals are converted in Victoria into speciality chemicals used in the agricultural, personal care, paint, ink, textile and lubricant industries. Cognis utilizes a highly efficient worldwide operating network with subsidiaries in close to 50 countries and with almost 10,000 employees. Its Australian headquarters is in Broadmeadows, Victoria, with the betacarotene production factory in Cheltenham, utilising algae farmed from Hutt Lagoon (Western Australia) and Whyalla (South Australia).

Profile:

CogState Ltd
Contact: Phone: Email: Internet: Address: Dr Peter Bick, Chief Executive Officer +61 3 9349 1300 Fax: +61 3 9348 2689

ACN 80 090 975 723

pbick@cogstate.com www.cogstate.com
51 Leicester Street Carlton South, VIC, 3053 Australia CogState Ltd is a Melbourne based neuroscience company with a focus on the development of diagnostics and therapeutics for early Alzheimer’s disease or mild cognitive impairment (MCI). CogState is developing a small molecule for MCI licensed from a Japanese pharmaceutical company and is also commercialising a simple computerised cognitive performance test developed by researchers from Australian universities. The computerized test takes about 15 minutes, and has found several uses in measuring the restoration of brain function in athletes who have been concussed (CogSport), and in testing pharmaceutical drug-related cognitive impairment (CogState). The test is unique in that it allows repeated measurements to be taken, so that cognitive changes can be detected and monitored. Several international pharmaceutical companies, including Pfizer, are already using the test. All 10 Melbourne-based Australian Football League teams, as well as a number of high-profile international rugby teams and other sporting organisations around the world, use the test to help make decisions about player fitness after head injuries. A product aimed at use by General Practitioners to monitor elderly patients cognitive health (CogHealth) is being developed and will be in trials by mid-2003. The company's therapeutic drug development strategy is to in-license promising candidates, take them through preclinical and early-stage clinical trials, and then out-license them for further commercialisation. The company licensed a series of small molecule drugs with agonist activity for brain angiotensin receptors from a Japanese biopharmaceutical company. These drugs target the hippocampus and appear to improve learning and memory in rats. Preclinical trials were underway in Melbourne by September 2002, and the company hopes to move this first drug product into clinical trials in 12-18 months. CogState has been backed by GBS Ventures (formerly Rothschild Bioscience) and a consortium of private investment funds. ACN 95 006 854 897 Compumedics Limited

Profile:

Contact: ASX: Phone: Email: Internet: Address:

Mr David Lawson, Chief Financial Officer CMP +61 3 8420 7300 Fax: +61 3 8420 7399

dlawson@compumedics.com.au www.compumedics.com
1 Marine Parade Abbotsford, VIC, 3067 Australia ASX-listed Compumedics Limited designs, manufactures and markets computer-based medical monitoring and diagnostic equipment and is the supplier of choice for an increasing number of leading sleep researchers, universities and hospitals around the world. In 1987, Compumedics was the first company to install computer-based sleep centres in Australasia, and its equipment is now in a number of highly acclaimed sleep centres in Australia, New Zealand, USA, Germany, Italy, Spain, France, Netherlands, Belgium, England, Scotland, India, China, Singapore, Malaysia and Japan. The majority of Compumedics' income is from export sales, although the company still has a 70% share of the Australian sleep market. All products are developed, designed, manufactured and marketed from the company's Australian headquarters in Melbourne. Products include systems for sleep disorder monitoring and analysis, neurophysiological and cardiology monitoring and analysis, telemedicine and imaging and electromyography. The Compumedics Voyager imaging system includes image viewing, image archiving and integrated physiology with video conferencing facilities.

Profile:

Connetics Australia Pty Ltd
Contact:

ACN 78 006 363 891

Mr Ross Macdonald, Vice President, Business Development, Connetics Corporation

Phone: Email: Internet: Address:

+61 3 9763 0022 Fax: +61 3 9763 0354

rmacdonald@connetics.com www.connetics.com
8 Macro Court Rowville, VIC, 3178 Australia Connetics Australia Pty Ltd (formerly known as Soltec Research Pty Ltd) has a wide range of innovative, proprietary technologies for topical and transdermal drug delivery. Products developed using Connetics Australia’s delivery technologies are sold in major markets around the world and the company has commercial alliances with many major global pharmaceutical companies. Connetics Australia’s four key technologies are: a gel delivery system for transdermal and topical delivery; dermal penetration enhancers for transdermal delivery of certain drugs; emulsion technologies for topical delivery; and aerosol mousse technologies for topical delivery. Formerly a subsidiary of Adelaide-based pharmaceutical company F.H. Faulding & Co. Limited, Connetics Australia was acquired in 2001 by Connetics Corporation, a dermatology pharmaceutical company based in Palo Alto, California.

Profile:

Cooperative Research Centre for Discovery of Genes for Common Human Diseases (Gene CRC)
Contact: Phone: Email: Internet: Address: Ms Linda Peterson, Business Manager +61 3 9208 4444 Fax: +61 3 9208 4030

genecrc@cerylid.com.au www.genecrc.org
576 Swan Street Richmond, VIC, 3121 Australia The Cooperative Research Centre for Discovery of Genes for Common Human Diseases (the "Gene CRC"), an unincorporated joint venture established under the Federal Government’s Cooperative Research Centres scheme, was established in July 1997. Its core participants include the University of Queensland’s Institute for Molecular Bioscience, the Queensland Institute of Medical Research, the Murdoch Childrens Research Institute, the Walter and Eliza Hall Institute of Medical Research, and Cerylid Biosciences Ltd. The Menzies Centre for Population Health Research is an associate participant. The Gene CRC has developed an exciting and highly competitive research portfolio, with major projects directed towards endometriosis, insulin dependent diabetes mellitus and multiple sclerosis. In addition, the Gene CRC also aims to identify genes contributing to Non-Insulin Dependent Mellitus (Type 2 diabetes), Basal Cell Carcinoma, Attention Deficit Hyperactivity Disorder (ADHD), predisposition to Melanoma and propensity for multiple ovulation/dizygotic twinning. The Gene CRC also provides post-graduate and post-qualification education for clinicians, scientists and technologists. Further, in recognition of the need for continuing education with regard to the ethical and social implications of genetic research, the Gene CRC has developed an innovative educational program, that provides accurate and topical information and discussion of the results of human genetic research.

Profile:

Cooperative Research Centre for Innovative Dairy Products
Contact: Phone: Email: Internet: Address: Dr Paul Donnelly, Chief Executive Officer +61 3 9607 8607 Fax: +61 3 9600 2044

service@dairycrc.com www.dairycrc.com
Level 1 84 William Street Melbourne, VIC, 3000 Australia The Cooperative Research Centre for Innovative Dairy Products is a joint venture funded under the Federal Government’s Cooperative Research Centre’s program. The joint venture brings six research organisations which are leaders in the genetics and reproduction of lactation into the joint venture arrangement with milk processors, commercial genetics groups and IP managers. ACN 71 094 240 776 CopyRat Pty Ltd Mr Martin Gore, CEO +61 3 9544 0033 Fax: +61 3 9594 7111

Profile:

Contact: Phone: Email: Internet: Address:

mgore@copyrat.com.au www.copyrat.com.au
C/- Monash IRD27-31 Wright Street Clayton, VIC, 3168 Australia Postal Address: C/- Monash IRD Monash Medical Centre 246 Clayton Road Clayton, VIC, 3168 Australia

Profile:

CopyRat Pty Ltd was established in August 2000 with the aim of becoming a world leading supplier of rat models of human disease to the biomedical industry and the academic community for medical research. CopyRat, located in Melbourne, Australia, is a spin out of Monash University, one of the world’s leading research institutions in embryology and stem cell research. CopyRat has exclusive rights to intellectual property and know-how developed by Monash University in the areas of rat embryology and rat stem cells. The rat is a small, low-cost animal with a short gestation period. The size of the animal allows for measurement of many physiological parameters that are not possible in its smaller relative, the mouse. As such, the rat has long been the model of choice for the biomedical industry, as well as being extensively studied by scientists for a wide range of complex diseases. Currently, a serious limitation to the use of the rat model for research has been the lack of technology to enable its genetic modification. CopyRat recognises the development of this technology is essential to produce rat models of human diseases such as diabetes, cardiovascular disease, respiratory and neurological disorders. Once developed, the rat models will play a critical role in the future development of improved treatments for these diseases. The Company’s business strategy is aimed at generating significant future revenues from products now being developed in its R&D drive to develop the first genetically modified rat.

Corryong Essential Oils Pty. Limited
Contact: Phone: Email: Address: Mr Peter Nankervis, Managing Director +61 2 6076 1460 Fax: +61 2 6076 2360

oils@corryongcec.net.au
Waters Lane Colac Corryong, VIC, 3707 Australia Postal Address: PO Box 8 Colac Corryong, VIC, 3707 Australia

Profile:

Corryong Essential Oils Pty Limited started testing small trial plots of peppermint in 1988, and started commercial production of peppermint oil in 1990. The company has levelled its 97-hectare property on the Murray River to plant enough peppermint to meet domestic and world demand. They are currently in the process of expanding their other property on the Nariel Creek. The extracted peppermint oil is of the highest quality, and 99% of the production is sold to the American market. The oil is mainly used as food flavouring, and in products such as biscuits, toothpaste and chewing gum, with small amounts being used for aromatherapy and beauty treatments.

Cottee International Pty. Limited
Contact: Phone: Email: Internet: Address: Mr Doug Parrish, CEO +61 3 9278 7555 Fax: +61 3 9369 6730

ACN 11 085 855 803

dougp@pharmaction.com.au www.cotteehealth.com.au
73-83 Cherry Lane Laverton North, VIC, 3026 Australia Cottee International operates in purpose designed facilities in Melbourne, Australia. All activities and manufacturing are consistent with the international standards of Good Manufacturing Practice (GMP). The company offers a comprehensive range of services to the pharmaceutical and health industries. These include: (1) Contract manufacturing and packaging to a world class standard: Cottee has a Therapeutic Goods Administration (TGA) licence to manufacture sterile or pack nonsterile therapeutic goods and complementary and alternate medicines for human use. The company has an extensive portfolio of formulations that are available and ready to take to market in value-added finished product form; (2) Sourcing and supply of complementary and alternate medicines: Cottee is able to supply formulations in bulk. Cottee is also a primary source of supply for many high demand raw materials such as shark cartilage, glucosamine and BSE-free chondroitin; (3) A complete range of technical services to manufacturing and packaging: Cottee has a primary responsibility to ensure that all aspects of new and changed products are successfully transferred to operations from Cottee Product Development or, as a contract manufacturer, from other complementary and alternate medicines companies. The Technical Services/Quality Assurance Group performs the full service quality control and quality assurance function for Cottee; (4) Product Development: This involves the formulation, process development, and stability testing of therapeutic products from pre-formulation to marketing, including the development, validation and registration or listing of all formulations. It also involves analytical development, which supports the pharmaceutical development and manufacturing activities, including the selection, development and validation of methods for drug products. Other services include clinical trials, formulation, pilot batch manufacture and stability testing to support registration of products.

Profile:

CRC for Cellular Growth Factors
Contact: Phone: Email: Internet: Address: Ms Roslyn Clark, Executive Officer (03) 9345 2559 Fax: (03) 9345 2616

crccgf@wehi.edu.au www.ludwig.edu.au/CRC-CGF/
The Walter and Eliza Hall Institute 1G Royal Parade Parkville, VIC, 3050 Australia The Cooperative Research Centre for Cochlear Implant and Hearing Aid Innovation conducts innovative research leading to new hearing technology such as cochlear implants with increased capabilities and improved cosmesis, totally-implantable neuroelectric and acoustic hearing prostheses, intelligent digital hearing aids for those with mild and moderate hearing losses, and advances in speech intelligibility and noise reduction algorithms and techniques for use in hearing prosthetics or communications applications.In addition, the Centre also provides a range of postgraduate research programs in hearing and communication science. It is actively developing new approaches to expand professional training in the field and to make this accessible to geographically isolated regions.A comprehensive technology transfer strategy ensures that research and educational outcomes result in improved communication benefits for hearingimpaired people and increased skills in the Australian workforce.

Profile:

CRC for Cochlear Implant and Hearing Aid Innovation
Contact: Phone: Email: Internet: Address: Dr Robert Cowan, Director/Chief Executive Officer +61 3 9667 7500 Fax: +61 3 9667 7518

r.cowan@unimelb.edu.au www.bionicear.com.au/crc
384 Albert St East Melbourne, VIC, 3002 Australia The CRC has Federal Government funding of $14.2 million over seven years from July 1999, with commitments of a further $57 million from other participants. Research is focussed in several major disciplines: Bioengineering – aimed at determining how to structure new electrode arrays with improved control and higher capacity using new materials and fabrication techniques; Electrochemistry – aimed at understanding the electroneural environment in the auditory organs, and how to best utilise and manage the electrochemical tissue interface; Electrophysiology – investigation of objective means of programming hearing devices in infants and young children;BioSafety and Surgery – investigating the biosafety of electrical stimulus parameters and new materials, and surgical technique for placing advanced miniature devices. Advanced Habilitation and Training Programs – aimed at improving the performance of children using the cochlear implant or hearing aids through integration of new information into their speech and language repertoires. Clinical Procedures – aimed at improving the efficiency and effectiveness with which clinicians provide rehabilitation and habilitation using hearing aids and cochlear implants.

Profile:

CRC for MicroTechnology
Contact: Phone: Email: Internet: Address: Mr Clive Davenport, Chief Executive Officer +61 3 9214 8557 Fax: +61 3 9214 8008

clive.d@microtechnologycrc.com www.microtechnologycrc.com
Level 5 60 William Street Hawthorn, VIC, 3122 Australia Postal Address: PO BOX 218 Hawthorn, Victoria, 3122 Australia

Profile:

The CRC for MicroTechnology was formed in 1999. The CRC for microTechnology has a total budget of A$64 million, A$17 million of which is core Federal government funding. Through its participants, it has access to existing top-class research facilities, a pool of talented staff, built-in international networks and both industrial and academic background IP. The management structure is designed to encourage commercial outcomes by maximising support for the R&D programs, business development and technology transfer. Protective mechanisms exist for the participant’s IP through a bare trust company. Feedback from independent technical and advisory panels is built into the Centre management structure. The CRC has a governing board to oversee all aspects of its activities and a full-time Chief Executive Officer.

CryoLogic Pty. Ltd.
Contact: Phone: Email: Internet: Address: Dr Willem Lindemans, Research Director +61 3 9574 7200 Fax: +61 3 9574 7300

enquiry@cryologic.com www.cryologic.com
54 Geddes Street Mulgrave, VIC, 3170 Australia A Victorian based company, CryoLogic Pty. Ltd. is located in the South Eastern Melbourne metropolitan region, where it develops and manufactures biomedical instruments for a world-wide market. CryoLogic is dedicated to providing innovative solutions to instrumentation, measurement and control problems in medical, veterinary and biological sciences. Its goal is to deliver functional, reliable, and affordable equipment. Its FREEZE CONTROL® range of portable, controlled-rate cryo-preservation systems have been in use since 1985. They make a significant contribution to assisted reproduction (human IVF, domestic animal ET), and to conservation and gene banking, and facilitate research in microbiology, oncology, endocrinology, plant breeding, and aquaculture. Other controlled temperature products have been developed for specific applications and are supplied under the name BioTherm™. These include portable incubators for long distance transport of biological material, and microscope warm stages. Cryologic has also developed a cell fusion system, the Voltain™ EP-1. This equipment is used for the cloning of embryos, propagation of stem cells, production of hybridomas, and transgenic perfusion. The company maintains an active research and development program, provides customisation services, and develops new products in consultation with clients. A recent development was an incubator used for transportation of cells to, and for use in, the International Space Station. CryoLogic actively markets its products world wide and has representatives in 30 countries. All equipment is backed by a two-year warranty.

Profile:

Cryptopharma Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Charlie Day, Company Secretary +61 3 8344 5675 Fax: +61 3 8344 0241

ACN 77 094 788 897

astew@clyde.its.unimelb.edu.au www.pharmacology.unimelb.edu.au/pharmwww/LungInflamm.html
c/- Melbourne University Private 215 Grattan Street Parkville, VIC, 3052 Australia Cryptopharma was established in 2000 to focus on targeted delivery of novel pro-drugs for cancer and inflammation. The underlying concept is that Cryptopharma’s pro-drug remains inactive until in the vicinity of the target cancer or inflammatory site, where an enzyme there cleaves the link between the drug and the protective carrier, releasing the active drug at the site where it is needed. Normal tissues do not produce enough of the enzyme to release the drug - it is only released at the diseased site. Cryptopharma has coined the term ‘homeokinetics’ for this concept. In the first instance, Cryptopharma is developing pro-drugs of novel steroid analogues for therapeutic use to treat solid tumours and chronic inflammatory diseases. This class of estrogenrelated agents has demonstrated efficacy in extensive preclinical studies of three separate conditions: solid tumour growth, collagen-induced arthritis, and chronic asthma pathology. An active compound related to those being used by Cryptopharma, 2-methoxyestradiol, has been approved by the US Food and Drug Administration (FDA) for trial in breast cancer. Cryptopharma filed a PCT patent application 14 October 2000. Cryptopharma’s senior investigators have an established track record of collaboration on projects with commercial focus. They work extensively with industry and have succeeded in bringing products to clinical use. Expertise includes project management, organic chemistry, preclinical pharmacology and medicinal chemistry. The infrastructure available is world class.

Profile:

CSIRO Health Sciences and Nutrition
Contact: Phone: Email: Internet: Address: Dr Megan Fisher, Business Development Manager +61 3 9662 7100 Fax: +61 3 9662 7101

megan.fisher@csiro.au info@hsn.csiro.au www.hsn.csiro.au
343 Royal Parade Parkville, VIC, 3052 Australia Our focus is on the improvement of human well-being and community health, whilst enhancing the competitiveness of the Australian food, food-related pharmaceutical and pharmaceutical industries. Our research addresses the prevention of disease, treatments and diagnosis. Current programs are: Gastrointestinal Health and colon cancer, Consumer Science, Diagnostic and Therapeutic Technologies, Protein and Pharmaceutical Sciences, Structural Biology, Nutrition Clinic.

Profile:

CSL Limited
Contact: ASX: Phone: Email: Internet: Address: Mr Brian McNamee, Managing Director CSL +61 3 9389 1911 Fax: +61 3 9389 1434

ACN 99 051 588 348

brian_mcnamee@csl.com.au www.csl.com.au
45 Poplar Road Parkville, VIC, 3052 Australia Australia’s largest biotechnology company, CSL Limited, was established in 1916 to produce vaccines and sera for diseases such as diphtheria, smallpox, tetanus, cholera, plague, whooping cough and influenza. CSL develops, manufactures and markets pharmaceutical products of biological origin. Operating in the field of health care, CSL focuses on three main areas: - Life-saving products derived from human plasma - Pharmaceuticals and diagnostics essential to community health - Animal health vaccines and diagnostics to protect livestock and companion animals CSL's operations are divided into four business divisions: - CSL Pharmaceuticals - CSL/ZLB Bioplasma - CSL Animal Health - JRH Biosciences, Inc. (based in Kansas USA) In 2000, CSL completed the A$696-million acquisition of the plasma fractionation assets and business (ZLB) of Rotkreuzstiftung Zentrallaboratorium Blutspendedienst SRK, a foundation of the Swiss Red Cross. ZLB has the only FDA-approved plasma products plant outside the USA, and provides CSL access to the US plasma products market. The deal places CSL among the top four plasma processors globally. CSL has begun to build a new US subsidiary, ZLB Bioplasma Inc., based in Los Angeles. CSL is the largest investor in Australian pharmaceutical research and development, and one of the largest employers in Australia's pharmaceutical manufacturing industry. Products from CSL’s state-of-the-art blood plasma processing facility are used to treat bleeding disorders, for emergency trauma situations such as shock due to acute blood loss, and for preventing severe infections. Uniquely, CSL can process plasma from a country, and return it as finished products to the country of origin.

Profile:

Cytopia Pty Ltd
Contact: Phone: Email: Internet: Address: Dr Kevin Healy, Interim CEO +61 3 9522 6900 Fax: +61 3 9510 9292

ACN 14 082 492 680

cytopia@cytopia.com.au www.cytopia.com.au
Level 5, Baker Heart Research Institute Building Commercial Road Melbourne, VIC, 3004 Australia Postal Address: PO Box 6492, St Kilda Road Central Melbourne, VIC, 8008 Australia

Profile:

Cytopia is a privately-held Australian drug discovery company with a focus on cancer and inflammatory diseases such as asthma, rheumatoid arthritis, allergic rhinitis (hay fever), food allergy, and inflammatory bowel disease. As an adjunct to its high throughput screening facility and its medicinal chemistry capability, Cytopia is developing proprietary computer-based technology which allows large chemical collections to be tested for their ability to bind to any drug discovery target. Chemicals which are specifically active may be able to prevent certain inflammatory diseases. Cytopia has recruited a core group of highly qualified and experienced scientists and established a well-equipped laboratory in Melbourne. Cytopia has worked predominantly on the protein kinase family, with particular focus on members of the JAK family of protein tyrosine kinases. Cytopia has obtained worldwide exclusive rights to develop and commercialise technology relating to this family of kinases. Members of the JAK family of PTKs are critical for important cellular control mechanisms downstream of all cytokine receptors, and are excellent targets for drug discovery for diseases of the immune system and cancer. The goal of the Cytopia drug discovery program is to discover novel bioactive compounds from chemical libraries generated by means of intelligent use of combinatorial chemistry. In addition to the five granted US and Australian patents on the drug targets, Cytopia has filed five additional patents relating to new drug-like molecules that can be used to treat cancer and immune disease. Cytopia was established in 1998, and is 79% owned by Medica Holdings Limited, a Pooled Development Fund specialising in investments in the biotechnology sector.

Cytoscreen Pty Ltd
Contact: Phone: Email: Address: Dr Labrini Nassis, Consultant +61 3 8665 5274 Fax: +61 3 9639 8255

ACN 47 100 286 486

labrini@berthold.com.au
Level 4 257 Collins Street Melbourne, VIC, 3000 Australia Cytoscreen offers a new screening service for pharmaceutical companies seeking more timely and cost-efficient ways to screen chemical compounds that may be used in the treatment of cancer. Intellectual know-how and expertise from the Peter MacCallum Cancer Institute provides a competitive advantage to pharmaceutical companies, who currently spend at least US$350 million to successfully produce one new drug. The screening technology is a new approach in elucidating drug functionality that can reduce this cost of drug development by reducing time cycles or increasing the stringency of selection.

Profile:

Deakin University
Contact: Phone: Email: Internet: Address: Ms Alison Hadfield, Director Research Services 03-52272835 Fax: 03-52271275

Alison.Hadfield@deakin.edu.au www.deakin.edu.au
Pigdons Road Waurn Ponds, VIC, 3217 Australia

Dendritic Nanotechnologies, Inc.
Contact: Phone: Email: Internet: Address: Mr Tim Grogan, Director +61 3 9522 4391 Fax: +61 3 9521 1433

ACN 87 097 725 927

grogan@dnanotech.com www.dnanotech.com
Level 1, Old Baker Building Prahran, VIC, 3081 Australia Postal Address: PO Box 6535 St Kilda Road Central, VIC, 8008 Australia

Profile:

Dendritic Nanotechnologies Limited (DNT) was established in a venture between Starpharma Limited and Donald A. Tomalia, Ph.D., the President and Chief Technical Officer of DNT and pioneer of dendrimer technologies [see Starpharma entry]. DNT has a head office in Melbourne, Australia, and a laboratory and manufacturing facility in the Center for Applied Research and Technology at Central Michigan University (CMU), Mt Pleasant, Michigan, USA. DNT was established: - to design, manufacture and consistently supply a range of high quality dendrimers to customers/partners interested in the use of dendrimers for a broad range of research and commercial applications; and - to conduct research into novel dendrimer types and architectures. Dendritic compounds are a unique new class of synthetic nanostructure that allow for precise control of size, shape and functionality. Dendrimers may be used as macromolecular platforms suitable for a wide range of applications in nanotechnology (eg nano-drugs, drug delivery, diagnostics, nano-optics and electronics).

Dendy Pharmaceuticals Pty. Ltd.
Contact: Phone: Email: Address: Mr Avi Jaworowski, Managing Director +61 3 9591 0202 Fax: +61 3 9592 5335

ACN 32 007 180 985

dendyok@aol.com
752 Hampton Street Brighton, VIC, 3186 Australia Dendy Pharmaceuticals Pty. Ltd. supplies a range of laxatives and dental products to hospitals and gastroenterologists, surgeons, radiologists and dentists. Products are manufactured in Victoria and NSW under contract.

Profile:

Diagnostic Solutions Pty Ltd
Contact: Phone: Email: Internet: Address: Ms Elly de Gooyer, Managing Director +61 3 9817 7222 Fax: +61 3 9817 7200

ACN 13 081 347 319

Info@diagsolns.com.au www.diagsolns.com.au
74 Whitehorse Road Balwyn, VIC, 3103 Australia Postal Address: P.O. Box 702 Balwyn, VIC, 3103 Australia

Profile:

Diagnostic Solutions Pty Ltd imports and distributes diagnostic kits and reagents for the pathology laboratory market. Products distributed include kits and reagents for the diagnosis of a wide range of autoimmune diseases and quality control products for the haematology, immunology and flow cytometry markets. Suppliers include Immuno Concepts Inc., Aesku Diagnostics, Biomedical Diagnostics (BMD) and Streck Laboratories. Established in 1998, the company is based in Balwyn, in the eastern part of Melbourne.

Diamed Pty Ltd
Contact: Phone: Address: Ms Carol Braussard, PA to CEO (03) 8532 2700 14 Palmer Court Mt Waverley, VIC, 3149 Australia

ACN 050 104 875

DNA Solutions Pty. Ltd.
Contact: Phone: Email: Internet: Address: Mr Vern Muir, Managing Director +61 3 9800 1550 Fax: +61 3 9800 1792

ACN 37 085 282 855

dnanow@dnanow.com www.dnanow.com
2 / 23 Wadhurst Drive Boronia, VIC, 3155 Australia DNA Solutions offers: - Paternity testing services - Human relationship testing - Veterinary pathology DNA Solutions has assisted a third-world government in DNA laboratory set-up, design and training. The company’s DNA profiling systems are designed to be the most cost-effective system, with the lowest cost to implement, without loss of accuracy or reliability. DNA Solutions at mid-2002 is researching new fast diagnostic DNA tests.

Profile:

Dornier MedTech
Contact: Phone: Email: Internet: Address: Mr Michael Fehrmann, Managing Director +61 (0)418 354 626

fehrmann@ozemail.com.au www.dornier.com.au
3 Molan Street Ringwood, VIC, 3134 Australia Postal Address: PO Box 4230 Ringwood, VIC, 3134 Australia

Profile:

Dornier MedTech supplies therapeutic equipment, especially litotripsy and shockwave equipment for urology and orthopaedics. Other product areas include ultrasound equipment for urology, radiology and cardiology. Furthermore, the company supplies a range of surgical lasers for general surgery, urology and cosmetics. Equipment includes the Lithotripter S, Compact Alpha, Compact Delta, Epos, Medilas D, Medilas H and Fibertom Yag Laser. The company has a strong technical service background and offers coverage Australia wide.

Dynamic Hearing Pty Ltd
Contact: Phone: Email: Internet: Address: Dr Elaine Saunders, Chief Executive Officer +61 3 8420 8500 Fax: +61 3 8420 8599

ACN 16 098 878 212

esaunders@dynamichearing.com.au www.dynamichearing.com
2 Chapel Street Richmond, VIC, 3121 Australia Dynamic Hearing is a start-up company that aims to be a market leader in the development of advanced technology software applications for the emerging digital hearing aid industry. The company's first product is called ADRO™; advanced digital signal processing software, which produces improved speech perception for hearing aid users. Dynamic Hearing is a spin off from the CRC for Cochlear Implant and Hearing Aid Innovation, the core parties of which are the Bionic Ear Institute, University of Melbourne, Cochlear Ltd and Australian Hearing Services. Some of the brightest minds in audiological research and engineering have joined the Dynamic Hearing team. The company is dedicated to the pursuit of simple, innovative and highly effective solutions to the many challenges presented in interpreting the world of sound. Nanyang Ventures and GBS Ventures have both invested $2 million in Dynamic Hearing

Profile:

E.M.L. Consulting Services Proprietary Limited
Contact: Phone: Email: Internet: Address: Mr Peter Ogier, Victorian State Manager +61 3 9836 1999 Fax: +61 3 9836 0808

ACN 71 006 308 774

peter.ogier@eml.com.au www.eml.com.au
431 Canterbury Road Surrey Hills, VIC, 3127 Australia EML Consulting Services is an industrial microbiological laboratory specialising in testing and consultancy services for the pharmaceutical, medical devices, cosmetics, food and water industries. The laboratory is accredited by the National Association of Testing Authorities (NATA). EML Consulting Services’ key expertise includes the regulated testing of pharmaceuticals, including antibiotic assays and LAL bacterial endotoxin testing. EML Consulting Services has Therapeutic Goods Administration (TGA) registration for testing pharmaceuticals and medical devices and is quality system certified to ISO 9002. The company’s aim is to provide quality microbiology in a cost-effective manner by tailoring services to meet the client’s microbiological needs.

Profile:

EcoEarth Technologies
Contact: Phone: Email: Internet: Address: Mr Michael Burton, Managing Director +61 3 5265 6009 Fax: +61 3 5265 621

ACN 56 069 788 030

bwgroup@datafast.net.au www.ecoearthtechnologies.com.au
1565 Barrabool Road Gnarwarre, VIC, 3221 Australia EcoEarth Technologies is in the business of developing, manufacturing and marketing of naturally biodegradable polymer products as alternatives to plastics. The company can offer commercially viable environmentally sound biodegradable compostable alternatives to most disposable plastic products used in society today, such as plastic bags, and disposable packaging of any kind in the fields of commercial domestic use, agriculture, horticulture, medical and pharmaceutical. EcoEarth Technologies specialises in realising a new biodegradable plastic product or application envisioned by the customer. The new product can be processed using the same machines currently used to produce conventional plastics. The only difference is that the EcoEarth Technologies product biodegrades and composts after use, leaving no ecotoxicological effect on terrestial or aquatic life. Some examples of biodegradable disposable products are: all types of bags, plant pots, meat trays, cutlery and crockery, nappies (diapers), sanitary ware, bottles, jars and tubs, cups, food and packaging wrap, tree guards, snack and sweet wrappers, bale twine and strings, and mesh sacks. In fact, anything made as blown film, injection moulded, thermoformed, extruded or expanded may be created in biodegradable polymer products. The company’s marketing objective is to permanently replace plastics in all areas of use in society, with EcoEarth Biodegradable environmentally sustainable products.

Profile:

Eiffel Technologies Limited
Contact: ASX: Phone: Email: Internet: Address: Ms Christine Cussen, Chief Executive Officer EIF +61 3 9629 8022 Fax: +61 3 9629 8077

ACN 96 072 178 977

c.cussen@eiffeltechnologies.com.au www.eiffeltechnologies.com.au
Level 14 50 Market Street Melbourne, VIC, 3000 Australia Eiffel Technologies Limited, is listed on the Australian Stock Exchange. Its research and commercilisation activities are conducted by its' wholly owned subsidiary company Eiffel Research & Development Pty Ltd. which specialises in pharmaceutical particle architecture and drug reengineering. This involves the development and commercialization of a range of internationally competitive drug re-engineering and delivery technology platforms in conjunction with the international pharmaceutical and biotechnology industries. This technology can be used to modify pharmaceuticals to improve their effect and absorption, and to administer them in a more convenient way, such as once a day, long-acting sustained release formulations, and replacement of injections by inhalational drug delivery. The technologies can also be used to re-engineer biopharmaceuticals to improve absorption, bioavailability, and mode of administration. Eiffel Technologies’ suite of supercritical fluid technology platforms offers lifecycle management to the pharmaceutical and biotechnology industries by reformulating new drugs and extending the patent life of currently marketed drugs. For pharmaceuticals that are due to experience generic competition, Eiffel Technologies’ proprietary technology platforms includes particle sizing and engineering; drug encapsulation; implantation; and separation of optical isomers. Eiffel's research facilities are based at the Department of Chemical Engineering at the University of New South Wales. ACN 34 091 996 575 Emeritus Research Pty Ltd

Profile:

Contact: Phone: Email: Internet: Address:

Mrs Gail Grant, Clinical Project Manager +61 3 9832 0700 Fax: +61 3 9832 0701

gailgrant@emeritusresearch.com www.emeritusresearch.com
Suite 210 19 Milton Parade Malvern, VIC, 3144 Australia Emeritus Research is a Site Management Organisation (SMO) managing a network of clinical investigators in the primary care and private specialist setting, focusing on improving the quality, uniformity and efficiency of clinical trial conduct through centralised site management and the provision of staff and services. The principal objective of Emeritus Research's business model is to accelerate drug and medical device development by quickly identifying investigator sites that have access to an adequate number of the desired patients and rapidly initiating studies at these sites. Emeritus Research, through its central organisation, provides a 'one stop shop' for companies wishing to conduct clinical trials. Emeritus Research offers to clients: • Standard Operating Procedures (SOPs) • Multiple sites • Patient database numbering 350,000 • Single budget • Single contract • Single HREC submission • Central project management • Enhanced site management • Trained Clinical Research coordinators (CRCs) • Quality data

Profile:

Enecon Pty. Ltd.
Contact: Phone: Email: Internet: Address: Mr Colin Stucley, Managing Director +61 3 9817 6255 Fax: +61 3 9817 6455

ACN 34 006 087 494

mail@enecon.com.au www.enecon.com.au
Level 2 35 Whitehorse Road Deepdene, VIC, 3103 Australia Postal Address: PO Box 555 Deepdene DC, VIC, 3103 Australia

Profile:

Enecon Pty Ltd (Enecon) is involved in project development through the provision of innovative technology and engineering, with a particular focus on the utilisation of biomass such as plantation grown trees and timber industry wastes: - to provide renewable energy, as an alternative to energy from fossil fuels - to manufacture value-added products from biomass - principally activated carbons for applications such as water treatment, and charcoal for energy or for industry. Enecon offers state-of-the-art technology for recovery of carbon products and energy. This technology has been developed by the CSIRO in Australia and is now licensed exclusively to Enecon for commercialisation worldwide. Enecon offers practical engineering skills and commercial experience for the development of sustainable projects and industries in Australia and overseas, and its engineers are familiar with a wide range of technologies for energy and for biomass co-products. Services to help develop new projects range from pre-feasibility studies through to design, construction, commissioning and product marketing. Enecon is based in the Eastern suburbs of Melbourne in the State of Victoria, Australia, approximately 10 km east of Melbourne's central business district. ACN 11 004 395 242 Ensign Laboratories Proprietary Limited

Contact: Phone: Email: Internet: Address:

Mr Peter Thornborrow, Managing Director +61 3 9550 1500 Fax: +61 3 9560 5545

ensignlab@ensignlab.com.au www.ensignlab.com.au
490 Wellington Road Mulgrave, VIC, 3170 Australia Postal Address: PO Box 268 Glenways MDC Mulgrave, VIC, 3170 Australia

Profile:

Ensign Laboratories is a wholly owned private Australian company operating as custom and contract manufacturing chemists. It employs around 260 people, and operates from three sites in the Melbourne area. The head office is located on a 3.5-hectare site at Mulgrave. It has been operating since 1955. Ensign Laboratories is involved in the formulating and filling of a complete range of aerosol products, including therapeutics, personal care, sunscreen and suncare, veterinary, household, home garden, automotive, and industrial products. The company is TGA-licensed for non-sterile therapeutic goods and devices; is US FDA registered; is NRA-licensed to produce veterinary preparations; and holds a Dairy Food Safety Victoria licence covering the manufacture of dairy foods. It is also ISO 9002 certified. Ensign Laboratories operates a substantial product research and development facility involved in the development of a wide range of products: personal care, sunscreen, household (including detergents), and topical therapeutics. The customer base includes multinational and national brand owners, including leading supermarket chains, for which Ensign provides product development services such as product registration, stability testing and validations as necessary. During almost 50 years of activity, Ensign Laboratories has achieved international recognition for technical competence and service.

Environmental and Resource Technology Holdings (EARTH) Pty. Ltd.

ACN 40 052 326 744

Contact: Phone: Email: Internet: Address:

Mr Howard Mitchell, Chief Executive Officer 1300 301 691 Fax: +61 3 9551 2030

info@enviromix.com.au www.enviromix.com.au
Lot 2 Grange Road Dingley Village, VIC, 3172 Australia EARTH is a biotechnology company that produces horticultural growing media and allied products from waste vegetation using a patented microbiological process. EARTH solves the waste disposal problems and costs involved with a substantial component of the solid waste stream by recovering waste vegetation and producing quality topsoil equivalents, potting mixtures, mulches and allied products for home garden, landscaping and horticultural use. EARTH has developed its first regional bioconversion facility at Dingley in Southern Melbourne (ENVIROMIX™ Southern Melbourne) under licence and intends to establish other regional licensed facilities throughout Australia and internationally. ACN 14 069 201 752 Environmental Biotech (Systems) Pty. Limited

Profile:

Contact: Phone: Email: Internet: Address:

Mr Ted Fritz, Managing Director +61 3 9318 0996 Fax: +61 3 9318 0702

ebsaustralia@hotmail.com www.environmentalbiotech.com.au
32 Westside Drive North Laverton, VIC, 3026 Australia Environmental Biotech is a bioremediation company that manufactures and distributes proprietary non-pathogenic bacteria that have been isolated and developed to eradicate grease, fats, oils, starches and gelatin, especially the kind found in restaurants, hotels, hospitals, and other foodprocessing facilities. Environmental Biotech solves the operation problems experienced in these facilities due to these waste products. These problems include grease-related drain-line blockages which are endemic in the industry, rancid odour problems from smelly drains, disposal of waste, and the reduction of high strength waste water which often attracts government fines and surcharges. As the microorganisms eat the waste and convert much of it into carbon dioxide and water, these problems are reduced. Less waste means less landfill application and that is also good for the environment. Environmental Biotech is a complete services company that has trained service technicians who regularly service customers' drain systems, including the replenishment of the active bacteria.

Profile:

Enzyme Solutions Pty. Ltd.
Contact: Phone: Email: Internet: Address: Mr Geoff Bearzatto, Chief Executive Officer +61 3 9761 7999 Fax: +61 3 9761 7899

ACN 75 847 896 228

geoff@enzymesolutions.com.autom@enzymesolutions.com.au www.enzymesolutions.com.au
26 Research Drive Croydon South, VIC, 3136 Australia Enzyme Solutions Pty Ltd was established in 1997 in Melbourne. Enzyme Solutions is the Australia-based representative for both Genencor International, Inc. and Valley Research, Inc., and exports to six other countries. Enzyme Solutions is ISO 9001-2000 certified and is involved in sales and distribution of enzymes for many industries including grain processing, dairy, cleaning, wine and fruit juice production, brewing, baking, pharmaceutical, feed, paper, and waste treatment. The cornerstone of the business philosophy of Enzyme Solutions is technical support, which involves helping customers with enzyme selection, trials and process optimisation. Enzyme Solutions develops products locally to suit the market requirements and has registered the trademarks Optivin, Optibrew, Solvabrew and StarClear. ACN 88 089 644 119 EpiTan Limited

Profile:

Contact: ASX: Phone: Email: Internet: Address:

Dr Wayne Millen, CEO / Managing Director EPT +61 3 9662 4688 Fax: +61 3 9662 4788

mail@epitan.com.au www.epitan.com.au
Level 10 52 Collins Street Melbourne, VIC, 3000 Australia EpiTan Limited is an emerging biotechnology company with a pre-eminent position on the prevention of DNA & skin damage from ultra-violet (UV) radiation exposure. Based in Melbourne, Australia, EpiTan holds a unique technology platform centred on its leading drug candidate Melanotan. The company has the exclusive worldwide rights to develop Melanotan, which, like sunlight, stimulates the production of melanin in the skin resulting in a tan. It allows a tan to develop without exposure to harmful levels of UV light. Melanotan is currently in Phase IIb clinical trials at two sites – the Royal Prince Alfred Hospital in Sydney and the Royal Adelaide Hospital. These trials are designed to demonstrate that Melanotan can reduce the incidence of skin damage resulting from harmful exposure is ultra-violet light. EpiTan has now successfully developed a more user-friendly drug delivery formulation of Melanotan in the form of a slow release implant. This will be used in the remaining clinical programme and the commercialized product. EpiTan is also investigating Melanotan as a therapeutic agent for other indications such as vitiligo, albinism, psoriasis and various recognised sun allergies such as polymorphous light eruptions and solar urticaria. Potential markets worldwide for Melanotan for dermatology purposes are estimated at US$1.5 billion. An even greater market (more than US$5 billion) exists for Melanotan as a new safe (sunless) tanning drug. EpiTan’s commercialization strategy recognizes the need for strategic partnerships with other larger pharmaceutical companies and drug delivery companies. By entering licensing agreements at the appropriate times, EpiTan aims to maximize its potential for developing novel products in a wide variety of prophylactic and therapeutic areas.

Profile:

Epitope Technologies Pty. Ltd.
Contact: Phone: Email: Address: Mr Stephen Wilson, Business Development Manager +61 3 9315 6035 Fax: +61 3 9315 6006

ACN 88 075 293 775

epitope@office.net.au
Level 3 IBM Centre 60 City Road Southbank, VIC, 3006 Australia Epitope Technologies Pty Ltd is developing products for the immunodiagnostic reagents industry manufacturing, custom production and distribution. Epitope is working with various institutions to produce and market several sheep cytokine products that can be used in immunoassays (ELISA). Epitope is marketing these products through OEM (original equipment manufacture) arrangements in Europe and the USA. The company also markets a number of monoclonal and polyclonal antibodies for flow cytometry for clinical and research applications. Epitope has recently entered into the rapid test area and is currently marketing a range of infectious disease tests. The company also markets a rapid test for the cardiac marker Troponin I. Epitope benchmarks potential products and carries out market research through its extensive international network. Within Australia, Epitope distributes imported niche products.

Profile:

ES Cell International Pte Ltd
Contact: Phone: Email: Internet: Address: Ms Jane Halprin, Executive Officer +61 3 8532 1777 Fax: +61 3 8532 1771 jhalprin@escellinternational.com, contactus@escellinternational.com

ACN 32 097 482 632

www.escellinternational.com
4th Floor, Baker Medical Research Institute Commercial Road Prahran, VIC, 3181 Australia Postal Address: PO Box 6492 St Kilda Road Central Melbourne, VIC, 8008 Australia

Profile:

ES Cell International Pte Ltd (ESI) is a regenerative medicine company and a leading provider of products and technologies derived from human embryonic stem (hES) cells. ESI is developing a robust hES cell technology platform and an extensive intellectual property portfolio, building on established expertise in the area of hES cells and their directed differentiation. ESI is maintaining a pre-eminent position through the development, protection and dominance of manufacturing processes for hES cells and their progeny. ESI is achieving early commercial returns through the provision of cell lines and technologies to global research and therapeutic markets. ESI owns six of the hES cell lines listed on the USA's National Institutes of Health (NIH) Stem Cell Registry, and distributes its cell lines throughout the world, including the NIH's considerable network of stem cell researchers. SI is concentrating its therapeutic development resources on generating cell replacement therapies for insulin-dependent Diabetes and Parkinson's disease sufferers. In both cases there is a significant unmet clinical need, and a considerable commercial opportunity. ESI aims to be in clinical trials with its first therapeutic development candidate by 2006.

EvoGenix Pty Limited
Contact: Phone: Email: Internet: Address: Dr Merilyn Sleigh, Chief Executive Officer +61 3 9662 7170 Fax: +61 3 9662 7171

ACN 33 097 483 068

business@evogenix.com.au; m.sleigh@evogenix.com.au www.evogenix.com.
343 Royal Parade Parkville, VIC, 3052 Australia EvoGenix Pty Limited is developing platform technologies for optimising the value of proteins as pharmaceuticals and diagnostic agents. EvoGenix has laboratories in Melbourne and an administrative office in Sydney. EvoGenix operates within the rapidly growing biopharmaceutical sector, with a focus on protein therapeutics. There is an increasing number of highly successful products in this area, with markets exceeding US$ 1 billion annually. Current annual growth in the protein therapeutics market is around 15%, driven by introduction of new products as well as increased sales of existing products. Each new product in development is a candidate for optimisation via the EvoGenix technology platform. EvoGeneTM Technology developed by EvoGenix provides a method for protein drug developers to rapidly assess many variants of a natural protein, to find the ideal product candidate which combines high activity and specificity with capacity for efficient production, without damaging the inherent benefits of the starting protein. The technology thus provides the potential to overcome key disadvantages which have previously deterred many companies, particularly the larger pharmaceutical companies, from developing protein products. EvoGene is a process of “directed evolution”, an iterative process where at each step, protein variants (mutants) are created. Those with an improvement in the desired properties are selected as the starting point for the next round of mutation and selection until the required profile of properties for a product candidate is achieved. The competitive advantage of EvoGeneTM Technology lies in its speed in both generating and then selecting from an enormous range of protein variants. By combining efficiency and effectiveness, it can enhance the potential for clinical and commercial success of a product without a major additional burden in time and resources. The EvoGenix technology package is patent protected, and does not infringe patents held by other parties. As a process for directed evolution of proteins, EvoGene technology will be most effective for fine tuning of protein properties, used alone, or in combination with other protein evolution approaches. The technology has demonstrated impressive results in the improvement of antibody affinity and enzyme activity in model systems. EvoGenix is now applying its technology for protein improvement via two different avenues • In commissioned projects from biotechnology and pharmaceutical companies, where EvoGenix will identify improved versions of product candidates, for example an anticancer antibody with increased binding to its target cell, the greater activity resulting in a lower dose requirement (and hence lower cost per dose) as well as increased clinical effect. The first such project with a significant European antibody development company will commence in April. • In internal projects that may be undertaken in collaboration with academic research groups or with other biotechnology companies. EvoGenix will retain substantial ownership in these projects with the intention of licensing on to a major pharmaceutical company as the products enter clinical testing. EvoGenix has identified two such projects which offer very attractive potential for products to address large markets in areas of clinical need. Of course, EvoGeneTM technology is applicable, not only in the pharmaceutical sector, but also in the industrial and agricultural sectors for improvement in the properties of enzymes and other proteins used in paper or chemical manufacture, to generate food ingredients, in household products or as components of animal feeds. Because of the broad potential of its technology, EvoGenix will seek opportunities to work with companies outside of the pharmaceutical sector either by collaboration or via technology licensing.

Profile:

Farm Pride Foods Limited
Contact: ASX: Phone: Email: Internet: Address: Mr Glenn Abbott, National Business Manager-Egg Products FRM +61 3 9798 7077 Fax: +61 3 9701 5729

ACN 42 080 590 030

glenn@farmpride.com.au www.farmpride.com.au
551 Chandler Road Keysborough, VIC, 3173 Australia Postal Address: PO Box 141 Noble Park, VIC, 3174 Australia

Profile:

Farm Pride Foods Ltd is a publicly listed company (ASX: FRM), producing and marketing shell eggs and a range of egg products. Farm Pride Foods is a supplier of eggs and egg products to the biotechnology industry for raw material and specialty ingredient applications. Farm Pride Foods operates an export approved plant, and can offer caged, barn laid and free range eggs. The product range includes fresh, frozen and dried whole egg and egg yolk, fresh and frozen egg white, fresh and frozen salted egg yolk, hard boiled, poached and fried eggs, scrambled egg, crepes, low cholesterol egg and chicken powder. ACN 13 004 809 161 Felton Grimwade & Bickford Pty. Ltd.

Contact: Phone: Email: Internet: Address:

Mr Kerrin Michael, Research and Development Manager General Manager +61 3 9562 7711 Fax: +61 3 9562 7291

mail@fgb.com.au www.fgb.com.au
61-69 Clarinda Road Oakleigh South, VIC, 3167 Australia Postal Address: PO Box 74 Oakleigh South, VIC, 3167 Australia

Profile:

Felton, Grimwade & Bickford Pty Ltd has a company history which can be traced back to the 1860s. Today it is a Melbourne based independent private company wholly Australian owned and operated. The company manufactures and markets a range of proprietary products which are distributed through pharmacies and supermarkets throughout Australia and in a growing number of export markets. The company manufactures a range of pharmaceutical and non-pharmaceutical grades of eucalyptus oil for use in pharmaceuticals, toiletries, confectionery and industrial products. As Victoria's largest producer of eucalyptus oil, Felton, Grimwade & Bickford incorporates its oil into its own products as well as selling in bulk to other manufacturers in Australia and overseas. Medicinal eucalyptus oil produced from E. polybractea is extensively used as a raw material and active ingredient of cough lozenges, inhalation sprays and drops, gargles, mouth washes, toothpastes, embrocation balms and ointments, liniments and soaps. Eucalyptus oil is also used in antiseptics and germicidal disinfectants because of its pleasant odour and its effectiveness in killing bacteria. Industrial eucalyptus oils are used in the manufacture of household disinfectants and as an industrial solvent. Other products manufactured and marketed by the company include over-the-counter pharmaceuticals, herbal & nutritional supplements, medical devices, personal care and household products. The company is also working closely with The Mallee Oil Company in Western Australia, on a project to grow and harvest eucalyptus to reduce dry land salinity. Felton, Grimwade & Bickford expects this to become a new source of raw material for oil. The spent leaves after the eucalyptus oil has been extracted are marketed as a mulch and ground cover. Sold under the trade-name Bosisto's Euca-Mulch, it has been successfully tested by the Department of Agriculture. More work is being undertaken as it is believed the spent leaves could be an ideal addition to potting mixes.

Fisher & Paykel Healthcare Corporation Limited
Contact: ASX: Phone: Email: Internet: Address: Mr David Boyle, General Manager FPH +61 3 9879 5022 Fax: +61 3 9879 1598

ACN 52 005 484 999

david.boyle@fphcare.com.au www.fphcare.com
36 New Street Ringwood, VIC, 3134 Australia Postal Address: P.O. Box 167 Ringwood, VIC, 3134 Australia

Profile:

Fisher & Paykel Healthcare's lead product is used to treat sleep apnea (apnoea), a condition causing temporary cessation in breathing during sleep. The New Zealand based parent company claims a 6% market share of the A$500 million world market for sleep apnea products. Fisher & Paykel Healthcare also makes respiratory humidifiers, infant resuscitators, and patient warmers. The parent company listed on the ASX in November 2001. ACN 36 006 455 616 Florigene Limited Dr John Mason, R&D Manager +61 3 9419 9844 Fax: +61 3 9416 1761

Contact: Phone: Email: Internet: Address:

florigene@florigene.com.au www.florigene.com.au or www.florigene.com
16 Gipps Street Collingwood, VIC, 3066 Australia Improvements to flowers - whether in shape, colour, vase life, disease resistance or other characteristics - have historically been achieved by cross-breeding of existing varieties. This is typically a long and unpredictable process that might lead to only small improvements and cannot span the basic gaps imposed by the species' gene pool, e.g. the absence of the gene responsible for the producing the blue colour. Florigene is the world's first successful "molecular breeder" in the flower industry. Florigene uses genetic engineering technology to bridge genetic gaps and rapidly deliver valuable improvements to flower species. The company now has two proven core technologies - Blue Gene Technology and Long Vase Life (LVL) Gene Technology. The first commercial products from these technologies are now on the market. Florigene was founded in Melbourne, Australia in 1986. Since then, the company has developed, patented and refined an impressive portfolio of technology, and Florigene is now regarded as a world-leader in the genetic engineering of flowers. The company's research center and corporate headquarters are still located in Melbourne. Carnations were used as a model for research and in 1994, Florigene scientists succeeded in implanting the Blue Gene into carnations and were able to generate the first carnation to express colour in the blue range. This flower was called Moondust™ and was an important breakthrough. Other successes followed in Blue Gene research, and new technologies have since been added to Florigene's stable. In the meantime, Florigene's scientists continue to refine the Blue Gene Technology and plan to extend it to gerberas, chrysanthemums and, of course, the blue rose.

Profile:

Fluid System Technologies (ES) Pty Ltd
Contact: Phone: Email: Address: Mr Dugald Mackenzie, Business Development Manager +61 3 9387 6477 Fax: +61 3 9387 4528

dugaldm@fstau.com.au
4/1 Wilson Avenue P.O. Box 319 Brunswick, Victoria, 3056 Australia Fluid System Technologies (ES) was formerly known as North Melbourne Valve & Fitting Pty Ltd. Under new ownership we now offer specialist componentry to the Biotechnology, Pharmaceutical, Medical and Research industries. These products include valves, fittings, pumps, filters, sight glasses, tubing and many other components required to build production facilities whether they be pilot plants or full scale production facilities. With branches in Queensland and New South Wales and New Zealand, we service the Eastern States, New Zealand, the Pacific Islands and Papua New Guinea. Key brand names are Jensen and Swagelok. ACN 092379890 FMPR Communications

Profile:

Contact: Phone: Email: Internet: Address:

Ms Marnie Firipis, Director +61 3 96539650 Fax: +61 3 96539307

inquiry@fmpr.com.au http://www.fmpr.com.au
Level 50 - 101 Collins Street Melbourne, Victoria, 3134 Australia FMPR Communications provides medical writing and media communications services to the biotechnology and pharmaceutical industry.

Profile:

G.B.C. Scientific Equipment Pty. Ltd.
Contact: Phone: Email: Internet: Address: Mr Ross Grey, Managing Director +61 3 9213 3666 Fax: +61 3 9213 3677

ACN 30 005 472 686

gbc@gbcsci.com www.gbcsci.com
12 Monterey Road Dandenong, VIC, 3175 Australia G.B.C. Scientific Equipment designs, manufactures and markets a range of scientific instruments and is now leading the world in development of instruments such as the most technically advanced inductively coupled plasma time of flight mass spectrometers (ICP-TOF MS), the new micro Fourier rheometer (MFR 2100), and x-ray diffraction (XRD) instrumentation. Atomic absorption spectrometers (AAS), UV-visible spectrometers (UV-Vis), inductively coupled plasma optical emission spectrometers (ICP-OES), high performance liquid chromatographs (HPLC) and rheological analysis equipment are also manufactured and marketed by G.B.C. Since its inception in 1978, G.B.C. has become renowned in the elemental analysis field as a result of its successful AAS and ICP portfolio. Endorsed by the international quality standard, ISO 9001, the company prides itself on developing products which exceed market expectations. G.B.C. has been the recipient of many international export awards. The company's head office is based in Melbourne and it has a USA subsidiary office in Illinois. Worldwide, G.B.C. is represented an extensive distribution network covering over 85 countries.

Profile:

Genera Biosystems Pty Limited
Contact: Phone: Email: Internet: Address: Dr Suzanne Lipe, CEO +61 3 9345 2248 Fax: +61 3 9345 2242

ACN 098 063 837

suzanne.lipe@generabiosystems.com www.generabiosystems.com
WEHI Biotechnology Centre 4 Research Avenue, La Trobe R&D Park Bundoora, VIC, 3086 Australia Genera Biosystems is an early stage Australian biotechnology company established to further develop and commercialise DNA analysis technology originally developed by the Walter and Eliza Hall Institute of Medical Research (WEHI) and the Australian Genome Research Facility (AGRF). Genera's proprietary platform technologies, together, provide a fully integrated test system for rapid DNA analysis, for the medical research, biopharmaceutical and agricultural industries, which includes: - single nucleotide polymorphism (SNP) analysis, - novel mutation scanning, and - gene expression. Genera's AmpaSand™ Beads consist of silica beads which have been covalently coupled to a unique linker DNA sequence. The Universal Anchoring System™ provides a simple ligation procedure to link DNA of interest onto AmpaSand™ Beads, thereby customizing it for users’ own specific applications. The use of Genera's SiFT™ (Sequence Identification by Flow Test) technology, an ultra-sensitive form of competitive hybridization, allows genetic analysis of results by standard flow cytometry instrumentation. Software under development will allow accurate and rapid interpretation of this flow data, producing an integrated DNA analysis system which is gelfree, high-throughput, multiplexing capable and cost effective..

Profile:

Genetic Science Services Pty Ltd
Contact: Phone: Email: Internet: Address: Mr George Sofronidis, Managing Director +61 3 8412 7077 Fax: +61 3 9416 4076

ACN 34 097 626 885

George@geneticscienceservices.com www.geneticscienceservices.com
60-66 Hanover Street Fitzroy, Vic, 3065 Australia Postal Address: P.O. Box 115 Fitzroy, Vic, 3065 Australia

Profile:

Genetic Science Services Pty Ltd commenced during May 2002, offering animal paternity and endangered species genetic testing. Genetic Science Services’ vision is to become a leading animal biotechnology service provider. It provides genetically based identity, parentage, disease and productivity tests for farmers, breeders, collectors and animal lovers. Its range of genetically based tests provides managers with a source of certainty in the uncertain world of inherited animal traits causing illness or affecting productivity. Its staff are qualified genetic scientists with long-term experience and first class qualifications. Coupled with a commitment to ongoing training and active research and development, Genetic Science Services is poised to provide superior service for animal managers. Genetic Science Services has established a unique partnership with Box Hill Institute, a leading Victorian vocational institute. It is thus equipped to perform its services in secure, state-of-the-art facilities.

Genetic Technologies Corporation Pty Limited
Contact: Phone: Email: Internet: Address: Mr Ian Smith, Director +61 3 9415 7688 Fax: +61 3 9416 4076

ACN 92 075 962 800

gtc@genetictechnologies.com.au www.genetictechnologies.com.au
60-66 Hanover Street Fitzroy, VIC, 3065 Australia Postal Address: PO Box 115 Fitzroy, VIC, 3065 Australia

Profile:

Genetic Technologies Corporation Pty Limited (GTCPL) is the largest DNA parentage testing laboratory in Australia, and is part of the listed Melbourne-based group Genetic Technologies Limited. Established in 1988 to undertake DNA identity testing, GTCPL was the first commercial organisation in Australia to perform DNA parentage testing. Since then GTCPL has continued to rate on this market and has expanded to provide other DNA-based services. In the last two years GTCPL has built a new DNA laboratory and invested heavily in state-of-theart DNA typing equipment. This equipment allows the company to perform very accurate DNA typing. In Australia, the Family Court, and the Registry of Births, Deaths & Marriages, only recognise reports performed by laboratories authorised by the Federal Attorney General and accredited by the National Association of Testing Authorities (NATA). GTCPL has the necessary authorisation and accreditation to perform these tests. GTCPL offers a range of DNA tests for parentage, immigration, forensic investigation, twins analysis, resolution of deceased estates, and sibship analysis.

Genetic Technologies Limited
Contact: ASX: Phone: Email: Internet: Address: Dr Mervyn Jacobson, Executive Chairman GTG +61 3 9415 1135 Fax: +61 3 9417 2987

ACN 17 009 212 328

info@gtg.com.au www.gtg.com.au
60-66 Hanover Street Fitzroy, VIC, 3065 Australia Postal Address: PO Box 115 Fitzroy, Victoria, 3065 Australia

Profile:

Genetic Technologies Limited, listed on the Australian Stock Exchange (ASX: GTG), heads a group of 11 companies, 8 of which are based in Australia: four DNA testing and analysis companies (Genetic Technologies Corporation Pty Limited, GeneType Pty. Ltd., Silbase Scientific Services Pty. Ltd.,Simons GeneType Diagnostics Pty. Ltd.)and Genetic Science Services Pty Ltd and two recently formed companies branching out into major new biotechnology areas (ImmunAid Pty Ltd, and RareCellect Ltd.) [See separate Directory entries]. In 2001, Genetic Technologies acquired the eighth, Perth-based DNA-ID Labs. The Group’s overseas companies are GeneType AG (Switzerland), Gtech International Resources (Vancouver Stock Exchange) and GeneType Corp. (USA). GTG operates Australia’s largest DNA paternity testing service. The original GeneType group was formed in 1989 in Melbourne. The group’s strong intellectual property portfolio includes two key DNA-related patents: the first on DNA analysis, covering noncoding regions of DNA from any species (misleadingly known until recently as "junk DNA"); and the second on an innovative method for gene mapping, also based on non-coding information. These broad-ranging patents potentially have wide application, initially in areas such as tissue matching for organ transplantation, DNA-based forensic work, detection of disease-causing organisms, and human, animal and plant diagnostics. Gene mapping applications include diagnostic tests for human genetic diseases such as nasopharangeal cancer, hemochromatosis and diabetes. Mapping in other species will be applied to breeding programs for cattle, sheep and pigs. GTG has recently entered into licence agreements with Genetic Solutions Pty Limited, Nanogen Inc,Sequenom Inc., Perelegen,, Myriad Genetics,Pyrosequencing, Orchid Biosciences, ARUP, Inguran LP and The University of Sydney for its non coding intron patents. GTG also owns 51% of AgGenomics Pty. Ltd., a new Victorian venture for DNA testing of plants [See separate entry]. A separate GeneType technology is the non-invasive recovery of foetal cells for prenatal genetic testing [see RareCellect Ltd. entry].

Genetics Australia Co-operative Limited
Contact: Phone: Email: Internet: Address: Mr Bernie Harford, Chief Executive Officer +61 3 5367 3888 Fax: +61 3 5367 5100

ACN 64 822 392 303

bharford@genaust.com.au www.genaust.com.au
Woolpack Road Bacchus Marsh, VIC, 3340 Australia Postal Address: PO Box 195 Bacchus Marsh, VIC, 3340 Australia

Profile:

Genetics Australia Co-operative Limited is Australia's largest artificial breeding organization. It provides over half of the Australian dairy industry's requirements for elite genetics. Genetics Australia invests in R&D in partnership with leading research institutes and the Dairy Research and Development Corporation. R&D covers dairy herd fertility and reproductive management; semen processing, bull fertility and semen production; the use of genetic markers; and cloning and genetic modification technologies. Genetics Australia maintains a large embryo recipient herd and a modern laboratory for in-vitro production to support cloning and genetic modification research. The research has produced advances in the technology, including Australia's first calves cloned from adult somatic cells in early 2000. ; Australia’s first cloned elite dairy bull (Rameses II) . Genetics Australia is a member of the Cooperative Research Centre (CRC) for Innovative Dairy Products, which commenced on 1 July 2001. The CRC is pursuing R&D and commercialisation of genetic and reproductive technologies of relevance to the dairy industry.

GeneType Pty. Ltd.
Contact: Phone: Email: Internet: Address: Mr Ian Goudie, Chief Executive Officer +61 3 9417 5711 Fax: +61 3 9417 2987

ACN 60 050 029 279

info@gtg.com.au www.gtg.com.au
60-66 Hanover Street Fitzroy, VIC, 3065 Australia Postal Address: PO Box 115 Fitzroy, VIC, 3065 Australia

Profile:

GeneType Pty. Ltd. is part of the ASX-listed Melbourne-based group Genetic Technologies Limited (GTG). GeneType was founded 1989 when Dr. Malcolm Simons (an immunogeneticist) and Dr. Mervyn Jacobson (a medical practitioner) met in Melbourne, Australia, and resolved to prove the non-coding ("junk" DNA) region of the human HLA gene complex on chromosome 6 is in reality not "junk", but in fact a valuable and highly ordered reservoir of useful genetic information, largely overlooked by the rest of the world. GeneType offers a DNA-based human identity testing service (see separate listings for Genetic Technologies Corporation and Simons GeneType Diagnostics) and conducts applied research programs, principally in human foetal cell recovery and animal parasitology. GeneType staff also support other priority research projects, including newly formed companies ImmunAid and RareCellect, and new opportunities in animal and plant genetics and genomics. [See separate entries for Genetic Technologies Limited, ImmunAid and RareCellect].

Genomic Disorders Research Centre
Contact: Phone: Email: Internet: Address: Prof Richard Cotton, Director +61 3 9288 2980 Fax: +61 3 9288 2989

cotton@medstv.unimelb.edu.au www.genomic.unimelb.edu.au
7th Floor, Daly Wing St Vincent’s Hospital 35 Victoria Parade Fitzroy, VIC, 3065 Australia Postal Address: PO Box 2900 Fitzroy, Victoria, 3065 Australia

Profile:

The Centre was established in 1996 as the Mutation Research Centre and was the first and remains the only organization, world wide, to focus exclusively on gene mutation, its measurement and documentation and its linkage to inherited genetic disease, neurological, heart, cancer and other common diseases. The Human Genome Variation Society and the HUGO Mutation Database Initiative are administered from the Centre together with editorial responsibility for Human Mutation journal. The Centre continues to develop its programme in the areas of gene mutation detection research and has developed cutting edge technologies for the detection of genetic mutations.

Gilead Sciences Pty Limited
Contact: Phone: Email: Internet: Address: Ms Fiona Palmer, Associate Director Marketing +61 3 9563 0433 Fax: +61 3 9567 2522

ACN 71 072 611 708

fpalmer@gilead.com www.gilead.com/wt/sec/australia
41 Stamford Road Oakleigh, VIC, 3166 Australia Gilead Sciences is a biopharmaceutical company that discovers, develops and commercialises therapeutics to advance the care of patients suffering from life threatening diseases worldwide. The company focuses its research and clinical programs on anti-infectives, including antivirals, antifungals and antibacterials. Headquartered in Foster City, California, Gilead has operations in the United States, Europe and Australia. Gilead Sciences Pty Limited, based in Victoria, is responsible for sales and marketing activities throughout Australia and New Zealand. The New Zealand activities are conducted in conjunction with Baxter Healthcare.

Profile:

GlaxoSmithKline Australia Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Daniel Tasse, Managing Director +61 3 9721 6000 Fax: +61 3 9729 5319

ACN 73 004 148 065

catherine.c.mcgovern@gsk.com www.gsk.com.au/home/Home.asp
1061 Mountain Highway Boronia, VIC, 3155 Australia GlaxoSmithKline Australia Pty Ltd (GSK), one of the largest and most highly resourced pharmaceutical companies in the country, was created in 2000 by the merger of Glaxo Wellcome and SmithKline Beecham. GSK employs more than 1500 highly skilled professionals engaged in research and development, medical, regulatory and clinical research, manufacturing, distribution, sales and marketing. Products are exported to more than 65 countries around the globe. Total export earnings in 2001 reached A$197 million. GSK Australia contributed over A$25 million to Australian research and development funding in 2001. Its product portfolio is closely aligned with the country’s key health priorities in asthma, immunisation, depression, diabetes, indigenous health, and antibiotic resistance. GSK’s Australian headquarters in outer eastern Melbourne undertakes pharmaceutical manufacturing, commercial, and administration functions. Boronia is the principal production site for all prescription products including tablets, capsules, aerosols, sterile liquids and creams. It also houses the Blow Fill Seal (BFS) facility, an innovative delivery system for medicines that allows glass ampoules to be replaced with safer, more convenient plastic ampoules. Built at an investment of A$50 million, this is GSK’s global development and manufacturing site for BFS technology. It has been utilised to deliver innovative medicines for the treatment of asthma and of the nausea and vomiting associated with chemotherapy and radiotherapy. Over the next four years, GSK Australia plans to invest in capital equipment and buildings and create new jobs in manufacturing. With plants in Latrobe, Tasmania and Port Fairy, Victoria, GSK’s Chemicals Division produces medicinal alkaloids. GSK produces 25% of global supplies and exports over 90% of finished product. In addition, GSK exports poppy seed for culinary purposes to 12 countries. Consumer health products are produced in Ermington, New South Wales.

Profile:

Glutagen Pty Ltd
Contact: Phone: Email: Address: Dr Ted Stelmasiak, Managing Director +61 3 9317 0122 Fax: +61 3 9317 0122

ACN 096 990 868

glutagen@bigpond.com
64 The Esplanade Maribyrnong, VIC, 3032 Australia Start-up pharmaceutical and nutritional supplement developer Glutagen Pty Ltd was established in Melbourne in 2001. Glutagen specialises in development of treatments for gluten intolerance and Coeliac Disease (CD). This genetically based condition affects about 1 in 300 people in Europe and the US. CD is a condition in which abnormalities in the small bowel are produced by gluten present in cereals such as wheat, rye and barley. At present, the only effective therapy for CD is a life-long glutenfree diet. The company has two products under development: Glutazyme – an enzyme supplement which might be an adjunct to a gluten-free diet; and Glutaren – a pharmaceutical product designed to prevent intestinal damage caused by gluten-derived toxic peptides. Glutagen’s lead product, Glutazyme, is to undergo clinical trials in 2003 at a Melbourne hospital.

Profile:

Grale Scientific Pty. Ltd.
Contact: Phone: Email: Internet: Address: Mr David Gray, Director +61 3 9874 8577 Fax: +61 3 9874 8040

enquiries@grale.com.au www.grale.com.au
Unit 18 / 107-113 Heatherdale Road Ringwood, VIC, 3134 Australia Postal Address: PO Box 5063 Ringwood, VIC, 3134 Australia

Profile:

The core business of Grale Scientific Pty Ltd is medical instruments to support the pathology sector. Grale supplies equipment and provides service and consumables to pathology and diagnostic laboratories, with particular emphasis on histology. As well as designing, manufacturing, selling and servicing its own brand of products, the company also sells and services a wide range of instruments from other manufacturers. A key instrument, designed and manufactured by Grale, is the Grale Cell Counter, used for performing differential white cell counts. This apparatus is used in many areas of the health sector, including hospitals and pathology and diagnostic laboratories. Grale is currently negotiating to add to its licensed range of products available from other manufacturers. Grale also makes fermenters with associated plant design and construction. A fermenter is a controlled-environment vessel for growing large-scale cultures of micro-organisms, and Grale custom-makes this equipment to order, from research bench/laboratory requirement up to large production machines. While it services and modifies other brands, Grale primarily designs, services and modifies its own equipment to order. Grale Scientific was established in 1984.

Halcyon Proteins Pty. Ltd.
Contact: Phone: Email: Internet: Address: Mr Phillip Strong, Managing Director +61 3 9768 2021 Fax: +61 3 9768 2291

halcyonproteins@iprimus.com.au www.halcyonproteins.com.au
430 Hammond Road Dandenong, VIC, 3175 Australia Halcyon Proteins Pty. Ltd. is a Melbourne-based manufacturer and wholesaler of food ingredients: enzymes, flavouring and colouring, food additives, and food ingredients, under the Flavex trade name. Established in 1946 to manufacture protein extracts, Halcyon Proteins Pty. Ltd. is Australia’s leading manufacturer of hydrolysed vegetable proteins. Halcyon Proteins Pty. Ltd. is a 100% family owned and operated company. This family involvement gives the company its strength, flexibility and versatility. Products include: hydrolysed vegetable proteins, soy sauce, yeast extract and fish sauce (flavour enhancers), enzymes, and natural enzyme formulations (papain, bromelain, ficin). Products can made to the customer’s specifications. The company designs and constructs process equipment, provides technical advice, and supplies tailor-made products to meet the customer’s specific requirements. Halcyon Proteins also provides contract drying services for selected food ingredients. The purpose-built, state-of-the-art manufacturing plant is located in Dandenong, Victoria, south of the city of Melbourne. Strict quality control and automation have been the keys to developing highquality products at economical prices.

Profile:

Hatchtech Pty Limited
Contact: Phone: Email: Address: Dr Vern Bowles, Chief Scientific Officer +61 3 8344 4439 Fax: +61 3 9347 5888

ACN 84 098 559 409

vmb@unimelb.edu.au
215 Grattan Street Parkville, VIC, 3052 Australia Hatchtech Pty Limited is developing a new generation of low-toxicity insecticides for controlling human ecto parasites, initially focusing on head lice. Head lice are a persistent problem throughout the world, particularly in younger school-aged children. The problem is becoming increasingly difficult to treat as head lice continue to develop resistance to conventional treatments. Hatchtech has applied its novel technology to successfully identify potential new targets for controlling head lice. In addition, the company has identified several compounds with strong ovicidal properties. These ovicides stop lice eggs from hatching, inhibiting the rapid spread of the parasite that is characteristic of infestations in humans. When combined with effective pesticidal treatments, this innovative approach will lead to a new generation of highly effective, low-toxicity treatments that target both the eggs and lice, overcoming the problems associated with resistance.

Profile:

Hepatope Pty Ltd
Contact: Phone: Email: Internet: Address: Dr David Anderson (03) 9282 2111 Fax: (03) 9282 2100

anderson@burnet.edu.au www.burnet.edu.au
McFarlane Burnet Institute for Medical Research Melbourne, VIC, 3001 Australia Postal Address: GPO Box 2284 Melbourne, Victoria, 3001 Australia

Profile:

Herbworx International Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Paul Sumner, Chief Executive Officer +61 3 9819 1370 Fax: +61 3 9819 1043

ACN 25 094 160 326

psumner@bigpond.net.au www.herbworx.com ; www.phytomedicine.com.au ; www.phytotherapies.org
14 Atkins Street Kew, VIC, 3101 Australia Postal Address: PO Box 3099 Cotham, VIC, 3101 Australia

Profile:

Herbworx International Pty Ltd is an international company with a commitment to supplying the world market with high quality, innovative and clinically effective herbal products. Based in Australia with strategic partners in Europe, Asia and the USA, Herbworx International is well positioned to make a significant contribution in the production and marketing of herbal products worldwide.

Hexima Limited
Contact: Phone: Email: Address: Mr Dan O'Brein, Executive Director +61 3 8629 2929 Fax: +61 3 8629 2990

ACN 64 079 319 314

dan.obrien@dromolandcapital.com
Level 17 200 Queen Street Melbourne, VIC, 3000 Australia Hexima Limited was launched in 1998 as a joint venture between the University of Melbourne, key researchers, and Pivot Limited, Australia's largest farmer-owned company. For the first three years, it was funded by Pivot Ltd, which invested a total of A$1.3 million. In August 1999, Hexima Ltd won a $750,000 Federal Government R&D START grant to research and develop gene technology that can create natural insect resistance in plants. The novel gene, identified and developed by researchers in the University of Melbourne's Plant Cell Biology Research Centre and La Trobe University's Department of Biochemistry, is being used to develop insect-resistant varieties of cotton. Based on research on the Nicotiana alata proteinase inhibitor (NaPI) gene, patents on the gene have been issued in Australia, New Zealand and USA, and are pending in Japan and Europe. The gene encodes a proteinase inhibitor that inhibits digestion of proteins in the insect gut. There are six "individual units" of inhibitor. Each of these could potentially inhibit a different enzyme in the insect gut. The gene has been expressed in cotton and is effective in inhibiting growth of insects feeding on transgenic cotton leaves. In November 2001, ownership of Hexima Limited was transferred to private investors and the intellectual property was transferred from the University of Melbourne to Hexima. A Biotechnology Innovation Fund (BIF) grant ($250,000) was announced in March 2002. The project involves greenhouse and field trials of transgenic plants in combination with a topical spray (technology owned by Nufarm Limited) to control pests in cotton.

Profile:

Howard Florey Institute of Experimental Physiology and Medicine
Contact: Phone: Email: Internet: Address: Dr Henry DeAizpurua, Research Development Manager +61 3 8344 5654 Fax: +61 3 9348 1707

h.deaizpurua@hfi.unimelb.edu.au www.hfi.unimelb.edu.au
The University of Melbourne Royal Parade Parkville, VIC, 3010 Australia Postal Address: The University of Melbourne Parkville, Victoria, 3010 Australia

Profile:

The Howard Florey Institute is known throughout the world as one of Australia’s leading medical research institutes. Under the direction of Professor Frederick Mendelsohn it undertakes leading edge research primarily into the brain and the cardiovascular system. The Institute has state-of-the art equipment for neuroimaging with facilities and skills encompassing genomics, electrophysiology, cell biology, neural development, whole animal physiology and functional brain imaging. The Florey’s mandate is to: advance the understanding of the detailed workings of the body, especially the brain; use this knowledge to discover the nature, origins and causes of disease; and prevent, diagnose and treat these diseases in humans and animals. In 1947 a young Melbourne doctor, Derek Denton was caring for a sick boy with a serious surgical complication. This led to an investigation into the control of salt and water balance in health and disease. The success of this research led to increasing international interest. This prompted Kenneth and Baillieu Myer, Sir Ian Potter and Dr H.C. Coombs along with the Rockefeller Foundation and the National Institutes of Health in the USA, to set about the development of outstanding laboratories to support the research effort. The laboratories were incorporated by an Act of the State Parliament in 1971 as the Howard Florey Institute of Experimental Physiology and Medicine. Professor Denton was its founding Director. Howard Florey, a brilliant Australian scientist who developed penicillin, gave his name to the Institute. In addition to research into hypertension and salt appetite, and endocrinology, peptide chemistry, molecular biology and biotechnology were also developed. New horizons and expertise in hormone research (relaxin) resulted in the delivery of a portfolio of patents. The Institute was expanded in 1975 and 1995 with funds from the State and Federal Governments and significant benefactions from the private sector. In recent years the Florey has focussed its research on deciphering how the brain develops and functions. The implications for community health are substantial when you consider that Alzheimer's disease, depression, stroke, Parkinson's disease or other brain disorders will directly or indirectly affect over 75% of all Australians at some time. In-depth programs now investigate how: the brain regulates most body function; the diversity of chemical messengers activate brain cells which enable us to behave, think, learn and remember; the enormously complex structure of the brain is developed; and specific areas of the brain become active in response to stimuli and tasks. The Florey plays a vital role in encouraging and nurturing potential scientists through the research training of postgraduates from leading universities. Currently there are over 45 PhD students at the Florey and some 100 research and support staff. Outstanding international scientists are invited to spend from three months to two years in our laboratories. The Institute also encourages participation in international symposia. The Florey’s annual research budget of about $10 million is mainly provided by the Federal Government’s National Health and Medical Research Council, with significant contributions from Philanthropic Foundations, Industry, the University of Melbourne, the State Government and private donors. Research at the highest levels is heavily dependent on financial support. The Institute, to reduce dependence on government funding, has initiated a major strategy of seeking partnerships with the corporate and other research institutes.

IATIA Limited
Contact: ASX: Phone: Email: Internet: Address: Mr Felix Thiang, Director of Marketing IAT +61 3 9898 6388 Fax: +61 3 9899 6388

iatia@iatia.com.au www.iatia.com.au
46 Rutland Road Box Hill, VIC, 3128 Australia Leaders in Vision Sciences, IATIA is an Australian based organisation actively involved in the development and marketing of breakthrough optical technologies in the scientific and medical fields. IATIA has exclusive worldwide rights to platform technology to quantify phase, known as QPI, that is the subject of international patents. Its first product, QPm, was launched in November 2001. QPm represents a breakthrough in microsocopy imaging technology, allowing for the digital phase imaging of samples and the measurement of physical thickness and refractive index. QPm can be attached to existing as well as new research-grade microscopes. This phase technology is being applied to electron microcopy (QPe), optometry (QPr) and ophthalmology (QPa), with these products being released in the next 2 years. IATIA also has an instrument division which has developed a wide range of revolutionary medical and surgical optical instruments based on technology originally developed by the Ophthalmology Department of the University of Melbourne. This product range is currently the subject of several granted patents and further pending international patents. IATIA has developed key strategic alliances and established an international distribution network for the sale of its products. IATIA has a strong commitment to staying at the leading edge of technology, providing high precision, technologically progressive and innovative solutions for the global market.

Profile:

Ilexus Pty. Ltd.
Contact: Phone: Email: Internet: Address: Prof Mark Hogarth, Director +61 3 9287 0666 Fax: +61 3 9287 0601

ACN 70 064 772 103

l.priest@ari.unimelb.edu.au www.ilexus.com.au
Kronheimer Building A&RMC Studley Road Heidelberg, VIC, 3084 Australia Since its incorporation in 1994, Ilexus Pty Ltd has managed intellectual property created by the Austin Research Institute (ARI), especially in the fields of inflammation and cancer. Ilexus is focused on developing technology platforms from the following projects: a portfolio of antibodies from ARI; CD46 complement regulator; and transferase enzymes (involved in organ transplantation). Therapeutic and diagnostic applications can be developed from these platforms. Ilexus’ technology portfolio includes research into cancer immunotherapy, some innovative compounds for tumour imaging and targeting, and the development of a test for faecal occult blood that overcomes many of the drawbacks of existing tests. Other aspects of the technology portfolio include research into the prevention of rejection in organ transplantation, inflamation and infectious disease. Under a mid-2001 deal with ASX-listed Prima Biomed Ltd, Prima gained first rights to commercialise other technology platforms arising from the ARI. This work will be pursued through three companies: Arthron Limited, for research into rheumatoid arthritis; Cancer Vac Limited, research involving clinical trials of a cancer vaccine; and Panvax Limited, research into areas of cancer and infectious disease using a protein carrier (DCtag) that leads to the production of T cells and antibodies. Ilexus has sublicensed the intellectual property rights to Arthron, Cancer Vac and Panvax, and Ilexus’ staff have joined Prima Biomed. [See separate entries].

Profile:

Iliad Chemicals Pty Ltd
Contact: Phone: Email: Internet: Address: Dr Bernard Flynn, Chief Executive Officer +61 3 9903 9673 Fax: +61 3 9903 9582

ACN 17 099 125 612

b.flynn@iliad.com.au www.iliad.com.au
c/- Victorian College of Pharmacy 381 Royal Parade Parkville, VIC, 3052 Australia Iliad Chemicals Pty Ltd is a biotechnology start-up company operating in two related areas: building novel chemical libraries for high-throughput screening; and the commercial development of a class of novel compounds as potential anticancer agents. Iliad Chemicals Pty Ltd has developed a series of synthetic protocols that give efficient and direct access to important structural classes of molecules that are recognized for their capacity to act as biomolecule inhibitors and that exhibit other important drug-like properties. These methods can be utilised in providing compound libraries for high-throughput screening programs in drug dicovery. The design features of this library are such that any bioactive compound discovered from it will have an increased likelihood of being easily administered to patients and a decreased likelihood of side effects. In collaboration with the National Cancer Institute (USA), the Iliad group has utilized its synthesis techniques in the development of a series of novel and very potent anticancer agents. These compounds have the potential to operate as dual purpose anticancer agents that are able to directly target both the cancerous tissue and the vascular system of tumours.

Profile:

ImmunAid Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Ian Goudie, CEO +61 3 9417 5711 Fax: +61 3 9417 2987

ACN 68 096 281 542

info@gtg.com.au www.gtg.com.au
60 - 66 Hanover Street Fitzroy, VIC, 3065 Australia Postal Address: PO Box 115 Fitzroy, VIC, 3065 Australia

Profile:

A member of the Genetic Technologies Limited group, ImmunAid Pty Ltd was formed to pursue opportunities in biotechnology and is funding Australian scientists who are researching novel areas relevant to the AIDS virus. ImmunAid Pty Ltd has taken over the project and owns all intellectual property arising from this project. ImmunAid is owned 60% by Genetic Technologies [see separate entry] and 40% by the scientists who developed the original concepts and who continue to work on the project. The original pilot study was undertaken at University of Western Australia, and with the formation of ImmunAid, it is intended that this work will be expanded in 2002, both at the University of Western Australia and at other leading institutes in Australia and USA.

Increasing Returns Pty Ltd
Contact: Phone: Email: Address: Profile: Mr John Perry, Chief Executive Officer +61 3 9226 6289 Fax: +61 3 9343 5281

ACN 70 086 139 157

johnperry@increasingreturns.com
276 Walsh Street South Yarra, VIC, 3141 Australia Increasing Returns Pty Ltd established a marine biotechnology division in 1999, to further develop university technology in terms of breeding and land-based grow-out of flounder and other flat fish. Work has been ongoing and parties to finance and take the breeding program further have been identified. The company intends to move forward into commercialisation phase during 2002-03 with private capital, and is currently completing investment and tax planning with a view to possibly including Commonwealth R & D funding in 2003 in the finance mix for the expansion and development of the technology. Other ventures, including the development of a seafood-derived food supplement, based on a synergistic mix of various forms of sea life, are currently on hold with the possibility of furthering the projects in the next 2-3 years.

IngenKO Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Martin Gore, Chief Executive Officer +61 3 9544 2526 Fax: +61 3 9594 7111

ACN 32 095 313 803

mgore@ingenko.com.au www.ingenko.com.au
27-31 Wright Street Clayton, VIC, 3168 Australia IngenKO Pty Ltd was established in June 2001 as a commercial supplier of gene targeted mice on a fee for service basis to customers in the pharmaceutical, biotechnology and medical research industries. The company was established to commercialise intellectual property, know-how and existing contracts of The Monash Institute of Reproduction and Development through the Centre for Functional Genomics and Human Disease. The Centre has 10 years of experience in the generation of transgenically modified mouse lines and over 7 years in specifically generating gene targeted mice. Mice modified in this way represent a valuable step in identifying those genes which are potential targets for the development of therapeutic and diagnostic products. In addition to the receipt of contract income for the generation of client-specified mouse knock-outs, IngenKO aims to generate royalty income on intellectual property rights received by IngenKO as part of a discounted fee for contract services.

Profile:

Institute of Drug Technology Australia Limited
Contact: ASX: Phone: Email: Internet: Address: Dr Graeme Blackman, Managing Director IDT +61 3 9801 8888 Fax: +61 3 9801 8773

ACN 66 006 522 970

gblackman@idtaus.com.au www.idtaus.com.au
45 Wadhurst Drive Boronia, VIC, 3155 Australia Melbourne’s Institute of Drug Technology Australia Limited (IDT) is a vital player in the Australian biomedical industry, being the country’s only fully integrated and accredited contract research, development and manufacturing firm. Established in 1975, IDT is an Australian-owned public company, listed on the ASX since 1988. The company has a number of modern manufacturing facilities and laboratories in Melbourne, and is licensed by the Australian Therapeutic Goods Administration (TGA) and the US Food and Drug Administration (FDA) for production of active pharmaceutical ingredients. The company has become especially well known internationally for its dedicated facilities for the production and testing of anticancer drugs. The company is a leading manufacturer of active pharmaceutical ingredients for local and international markets in its FDA inspected containment facilities located in Melbourne and also provides a comprehensive range of consultancy, analytical and research and development services to the pharmaceutical, chemical, biotechnology and allied industries. IDT also specialises in the entire post-discovery pharmaceutical life cycle. Their expertise in the development of new chemical entities from laboratory-scale to full-scale production, combined with the ability to conduct phase I-IV clinical trials, uniquely positions IDT to assist companies at many stages from synthesis to market level production. In April 2000, the FDA approved for sale a major anticancer product made from an active pharmaceutical ingredient produced by IDT. IDT is the sole supplier of this anticancer active ingredient for worldwide distribution by one of the largest multinational pharmaceutical manufacturers in the USA. In addition, in association with Virax Holdings Limited [see separate entry], IDT is responsible for undertaking vaccine manufacture in compliance with strict international quality standards. Other portfolio products include anti-psychotics, antibiotics, narcotics and anti-inflammatory drugs. In May 2002, IDT announced the acquisition of Adelaide-based clinical trials research company CMAX Pty Ltd from the Mayne group.

Profile:

International Diabetes Institute
Contact: Phone: Email: Internet: Address: Mrs Shirley Murray, Public Relations and Project Manager +61 3 9258 5050

smurray@idi.org.au www.diabetes.com.au
260 Kooyong Road Caulfield, VIC, 3162 Australia Professor Paul Zimmet's commitment to the study of lifestyle effects on health in developing countries in the 1970s was the catalyst for the establishment of the Institute. Since its conception in 1976 the Institute has developed into a world renowned organisation offering a unique program of integrated diabetes health management coupled with an extensive research program undertaken by its 80 dedicated staff. In 2000 the clinic registered its thousandth client, making it by far the largest Diabetes clinic in Australia. The development and implementation of innovative diabetes management practices through evidence based research are core activities of the Institute. Professor Zimmet has lead the Institute during its twenty years of continuous community service. In 1998 Malcolm Kinloch was appointed Chief Executive Officer. Governance of the Institute is in cooperation with a dedicated Board of community leaders. The Institute relies on philanthropy, sponsorship and fee for service to maintain its programs. ACN 79 008 467 034 Intervet Australia Pty Limited

Profile:

Contact: Phone: Email: Internet: Address:

Dr John McNally, General Manager +61 3 5442 5011 Fax: +61 3 5442 3162

sales@intervet.com www.intervet.com
91-105 Harpin Street Bendigo East, VIC, 3550 Australia Postal Address: Box 2800 Bendigo Delivery Centre, VIC, 3554 Australia

Profile:

Intervet Australia Pty Limited, based at Bendigo in central Victoria, is engaged in the research and development, production and marketing of veterinary products. Intervet’s product range consists of vaccines, reproductive hormones, anti-infectives, anti-parasitics, feed additives, and productivity enhancers for a wide variety of animal species. One of the most costly disease problems facing Australia’s feedlot cattle is Bovine Respiratory Disease (BRD), also known as Shipping Fever. BRD usually arises when cattle are stressed and then exposed to harmful bacteria such as Mannheimia haemolytica (M h), which in turn decreases their resistance to infection by respiratory viruses. CSIRO Livestock Industries discovered that vaccines able to stimulate antibody responses against a M h toxin significantly protected cattle from BRD. CSIRO, through the former Meat Quality Cooperative Research Centre, developed and improved a cost-effective 'bacterin' vaccine. This killed whole-cell vaccine was transferred to Intervet Australia's Bendigo operation for Mh vaccine commercialisation. Pre-registration vaccine trials conducted in commercial feedlots were very successful in reducing the costs associated with M h infection. Registration of the new vaccine is expected by early to mid 2003. Intervet Australia has launched a vaccine to guard against cattle ticks. TickGARD vaccine, which was previously available in Queensland, was included as part of Intervet Australia's product range by late 2002. Intervet Australia took over the Bendigo facilities from the former AusVac Pty Ltd. Intervet Australia is a business unit of Intervet International BV, headquartered in The Netherlands and part of the Akzo Nobel Pharma Group. Intervet is one of the world’s leading animal health companies, active in 120 countries and employing some 5,000 people.

Invetech Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Paul Wright, CEO +61 3 9211 7712 Fax: +61 3 9211 7703

ACN 45 004 301 839

instDevelopment@invetech.com.au www.invetech-idd.com
495 Blackburn Road Mount Waverley, VIC, 3149 Australia Postal Address: Private Bag 44 Mount Waverley, VIC, 3149 Australia

Profile:

Invetech Pty Ltd focuses on contract instrumentation development and manufacture. Since 1988, Invetech has worked with start-ups, multinationals and strategic partners to develop marketleading instruments for the healthcare industry. Invetech's core capability is design and development of integrated systems and advanced technologies for analysis and laboratory automation. The company has a proven record of more than 15 successful instrument developments, undertaken collaboratively with clients (detailed at . Many of these developments involve automating medical laboratory processes, where reliable, repeatable instrument performance is essential to market success. Invetech offers a complete idea-to-market outsourcing solution, with the option for contract instrument manufacturing supported by sister company Vision BioSystems. Both companies are part of the publicly listed Vision Systems group [see separate entries]. Invetech is also active in developing new manufacturing processes and developing consumer and industrial products. Invetech has a US Food and Drug Administration (FDA) registered manufacturing facility, and QSR-compliant ISO9001 accredited design and development.

Invitrogen Australia Pty Limited
Contact: Phone: Email: Internet: Address: Mr Peter Waterman, Senior Director of AustralAsian Research Products +61 3 9545 5522 Fax: +61 3 9544 5622

ACN 72 053 997 194

aumail@invitrogen.com www.invitrogen.com
2A / 14 Lionel Road Mt Waverley, VIC, 3149 Australia Postal Address: PO Box 4296 Mulgrave, VIC, 3170 Australia

Profile:

Invitrogen Corporation, Carlsbad, USA, develops, manufactures and markets research tools in kit form and provides other research products and services to biotechnology and biopharmaceutical researchers and companies worldwide. The company manufactures and markets products and services that simplify and improve gene cloning, gene expression, and gene analysis techniques for corporate, academic and government entities. The company also engages in technology licensing, research services, large-scale production, and life science technical expertise and support. Invitrogen Australasia provides a range of molecular biology and cell culture reagents to the Australian and New Zealand markets from operations based in Melbourne and Auckland. New Zealand is a premier source of animal sera and protein products. Invitrogen’s Auckland and Christchurch facilities manufacture and supply animal-derived products.

Joint Centre for Crop Improvement
Contact: Phone: Email: Internet: Address: Prof Jim Kollmorgen, Director +61 3 5362 2111 Fax: +61 3 5362 2187

jim.kollmorgen@nre.vic.gov.au www.jcci.unimelb.edu.au
The University of Melbourne Parkville Victoria Australia and Victorian Institute for Dryland Agriculture Natimuk Road Horsham Victoria Australia Horsham, VIC, 3401 Australia Postal Address: Private Bag 260 Horsham, VIC, 3401 Australia

Profile:

The Joint Centre for Crop Improvement (JCCI) is a collaborative venture between The University of Melbourne and the Department of Natural Resources and Environment. The Centre undertakes research for the benefit of Australia's grains industries and trains postgraduate students and research fellows. Members of the Centre are located at campuses of the University and at NRE Institutes. Biotechnology research in the JCCI is undertaken in the Centre's variety development program and is located at both the Parkville campus of the University and at the Victorian Institute for Dryland Agriculture, Horsham. The Molecular Plant Genetics and Germplasm Development Group is part of the JCCI and is located in the Crop Production Department at The University of Melbourne. The group is focused on the application of biotechnology to crop production; and research outputs are directed into the pulse and oilseed Brassica plant breeding programs at VIDA. Biotechnology research in the JCCI at Horsham focuses on the production of transgenic wheat and barley for Australia's breeding programs; and there is some work on molecular analysis of agronomic traits and disease resistance.

Kendle Pty Limited
Contact: Phone: Email: Internet: Address: Dr George Mihaly, Managing Director +61 3 9564 8090 Fax: +61 3 9564 8336

ACN 81 379 182 044

mihaly.george@kendle.com www.kendle.com
156 Drummond Street Oakleigh, VIC, 3166 Australia Globally, Kendle is the fifth largest pharmaceutical development organisation, servicing the pharmaceutical, medical device and biotechnology industries, with a presence in eleven countries. Kendle’s Australian business originated in 1994, and, following a merger with Synermedica Pty Ltd in March 2000, now has 40 staff with offices in Melbourne and Sydney as well as a presence in New Zealand. Kendle offers services in four related areas: Development and Commercialisation; Clinical; Regulatory; and Health Outcomes. Kendle can plan and manage clinical trials at all stages of drug development. With access to an international network, Kendle has available a broad base of physicians and therapeutic areas. With a comprehensive understanding of global drug development, Kendle integrates preclinical, regulatory, clinical, health economic and marketing imperatives. It provides strategic planning, project planning and management, technical appraisals and valuations, and business planning. Kendle offers a full range of regulatory services for drugs and devices. In addition, the company provides comprehensive health-economic and pharmacoeconomic services, including defining strategies in drug development, retrospective cost effectiveness analysis, and health economic studies.

Profile:

Kinacia Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Ken Windle, Chairman and Chief Executive Officer +61 3 9899 9588 Fax: +61 3 9899 9872

ACN 82 052 205 848

pam.wade@kinacia.com.au www.kinacia.com.au
Suite 4 899 Whitehorse Road Box Hill, VIC, 3128 Australia Kinacia Pty Ltd is a leading, privately owned, Australian bioscience company with a primary research focus on blood clotting and kinases. Kinacia scientists first became interested in a particular target kinase after discovering its importance in shear induced platelet adhesion, aggregation, and subsequent clot formation. Further work has now identified that there are several different isoforms of the kinase and that these have specialised functions within specific cells: cells not only involved in blood clotting, but also in tumour cell proliferation and inflammation. A very successful ongoing chemistry effort has produced over 300 patented novel compounds with mixed isoform selectivity. Clinical studies are currently being undertaken on the lead anti-clotting compound. Potential markets for the anti-clotting compound include unstable angina, heart attack and stroke. Lead compounds in other areas, including restenosis, inflammation and cancers, are also under investigation. The company is also developing a diagnostic instrument which may assist in identifying patients at risk of a blood clotting event. A laboratory version of the instrument is being tested using blood from patients. Kinacia's research and development program continues to be underpinned by a strong alliance between the company and researchers from the Australian Centre for Blood Diseases (ACBD) at Monash University in Melbourne. Kinacia commenced operation in July 1997 and has secured investment funds from venture capital and private investors, including Australian Technology Group Limited, Macquarie Technology Funds Management, Momentum Ventures, GBS Venture Partners (formerly Rothschild Bioscience Fund), the Thorney Group (a division of the Pratt Group), Macquarie PRISM and Macquarie Investment Managers. In addition, the company has secured two Australian Government R&D Start Grants totalling $3.5m.

Profile:

Kryocor Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Hugh McCormack, Chief Executive Officer +61 3 9326 6955 Fax: +61 3 9329 8071

ACN 46 071 858 387

bni@bionova.com.au www.bionova.com.au
36 Munster Terrace North Melbourne, VIC, 3051 Australia Postal Address: PO Box 359 North Melbourne, VIC, 3051 Australia

Profile:

Kryocor Pty Ltd was established in 1995 as the R & D arm of Bio Nova International Pty Ltd. It was awarded an R & D Start grant in June 1997 to develop a coronary bypass prosthesis. This will enable a unique patented technology, currently used in the manufacture of a range of vascular prostheses, combined with specific aspects of cell biology, to be the basis for the development of the world's first "off the shelf" dedicated coronary artery prosthesis which is patient specific. Coronary artery bypass grafting (CABG) continues to be one of the most commonly performed surgical procedures in the developed world. The patient's own vessels are currently used for this procedure. Secondary harvesting of vessels in redo surgery imposes added surgical morbidity and mortality. An "off the shelf" coronary artery prosthesis which can match the performance of the patient's natural vessel would be of great benefit by reducing the surgical risk to the patient and reduce the costs associated with operating time and hospital stay. Testing for the coronary bypass prosthesis is in the preclinical stage, with research work being conducted in Kryocor’s labs and certain requirements contracted out to other companies and institutions. Kryocor Pty Ltd is a wholly owned subsidiary of Bio Nova International Pty Ltd [see separate entry].

Ludwig Institute for Cancer Research
Contact: Phone: Email: Internet: Address: Dr Cassandra Thumwood, Scientific Administrative Officer +61 3 9341 3155 Fax: +61 3 9341 3104

Cassandra.Thumwood@ludwig.edu.au www.ludwig.edu.au
Level 6, Centre for Medical Research Entrance 5, Royal Parade Royal Melbourne Hospital Melbourne, VIC, 3050 Australia Postal Address: PO Box 2008 Royal Melbourne Hospital Parkville, Victoria, 3050 Australia

Profile:

The Ludwig Institute for Cancer Research consists of an international network of ten branches specialising in basic and clinical cancer research. The Melbourne Branch of the Institute was established in 1980 in collaboration with the Royal Melbourne Hospital, the University of Melbourne and the Walter and Eliza Hall Institute. The Ludwig Institute extended its affiliations in 1990 by establishing a clinical program at the Austin Campus of the Austin & Repatriation Medical Centre in 1990. The Director of the Melbourne Branch is Professor Tony Burgess. The Branch’s aims in basic and clinical cancer research are to identify and characterise molecules that contribute to the tumourigenic state. This information is used as a starting point for identifying agents that might be able to be incorporated into new and innovative treatments to improve cancer outcomes. In addition to cell signalling based strategies, the research and clinical staff at Ludwig Institute are actively involved in identifying molecules that can serve as specific cancer markers for imaging analysis and also as targets for immune based approaches, including the stimulation of host immune responses to cancer. Currently, the Branch employs 180 staff, including 20 postgraduate students. In the laboratories there is a strong theme of research into the mechanisms governing the regulation of cellular proliferation, movement and control with respect to growth factors and signal transduction. Areas of particular interest clinically are colon cancer, leukaemia, breast cancer, melanoma, tumour targeting, cancer immunotherapy and the molecular pathology of cancer. Austin Campus - Ludwig Joint Oncology Unit & Tumour Targeting Program Harold Stokes Building, Austin & Repatriation Medical Centre, Heidelberg, Victoria Ludwig Joint Oncology Unit - Phone: 61 3 9457 6933 Fax: 61 3 9457 6698 Tumour Targeting Program - Phone: 61 3 9496 5876 Fax: 61 3 9496 5892

M 7 Pty. Ltd.
Contact: Phone: Email: Address: Dr Christine Hirst, Managing Director +61 3 9866 5024 Fax: +61 3 9821 5047

ACN 74 088 964 989

chirst@magnet.com.au
86 Caroline Street South Yarra, VIC, 3141 Australia M7 Pty Ltd is developing an implantable medical device to provide a patient with control over urinary incontinence. A surgical procedure has been identified in which a small piece of a patient's existing muscle is taken from another part of the body and transplanted around the urethra. An electronic device will then be inserted in the area of the muscle. With the aid of a small transmitter worn by the patient, the muscle can be activated to constrict or relax, thereby enabling the control of the flow of urine at will. The company was awarded a Commonwealth Government Biotechnology Innovation Fund grant of A$250,000 in August 2001 to assist in developing this device. The grant was used to demonstrate the concept in rabbits rendered incontinent surgically, and with isolated muscle preparations. The general characteristics of the implantable device were also determined. Work is continuing to demonstrate the longevity of the transplant and technology in rabbits, and in a larger animal, to ultimately gain approval to trial the technology and the implantable medical device in man. It is expected the technology will be applicable to males and females.

Profile:

Mabtech Limited
Contact: Phone: Email: Internet: Address: Prof Anthony Linnane, Director +61 3 9426 4200 Fax: +61 3 9426 4201

ACN 99 062 965 619

tlinnane@cmbm.com.au www.mabtech.com.au
2nd Floor 185/187 Hoddle Street Richmond, VIC, 3121 Australia Mabtech Limited is a Victorian biotechnology company offering high quality immunological reagents and services at competitive prices. The company was established in 1993, and adopted the Mabtech name in 1994. It is the commercialisation arm of the Centre for Molecular Biology and Medicine, a non-profit research institute working on cancer and aging and funded almost entirely from commercial sources. Mabtech has been working on tumour diagnostics as its primary product and has developed a gastrointestinal cancer diagnostic kit to detect stomach and colon cancers, providing an overlapping but not identical detection of cancers to CEA (carcinoembryonic antigen) detection. Current research shows that together with CEA, the diagnostic kit can detect over 50% of cancers. The kit is now being sold on the international market, with Mabtech working hard to get the product listed on the Pharmaceutical Benefits List to make it more widely available to the domestic market.

Profile:

Mayne Health Dorevitch Pathology
Contact: Phone: Email: Internet: Address: Ms Rachelle Michie, Clinical Trials Manager +61 3 9244 0421 Fax: +61 3 9244 0432

ACN 84 007 190 043

michie@maynegroup.com www.maynegroup.com
Main Laboratory 16-18 Banksia Street Heidelberg, VIC, 3084 Australia Mayne Health Dorevitch Pathology is a leading provider of pathology and medical diagnostic services to doctors, specialists and hospitals throughout Victoria. The company’s focus is on world leading diagnostic technology. Mayne Health Dorevitch Pathology is part of one of the largest private pathology groups in Australia, including Mayne Health Laverty Pathology in New South Wales and Mayne Health Western Diagnostic Pathology in Western Australia. Mayne Health Pathology comprises a network of specialist pathologists with more than 4000 staff, in 41 laboratories. Mayne Health Dorevitch Pathology provides services to over 70 private and public hospitals in Melbourne, regional Victoria, and New South Wales. Services to community-based patients are provided through more than 100 collection centres, and a network of 16 laboratories spread throughout these regions.

Profile:

Mayne Pharma Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Alex Bell, Vice President - Technical Operations +61 3 8541 5474 Fax: +61 3 8541 5788

ACN 58 097 064 330

alex.bell@au.maynepharma.com www.maynegroup.com
1-23 Lexia Place Mulgrave, VIC, 3170 Australia Postal Address: PO Box 394 Mulgrave, VIC, 3170 Australia

Profile:

Mayne Pharma is a leading international pharmaceutical organisation, built on a heritage of 150 years of pharmaceutical excellence. With products marketed in more than 50 countries, our intimate knowledge of local markets allows us to provide tailored pharmaceutical solutions to hospital pharmacy and to health professionals. Our global manufacturing infrastructure operates across 145,000 square feet (13,500m2), producing more than 44 million ampoules and 26 million vials annually, in addition to the production of specialised modified release oral pharmaceuticals. Mayne Pharma’s facilities are world-class and have been cGMP certified by the major authorities, including the FDA (USA), the MCA (United Kingdom), the HPFB (Canada) and the TGA (Australia). Our Australian research and development centres and manufacturing plants are located in Adelaide, South Australia, for capsule and tablet oral pharmaceuticals, and Melbourne, Victoria, for injectable products. Mayne Pharma has established and proven injectable contract manufacturing expertise - developing projects from clinical trial stage, through validation and registration, to commercial manufacture. Based on our core manufacturing competencies and more than ten years experience, we offer full contract services, from formulation through to final packaging, and clinical trial quantities to fullscale production.

McFarlane Laboratories Pty. Ltd.
Contact: Phone: Email: Address: Mr Andrew Broadbent, +61 3 8415 1099 Fax: +61 3 8415 1799

ACN 54 064 190 003

mail@maclab.net
18 Harper Street Abbotsford, VIC, 3067 Australia McFarlane Laboratories, registered in 1973, markets and manufactures over-the-counter pharmaceutical products to benefit arthritis sufferers and those with excessively oily skin. The majority of the company's products are exported. Seatone, an anti-inflammatory agent extracted from New Zealand greenlipped mussels, was developed in collaboration with Victoria's RMIT University. Concentrated mussel was used originally as a natural food supplement for the prevention of pain normally associated with arthritis, swelling and muscle discomfort. After critical review by researchers at the Universities of Adelaide and Queensland, it was found that persons with a diet which included concentrated mussel seemed to have less discomfort as they aged. These compounds were patented and named Lyprinol. Lyprinol was approved and released for sale in 2000. Seatone and Lyprinol have been used all over the world and have also been used to treat arthritis in animals. Another product, Ketsugo, contains Isolutrol, a cosmetic ingredient developed in collaboration with RMIT University and CSIRO which is used for treatment of excessively oily skin. It eliminates the cause of shiny skin, open pores, blackheads, whiteheads, pimples and acne by gently reducing the skin's overproduction of oil, keeps pores free from clogging, even under make-up. Ketsugo has successfully undergone a number of safety and efficacy tests. Among these were the independent trials conducted by a French dermatologist on 40 men and women with severely oily skin. Within 21 days of using Ketsugo, 85% of the group had skin within the normal oiliness range. All showed an improvement in the tone and texture of their skin. The active ingredient, Isolutrol, is used in the product range of one of the world’s leading cosmetic companies. Both products are manufactured in Melbourne and are available from pharmacies and health food stores.

Profile:

Medical Developments Australia Pty. Ltd.
Contact: Phone: Email: Address: Mr Allan Eagle, CEO +61 3 9547 1888 Fax: +61 3 9547 0262

ACN 43 004 903 682

mda@bigpond.com
Facility 7 56 Smith Road Springvale, VIC, 3171 Australia Medical Developments Australia Pty. Ltd. develops and manufactures medical and surgical equipment, mainly for aiding respiration. The company commenced activity in 1972, assisted by a Victorian Government grant to develop the OXI-saver, an oxygen resuscitation system. In Victoria today, every ambulance is equipped with the OXI-saver. Since 1972, the company, based in Springvale, Melbourne, has expanded dramatically. By April 2002, Medical Developments Australia was employing 12 people and producing over 80 products, including asthma devices, human and veterinary anaesthesia machines, emergency oxygen equipment for diving accidents, pre-hospital pain relief devices, oxygen resuscitators and oxygen therapy equipment. The company has also developed the Clare Anaesthetic Ventilator (CAV) in a joint venture with Melbourne’s Royal Children’s Hospital. The CAV automatically ventilates patients while they are under anaesthesia. The company has a strong focus on research and development, and is diversifying its activities into pharmaceuticals, as a result of a major collaborative project with the CSIRO, now completed. The company intends to establish a pharmaceutical division. Medical Developments Australia has a burgeoning export base, which accounts for about 33% of its current turnover. It has major distributors in United States, New Zealand, South Korea, Singapore, Europe and Canada.

Profile:

MediClin Pty Ltd
Contact: Phone: Email: Internet: Address: Mr John Varigos, Managing Director +61 3 9822 9215 Fax: +61 3 9822 7395

ACN 88 633 054 548

jvarigos@mediclin.com.au www.mediclin.com.au (under construction)
1022 Malvern Road Armadale, VIC, 3143 Australia MediClin is a clinical trial management organisation servicing the pharmaceutical and biotechnology industries to assist with all facets of clinical trial management. As patient recruitment is often the rate-limiting step in the clinical development of pharmaceuticals, MediClin utilises a network of physicians, in both primary care and hospital settings, to facilitate the rapid recruitment of patients into clinical trials. Each study is custom managed to meet the requirements of the sponsor. Utilising both in-house and contract staff, MediClin can act as a Site Management Organisation or as a Contract Research Organisation, depending on the study requirements. MediClin ensures that all clinical investigative sites have been evaluated for suitability and commitment to the study, and staff are trained on the requirements of ICH - GCP to ensure all studies meet the rigid international regulatory standards. With a staff of experienced Clinical Research Coordinators (CRC) working with company standard operating procedures (SOPs), MediClin ensures that the busy primary health care physicians are provided with the support required to ensure speedy and precise recruitment of patients and accurate completion of case report forms. All CRCs receive in-house training on the therapeutic specifics for each study before commencement of the study. Utilising the combination of custom management of each project, therapeutically experienced staff and a network of primary care and hospital physicians, MediClin ensures that each study is performed accurately, in the minimum of time, and cost effectively. MediClin approaches clinical trial management by partnering with the investigative site and the sponsor to ensure that the study time lines are achieved through effective site management.

Profile:

Meditech Research Limited
Contact: ASX: Phone: Email: Internet: Address: Mr Chris Carter, CEO MTR +61 3 9296 2026 Fax: +61 3 9296 2192

ACN 60 058 390 953

mrl@mrl.com.au www.mrl.com.au
TOK Corporate CentreLevel 1 459 Toorak Road Toorak, VIC, 3142 Australia Meditech Research Limited (MTR ) is a publicly listed company on the Australian Stock Exchange engaged in the development of human pharmaceuticals based on naturally occurring carbohydrates. Meditech aims to develop its two platform technologies, HyACT™ and GAGs, with a view to multiple licensing of each to major pharmaceutical companies: 1. Hyaluronic Acid Chemosensitising Transport or HyACT™: involves the use of hyaluronan or hyaluronic acid (HA) as a drug delivery vehicle for anticancer agents. MTR has been able to demonstrate that hyaluronan binds several receptors including the CD44 receptor, which is overexpressed on cancer cells. MTR’s technology combines anticancer drugs with hyaluronan to produce a drug delivery mechanism that delivers anticancer drugs directly and preferentially to cancer cells. MTR holds several patents covering the HyACT™ technology. Encouraging animal and preclinical studies prompted MTR to conduct and successfully complete two Phase I human trials at Royal Melbourne Hospital. MTR intends to continue with clinical development of the HyACT™ technology in a Phase II clinical trial in 2003. 2. Glycosaminoglycans (GAGs) Project: GAGs is a new pharmaceutical development project centred on naturally occurring sugar-based polymers, GAGs. GAG fragments attach themselves to a number of important proteins that are associated with asthma, melanoma and HIV infection. The identified sugars form the basis for developing drugs to treat the aforementioned diseases. The project is based at Curtin University in new, well-equipped facilities at the Royal Perth Hospital. In addition to the two platform technologies, Meditech has also completed a licensing deal with SkyePharma in the UK that will see MTR gaining royalties from SkyePharma’s sales of Solarase in S-E Asia.

Profile:

Melbourne IVF Pty. Ltd.
Contact: Phone: Email: Internet: Address: Ms Donna King, Administration Manager +61 3 9473 4444 Fax: +61 3 9473 4454

ACN 007 243 352

peterh@mivf.com.au www.mivf.com.au
Suite 10 320 Victoria Parade East Melbourne, VIC, 3002 Australia Melbourne IVF was established in 1989 for couples experiencing fertility problems, and has made many significant advances in assisted reproductive technology. It is now possible to detect some genetic diseases in very early embryos by a procedure known as preimplantation genetic diagnosis (PGD). To achieve this, the couple has a cycle of in vitro fertilisation (IVF) treatment to produce embryos in the laboratory. Each embryo is tested for the disease the parents carry and unaffected embryos are selected for transfer back to the woman's uterus. To perform the genetic test, embryos are grown to the 8-cell stage (about 3 days) and then two cells are carefully removed using a fine glass needle. The two biopsied cells are used for the genetic diagnosis. PGD has primarily been used to determine the sex of embryos for couples who carry a sex-linked disease, such as haemophilia or muscular dystrophy (which affect only boys). An increasing number of diseases can be diagnosed in early embryos by PGD including cystic fibrosis and thalassaemia, and other chromosomal errors such as Down Syndrome. This test is currently being used at Melbourne IVF to detect genetic disorders in very early embryos. Future research efforts will focus on the use of this technology for couples with recurrent miscarriage or repeated implantation failure with IVF. In both these conditions there is thought to be a high rate of chromosomal abnormality, and PGD could be used in conjunction with IVF to determine a normal karyotype (chromosome complement) before embryo replacement. Melbourne IVF has also been testing a new technique which makes it possible to identify chromosomes in embryos.

Profile:

Merck Pty. Limited
Contact: Phone: Email: Internet: Address: Dr Gail-Eller Roswitha, Divisional Manager - Laboratory Products +61 3 9728 5855 Fax: +61 3 9728 1351

ACN 25 005 064 791

roswitha@merck.com.au www.merck.com.au
207 Colchester Road Kilsyth, VIC, 3137 Australia Merck Pty. Limited, part of the 330-year-old global Merck group with headquarters in Germany, operates two core businesses: Laboratory Products, serving the scientific market with analytical reagents, test kits and equipment; and Specialty Fine Chemicals, a unique range of high purity fine chemicals and pearl lustre pigments for manufacturing industries. Merck sells a range of products in areas such as bioprocessing and bioseparation, cell signalling; cloning, expression & purification systems; apoptosis & cell cycle, peptide chemistry and combinatorial chemistry, microbiology and microscopy. Specialised niche catalogues for these areas are available. The brands include Calbiochem®, Oncogene Research Products®, Novagen®, Novabiochem® and Clinalfa®. Merck also sells the BDH, Merck and EM Science range of analytical reagents and solvents. In addition, there is a range of standards for instrumental analysis. In the environmental testing equipment area, Merck carries the WTW range and the Brand liquid handling range. Merck Pty. Limited is headquartered in Kilsyth, Melbourne, and employs 60 staff located around Australia.

Profile:

Mercy Tissue Engineering Limited
Contact: Phone: Email: Internet: Address: Dr Steven Mercer, Managing Director +61 3 9928 6030 Fax: +61 3 9928 6033

ACN 77 082 345 953

info@mercytissue.com.au www.mercytissue.com.au
159 Grey Street East Melbourne, VIC, 3002 Australia Mercy Tissue Engineering Pty Ltd is a human tissue culture facility, established by Mercy Health and Aged Care (Sisters of Mercy) in Melbourne, to offer cell culture treatments and implants for Australian patients, using the patient’s own tissues ('autologous'). The company has ISO certification and a Therapeutic Goods Administration (TGA) GMP licence. The initial biologic implant product is autologous cultured cartilage for repair of articular cartilage defects. The technology used incorporates proprietary methods developed by the company. Further R&D is directed at the production of other autologous human tissue implants.

Profile:

Metabolic Pharmaceuticals Limited
Contact: ASX: Phone: Email: Internet: Address: Dr Chris Belyea, Managing Director MBP +61 3 9824 0083 Fax: +61 3 9826 0949

ACN 96 083 866 862

info@metabolic.com.au www.metabolic.com.au
Level 1 10 Wallace Avenue Toorak, VIC, 3142 Australia Postal Address: PO Box 23 Toorak, VIC, 3142 Australia

Profile:

Metabolic Pharmaceuticals Limited has the mission of developing therapies for metabolic diseases. Metabolic listed on the Australian Stock Exchange (MBP) in 1998, and major shareholders are Circadian Technologies Ltd and Monash University. Adopting a "virtual" structure, it focuses on clinical development of purchased or in-licensed drugs. Metabolic’s major project is to develop Advanced Obesity Drug 9604 (AOD9604), an orally administered anti-obesity drug. AOD9604 is the most potent of a series of anti-obesity compounds modelled on a fat-reducing region of the human growth hormone molecule. Growth hormone occurs naturally in the body and, along with its growth-promoting function, also acts directly to reduce stored body fat. Animal studies indicate that AOD9604 may reduce fat in humans, without the other unwanted effects of growth hormone. A successful Phase I clinical trial was followed by a Phase 2A trial in obese patients in February 2002 that gave positive results in respect of safety, fat metabolic activity and indications of weight reduction. An oral Phase 2A trial is scheduled for May 2002. This technology also has potential veterinary applications. Pig feed containing AOD9604 could be used to safely reduce back fat in pigs. Domestic pets may also benefit from this technology. Metabolic’s candidate drugs for type II diabetes act via a novel mechanism to potentiate the action of the body’s own insulin, and in animal experiments have been shown to normalise diabetic symptoms. Lead selection is nearly complete. MBP0201 is an orally-available iron chelator, recently licensed from Sydney’s Heart Research Institute to treat iron overload. MBP0250 and MBP0260 are fragments of amylin and adrenomedullin, respectively, discovered by the Auckland University, for treatment of osteoporosis. Both projects will enter preclinical toxicity studies in 2003 if animal efficacy experiments confirm promise.

Micronized Foods Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Philip Delacretaz +61 3 9338 3911 Fax: +61 3 9330 3748

ACN 17 071 914 013

phildel@e-merch.com.au www.e-merch.com.au
15 Catalina Drive Tullamarine, VIC, 3043 Australia Micronized Foods Pty Ltd is a grower and producer of wild rice and amaranth. With assistance from a Commonwealth Government R&D START grant, the company has developed a new food additive from amaranth with elevated levels of tocotrienol compounds (vitamin E).

Profile:

Mimotopes Pty Ltd
Contact: Phone: Email: Internet: Address: Dr Andrew Milner, Managing Director +61 3 9565 1111 Fax: +61 3 9565 1199

ACN 90 090 841 286

andrew_milner@mimotopes.com www.mimotopes.com
11 Duerdin Street Clayton, VIC, 3168 Australia Postal Address: PO Box 1415 Clayton South MDC, VIC, 3169 Australia

Profile:

Mimotopes is an internationally focused biotechnology company formed in 1988 with headquarters in Melbourne. Since late 2002, Mimotopes has been a subsidiary of Fisher Scientific International Inc. Fisher serves as a one-stop source of products, services and global solutions for its customers. The company's primary target markets are scientific research and healthcare. Fisher's drug discovery chemistry products and services span the drug discovery and development process from manufacture of compound libraries for identification of hits in biological screening assays, through lead optimisation, to large-scale GMP manufacture of actives. Mimotopes develops, markets and distributes products for proteomics (eg peptide libraries, cyclic peptides and custom peptides), small molecule drug discovery (eg SynPhase™ solid phase products for combinatorial chemistry, custom small molecule libraries, and lead optimisation services), and partners small to large pharmaceutical companies in novel drug discovery. Mimotopes has developed a powerful platform of technology and know-how by combining its unique solid phase technology (grafted polymers) with expertise in solid phase chemistry, medicinal chemistry and biological applications.

MiniFab (Aust) Pty Ltd
Contact: Phone: Email: Internet: Address: Prof Erol Harvey, CEO 03 9764 2241 Fax: 03 9763 9867

ACN 100 768 474

erolharvey@minifab.com.au www.minifab.com.au
1 Dalmore Drive Scoresby, VIC, 3179 Australia

Profile:

MNT Innovation Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Damian Lismore +61 3 9214 4414 Fax: +61 3 9214 8008

ACN 16 101 074 855

damian.l@microtechnologycrc.com www.microtechnologycrc.com
Level 5 60 William Street Hawthorn, VIC, 3122 Australia Postal Address: PO Box 218 Hawthorn, VIC, 3122 Australia

Profile:

MNT Innovation Pty Ltd is the commercialisation agent for the Cooperative Research Centre (CRC) for microTechnology. This CRC focuses on microtechnology – the convergence of technologies and disciplines such as nanotechnology, materials sciences, microelectronics, biotechnology, life sciences, medicine, lithography, information technology, physics, chemistry and engineering – deployed in structures and devices with features in the micron domain. Microtechnology is a combination of many different technologies. Its significance is that it offers an alternative to conventional technologies, and it has already made great contributions to the areas of computer peripherals, sensors, bioscience systems and small actuators. The CRC for microTechnology combines the ability to make things smaller and inventing new ways and new products that add to the quality of everyday life. MNT Innovation Pty Ltd is headquartered in Melbourne. CRC participants are Swinburne University of Technology, RMIT University, Griffith University, CSIRO, Bioproperties (Australia) Pty. Ltd. [see separate entry], Motorola (Australia) Pty. Limited, Robert Bosch (Australia) Proprietary Limited, Alcatel (Australia) Limited, the Department of Defence, the Australian Institute of Sport, the Victorian Department of Innovation, Industry and Regional Development (DIIRD), and the Queensland Department of State Development.

Monash Institute of Reproduction and Development
Contact: Phone: Email: Internet: Address: Ms Kat Hodgins, Public Relations Co-ordinator +61 3 9594 7138 Fax: +61 3 9594 7111

Kat.Hodgins@med.monash.edu.au www.monashinstitute.org
27-31 Wright Street Clayton, VIC, 3168 Australia Postal Address: Monash Medical Centre 246 Clayton Road Clayton, Victoria, 3168 Australia

Profile:

The Monash Institute of Reproduction and Development was established in 1991. It brought together scientists and clinicians undertaking research into conception, birth and development at the (then) Centre for Early Human Development with scientists working in the field of male reproductive health in the Department of Anatomy at Monash University. The Institute is part of Monash University’s Faculty of Medicine. Located at the Monash Medical Centre, the Institute has close links with clinical units including newborn services. A Management Advisory Board comprising members of the community and the education and health sectors has been appointed to support the Director of the Institute and the Institute’s Executive Team. In 1993, the Monash Research Foundation for Reproduction and Development was established to raise and manage funds for the Institute’s research into reproduction, development and growth. An Executive Board and Board of Trustees manage these functions and are subordinate to the Management Advisory Board. The Monash Institute of Reproduction and Development is committed to excellence in the performance of medical and biological research into the science of reproduction, development and growth. The Institute promotes the applications of its research for the benefit of the reproductive health of women and men, the growth and development of the foetus, infants and children; the development of Australia’s agricultural industry and the preservation of the Australia’s and the world’s endangered species. The Institute employs its research knowledge to enhance the education of students, the professional advancement of medical practitioners and scientists as well as educating members of the community. Key Research Areas (Keywords): embryonic adult stem cell biology, genetics of infertility, immunocontraception, cell-based therapies and transgene/gene knockout technology, prostate development, prostate cancer and disease, early human development, human infertility and IVF, fertilisation and embryogenesis, nuclear transfer, cloning and transgenesis in animals, gene expression in oogenesis and development, primate reproductive biology, mammalian developmental biology, molecular embryology and birth defects, fetal physiology, neonatal physiology, neonatal intensive care, sleep physiology and medicine, functional genomics, genetics and human disease, Down Syndrome, cancer biology and genetics, tumour immunity, cytokine signalling, transcription factors, apoptosis and inflammatory diseases

Monash Institutes of Health (MIH)
Contact: Phone: Email: Internet: Address: Ms Kat Hodgins, Public Relations Co-ordinator +61 3 9594 7138 Fax: +61 3 9594 7111

Kat.Hodgins@med.monash.edu.au www.monashinstitutes.org
Monash Institutes of Health (MIH) Monash Medical Centre 246 Clayton Road Clayton, VIC, 3168 Australia The MIH is one of Australia's leading medical and biomedical science research complexes located less than 30 minutes from the centre of Melbourne. With state of the art facilities for health and medical research, MIH provides both incubator space for new companies and allows existing companies access to a research environment with a proven commitment to excellence. MIH is a full service biotechnology facility taking research from the molecule through to the clinical stage and ultimately benefiting the broader population through commercialisation. It combines Australia's largest university, three of Melbourne's most prominent hospitals and three of the nation's leading independent research institutes. Major research programs of MIH include embryonic stem cell research, diabetes and cancer research, functional genomics and cell biology, drug discovery, cardiovascular disease, haemostasis, reproductive medicine, prostate disease, bioinformatics, infectious disease and neuroscience.

Profile:

Monash IVF Pty Ltd
Contact: Phone: Email: Internet: Address: Ms Donna Howlett, Managing Director +61 3 9429 9188 Fax: +61 3 9428 2715

ACN 63 006 942 990

info@monashivf.edu.au www.monashivf.edu.au
Epworth Hospital, Level 4 89 Bridge Road Richmond, VIC, 3121 Australia Monash IVF has made many significant advances in assisted reproductive technology since its establishment in 1971, and the company continues to be a global leader in this field. Since the early 70’s Monash IVF has helped many families achieve their goal of having a healthy baby. More than 7000 children have been born as a result of successful treatment in our programs. Twelve out of the first fifteen IVF babies born in the world are Monash IVF babies. Some of our team’s groundbreaking achievements include: • First frozen embryo birth in the world • First donor egg baby in the world • World’s first pregnancy and birth from a sperm retrieval operation • Australia’s first surrogate birth • Australia’s first open testicular biopsy twins • Australia’s first Blastocyst baby In vitro fertilisation (IVF) research began in 1971 at Queen Victoria Medical Centre and Royal Women's Hospital as a joint venture between Monash and Melbourne Universities, and the first IVF birth in Australia occurred in 1980. The company diversified in the second half of the 1980s to provide diagnostic services in pathology (andrology and hormone assays) and ultrasound. One central location was expanded into several permanent sites plus regional programs throughout Victoria, in Bairnsdale, Ballarat, Bendigo, Casterton, Geelong, and Sale. In Queensland there are clinics in Southport and Brisbane, and a regional program in Ipswich. An active research and development arm ensures couples receive world-class care using the latest technology in reproductive medicine. The company also offers a DNA Genetics Service. In the field of assisted reproduction, Monash IVF, through both technology transfer arrangements and ongoing partnerships, continues to assist numerous programs internationally.

Profile:

Monash Mouseworks
Contact: Phone: Email: Internet: Address: Ms Tim Ambrose, Manager +61 3 9905 5466 Fax: +61 3 9905 2547

ACN 12 377 614 012

Tina.Ambrose@med.monash.edu.au www.med.monash.edu.au/mouseworks
c/- Monash UniversityDepartment of Physiology Clayton, VIC, 3168 Australia Monash Mouseworks provides a specialist facility to produce and house highest quality, germ-free, genetically modified mice for cutting edge research into genetic disease and cancer.

Profile:

Monash Reproductive Pathology and Genetics Pty Ltd
Contact: Phone: Email: Internet: Address: Dr Adrianne Pope, Director of Laboratory Services +61 3 9429 9188 Fax: +61 3 9427 8545

ACN 74 067 416 786

info@monashivf.edu.au www.monashivf.edu.au
4th Floor, Epworth Hospital 89 Bridge Road Richmond, VIC, 3121 Australia Monash Reproductive Pathology and Genetics Pty Ltd (MRPG) was established in 1988, as a wholly owned subsidiary of Monash IVF. MRPG is a NATA-RCPA accredited laboratory, specializing in diagnostic services for reproductive medicine. All profits generated by Monash Reproductive Pathology and Genetics are donated to Monash University for research and development in reproductive medicine. MRPG has two laboratory sites located in Melbourne. Monash Reproductive Pathology and Genetics is one of a few laboratories to specialise in reproductive medicine and to comply with stricter international standards for semen assessments. The range of tests available include reproductive endocrinology, serology, semen analysis, and specialised andrology procedures, such as retrograde ejaculation assessments. MRPG also carries out Y chromosome deletion testing, a specialised blood test for those patients with low sperm counts who are considering assisted reproductive technologies to determine whether a genetic cause for male infertility exists. Other services provided include a referral service for sperm antibody assessments from other major diagnostic laboratories within Victoria; genetic testing, including cystic fibrosis screening and semen cryopreservation, for patients who are undergoing a procedure that may impair fertility, such as chemotherapy, radiotherapy or vasectomy. This large cryostorage service has been in operation for 20 years and complies with Infertility Treatment Authority requirements. Additional tests are continually being evaluated and added to the reproductive range, and all tests are carried out according to World Health Organisation guidelines.

Profile:

Monash Research Cluster for Biomedicine
Contact: Phone: Email: Internet: Address: Prof Warwick Anderson, Head of School of Biomedical Sciences +61 3 9905 2355 Fax: +61 3 9905 2566

warwick.anderson@med.monash.edu.au www.med.monash.edu.au
Monash University Faculty of Medicine Wellington Road Clayton, VIC, Australia Postal Address: PO Box 13F Monash University Clayton, VIC, 3800 Australia

Profile:

The Monash Research Cluster for Biomedicine (MRCB), formed by the Monash University School of Biomedical Sciences (SOBS); The cluster encompasses the Departments of Anatomy & Cell Biology, Biochemistry & Molecular Biology, Microbiology, Pharmacology, Physiology, and Radiography & Medical Imaging, together with the Faculty of Medicine, and Nursing & Health Sciences. The organisational structure brings together a unique combination of outstanding academics, researchers, students, state-or-the-art technologies, industry collaboration, and expertise. The objective of the Cluster to provide excellent facilities and services for academic and industry researchers whilst encouraging collaboration in multidisciplinary research (for the commercialisation of biotechnology research in Victoria).

Mondo Medical Ltd.
Contact: Phone: Email: Internet: Address: Mr Peter Taylor, Chief Executive Officer +61 3 9887 7066 Fax: +61 3 9887 7044

ACN 66 074 294 072

ptaylor@mondo.com.au www.mondo.com.au
9 Leicester Avenue Glen Waverley, VIC, 3150 Australia The Mondo Medical objective is to establish partnerships with Australian medical institutions to further their research and development objectives by commercialising their scientific discoveries, particularly in the area of medical instruments and devices. Mondo Medical was originally established in 1996 to bring to the market science that had been developed jointly between Melbourne University and The Royal Melbourne Hospital. Mondo Medical was awarded Victorian Start up company of the year in 1999. Mondo’s first major research project was the Mondo Adaptive Patient Controlled Analgesia (APCA) system, which interacts with the physiology of the patient by non-invasive electronic means. The aim of the research is to overcome the uncertainty and risk that could lead to such consequences as overdose, patient sensitivity, and mis-prescription. Applications are in hospitals where there is an acute postoperative need for the control of blood pressure - in intensive care, cardiac care, neurosurgery, recovery wards or other high-dependency bed areas. Other research projects under development include a non-invasive cardiac output monitor, which at May 2002 is at the beta prototype stage, and a muscle relaxant controller, which has been proved in principle and clinically trialled. A blood pressure controller is presently at alpha prototype stage. Mondo is also jointly developing biosensor technology, to monitor heart rate, temperature, respiratory rate, oxygen saturation and blood pressure. A reusable transmitter with a range of 2-5 metres is attached to the biosensor, and signals can be received in a mobile phone and analysed according to preset instructions from a clinician. If readings are outside of the parameter, the signal is immediately relayed to a monitoring bureau where appropriate responses are coordinated. Working prototypes were available by May 2002.

Profile:

Monsanto Australia Limited
Contact: Phone: Email: Internet: Address: Mr Terry Bunn, Managing Director +61 3 9522 7122 Fax: +61 3 9525 2253

ACN 86 006 725 560

Terry.j.bunn@monsanto.com www.monsanto.com.au
12th Floor 600 St Kilda Road Melbourne, VIC, 3004 Australia Postal Address: PO Box 6051 St Kilda Road Central Melbourne, VIC, 3008 Australia

Profile:

Monsanto is a leading provider of agricultural products for farmers. Monsanto's operations in Australia commenced in 1928 with a focus on the commodity chemicals business before expanding into agricultural products in the 1950s. Monsanto has developed products that have become indispensable for Australian agriculture. Roundup® herbicide was introduced in the 1970’s and today the Roundup brand and other glyphosate herbicides produced by Monsanto are among the world’s most widely used herbicides. To meet the increasing demand for the Roundup family of products, a glyphosate technical plant was built at West Footscray which became operational in 1987. In 1990, amination, formulation and packout equipment were transferred from Sydney. After more than 20 years of directly supplying Roundup branded products to distribution in Australia and New Zealand, Monsanto has recently entered into an agreement to give exclusive distribution rights to the locally based, but globally operating, crop chemical company Nufarm. Monsanto will continue to support the marketing and regulatory compliance of these brands. Monsanto is proud to be a world leader in plant biotechnology. Biotechnology enables researchers to develop improved crop plants, such as crops naturally protected from diseases and insects. The new direction for Monsanto Australia Ltd will allow the company to concentrate on its biotechnology crops and seeds business which began here with the commercialisation of INGARD® cotton in 1996. INGARD cotton contains a gene derived from a naturally occurring soil bacterium, Bacillus thuringiensis (Bt). The gene enables cotton to produce a specific insecticidal protein that controls the most serious insect pests for cotton growers, Heliothis. During the 2000/2001 growing season in Australia, the use of INGARD cotton led to reduction in over 40% of insecticide sprays needed to control this pest. INGARD cotton is one of a combination of tools within an overall Integrated Pest Management strategy and reduces the environmental impact from pesticides and pesticide application. Monsanto’s second generation insect protected cotton, Bollgard II™, approved by the Office of the Gene Technology Regulator (OGTR) in 2002 will be launched in Australia in 2003. Bollgard II cotton expresses two insecticidal Bt proteins and provides additional insect protection compared with INGARD. It also offers an improvement in the management of potential insect resistance. Monsanto has also developed crops that can tolerate the application of Roundup herbicide over the top of the crop. Roundup Ready® cotton was commercialised in Australia in 2001. Roundup Ready cotton provides cost effective and more environmentally benign control of a broad spectrum of weeds compared to conventional weed control practices. Monsanto has applied for regulatory approval for Roundup Ready® canola. Roundup Ready canola provides farmers with a new weed management option, offering greater productivity, more effective weed control and a more environmentally sustainable farming system compared with current canola farming systems such as triazine tolerant (TT) canola.

Murdoch Childrens Research Institute
Contact: Phone: Email: Internet: Address: Ms Anne Cronin, Director - Operations +61 3 8341 6200 Fax: +61 3 9348 1391

cronin@cryptic.rch.unimelb.edu.au www.murdoch.rch.unimelb.edu.au
Royal Children's Hospital Flemington Road Parkville, VIC, 3052 Australia Postal Address: PO Box 1100 Parkville, Victoria, 3052 Australia

Profile:

(MCRI) is a medical research institute of more than 540 staff and associates with an operating budget for 2002 of $35 million. The Institute is a world leader in infant, child and adolescent health research and is distinguished by its innovative and integrative approach to research. It encompasses laboratory, clinical and public health approaches, with an emphasis on application of advances in functional genomics to child health, and an awareness of the importance of ethics and community education. It is located at the Royal Children's Hospital, Parkville, Victoria and is affiliated with the University of Melbourne. It has a strong focus on Biotechnology Commercialisation and has established three startup companies to support commercial initiatives.

MuriGen Pty Ltd
Contact: Phone: Email: Internet: Address: Dr Simon Foote +61 3 9345 2611 Fax: +61 3 9347 0852

ACN 80 089 736 434

foote@murigen.com.au www.murigen.com.au
c/- Walter and Eliza Hall Institute Parkville, VIC, 3050 Australia Postal Address: Post Office Royal Melbourne Hospital, VIC, 3050 Australia

Profile:

Melbourne’s Walter and Eliza Hall Institute of Medical Research in 1999 established a spin-off company focusing on genetics for identifying new pharmaceutical targets, MuriGen Pty Ltd. MuriGen’s innovative approach relies on large-scale mutagenesis screens for genes that suppress disease in mice. The Walter and Eliza Hall Institute during 2001 is completing the construction of a new biotechnology centre for start-up companies. MuriGen will be the first occupant. The centre, located at Bundoora in the north of Melbourne, houses a large, specialised mouse facility, 60% of which will be occupied by MuriGen. The facility is expected to be opened in July 2001.

Nanotechnology Victoria Ltd
Contact: Phone: Email: Internet: Address: Dr Peter Binks, CEO +61 3 9532 3177 Fax: +61 3 9532 2512

enquiries@nanovic.com.au www.nanovic.com.au
Kingston Trade Centre 479 Warrigal Road Moorabbin, Vic, 3189 Australia Postal Address: PO Box 229 Dingley, Vic, 3172 Australia

Profile:

Nanotechnology Victoria was established in September 2002 as a vehicle for facilitating investment in Victorian nanoscience and commercialisation of nanotechnologies for benefits to Victorian and Australian industry. It is an incorporated company in which Monash University, Swinburne University of Technology, RMIT University, and the CSIRO are founding Members. Its funding consists of a $12 million Grant from the Victorian Government and matching contributions from the founding Members. Other Members are expected to join over time to strengthen the research and commercialisation capabilities of the company.Nanotechnology Victoria's three main Program activities will be in Nanofabrication and Characterisation, production of Nanostructured Materials, and Biomolecular Nanotechnology. Its commercial objective is to become self-sustaining within three years. It will commence with a portfolio of around 30 technologies from its founding Members.

National Ageing Research Institute Inc.
Contact: Phone: Email: Internet: Address: Prof Allan McLean, Director +61 3 8387 2148 Fax: +61 3 9387 4030

a.mclean@nari.unimelb.edu.au www.nari.unimelb.edu.au
Poplar Road Parkville, VIC, 3052 Australia Postal Address: PO Box 31 Parkville, Victoria, 3052 Australia

Profile:

The National Ageing Research Institute (NARI) has developed as a centre of excellence in biomedical research in ageing, health service evaluation and delivery of quality aged care education programs for health professionals and undergraduate education in Geriatric Medicine for 4th year medical students of the University of Melbourne. NARI is affiliated with Melbourne Extended Care and Rehabilitation Service and the University of Melbourne, and comprises three divisions: Biomedical Research Division, Public Health Division and the Education division. NARI’s aims are to enhance quality of life, help older people live independently and ensure ageing well for all. NARI is equipped to deal with age related issues from cell biology to service delivery. We undertake high quality biomedical, clinical, public health research and educational activities in a unique multidisciplinary approach to ageing.

Natraherbal Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Steve Friedmann, Investor Relations Manager, Vital Capital Limited +61 3 9605 5900 Fax: +61 3 9605 5999

ACN 31 085 968 547

info@vitalcapital.com www.vitalcapital.com/key_invesments/natraherbal/index.htm
C/- Mr S Friedmann, Vital Capital Limited Level 2 90 William Street Melbourne, VIC, 3000 Australia Natraherbal Pty Ltd is developing nutritional products, including superior quality garlic powder and antioxidants, for the global health and supplements markets. Natraherbal has the exclusive worldwide marketing rights to elite varieties of French garlic, believed to produce some of the world’s highest levels of alliin. Alliin is one of the compounds in garlic which give it its reputation of being beneficial to health by preventing infections, coughs and colds, lowering cholesterol levels, and acting as a natural antibiotic. Natraherbal has already patented a commercial-scale process that maximises alliin levels in powdered garlic. The powder retains most of the benefits of fresh garlic, but is more easily made into tablets and can be stored longer. Natraherbal is also identifying commercial sources of, and production methods for, the compounds glutathione and coenzyme Q10 (CoQ10). Glutathione is one of the most important self-generated antioxidants, and Natraherbal is researching precursors that can be easily absorbed into the human bloodstream and converted into glutathione. CoQ10 helps produce energy within cells. It functions as an antioxidant and is claimed to decrease heart problems and strengthen the immune system. Natraherbal is researching food-based sources and devising ways to produce it through fermentation. Natraherbal is also evaluating the therapeutic value of selected peptides extracted from milk, or by fermentation. The applications potentially include treatments of diarrhoea and constipation, and in the dental industry. The Company's research into peptides may also benefit from water-solubility research being conducted by Tocovite Pty Ltd [see separate entry]. Natraherbal was established in 1999 as a key investment for Melbourne-based Vital Capital Limited, which as of May 2001 owns 40% of Natraherbal.

Profile:

Neurosciences Victoria Limited
Contact: Phone: Email: Internet: Address: Prof William Hart, CEO +61 3 8344 1800 Fax: +61 3 9347 9543

ACN 56 094 548 973

info@neurosciencesvic.com.au www.neurosciencesvic.com.au
National Neuroscience Facility Level 2, 161 Barry St Parkville, VIC, 3010 Australia Neurosciences Victoria Limited (NSV) has scientific and technological capabilities to support research in the field of neuroscience. We act to promote commercialisation of neuroscience research from our seven Member Institutes. NSV manages IP legal and commercialisation issues through a common multi-Institute IP management policy. NSV also provides administrative and communication infrastructure. NSV's current capitalisation is AUD$66 million, committed over five years.

Profile:

Norwood Abbey Ltd
Contact: Phone: Email: Internet: Address: Mr Bernie Romanin, Director of Marketing +61 3 9782 7333 Fax: +61 3 9782 7334

ACN 085 162 456

Bromanin@norwoodabbey.com.au www.norwoodabbey.com
63 Wells Road Chelsea Heights, VIC, 3196 Australia OverviewNorwood Abbey Limited is a biotechnology and medical instruments company. Norwood’s strategy is to develop and commercialise: Transdermal and cellular technologies; and Potential therapies of the thymic function.The Company has with three proprietary delivery platforms in various stages of commercialization and development. Its delivery technologies include laser-assisted delivery, micro-needle arrays, needle-less injection system and pressure wave technology for the transfer of both drugs and genetic material.TechnologyTransdermal drug delivery Laser Assisted Delivery (LAD) - The LAD enhances the penetration of topical anaesthetics providing faster onset of dermal anaesthesia: • Safety and efficacy demonstrated; • Painlessly alters the 10-20 micron outer barrier of the skin; • Faster onset of dermal anaesthesia – 3-5 minutes; • TGA approved; • FDA (510k) clearance; • Hand-held and portable; • Hygienic single use disposable tip; and • Smart engineering ensuring simple and safe operation.Microneedles Norwood's Microneedle transdermal technology is a very safe and sophisticated platform designed to deliver a controlled amount of drug (both with respect to volume and time) to a specific depth below the skin: • Drug delivery with no pain or bleeding; • Microprocessor controller allowing dosage programming and varying rate and time of delivery; • Needles thinner than human hair; and • Wafer-thin, lightweight and comfortable.Needleless Injection Technology Norwood is developing a needle-less injection technology, in the form of a portable, handheld device aimed at injecting drugs in a similar manner to a syringe but without the use of a needle. • Potential applications in both human and veterinary markets; • Fast and powerful fibre-activated pump penetrating into the skin without using a needle; • Controlled dosage delivery; • Delivery of a single drug; delivery of multiple drugs at the one time; and for rapid repeat deliveries of vaccines; • Silent; and • Hygienic disposable drug vials.Cellular Drug DeliveryGene Transfer Technology Norwood’s Gene Transfer Technology uses pressure waves, which provides the opportunity for efficient, non-toxic delivery of genetic material into cells both ex vivo and in vivo: • Safety in deliver; • Low toxicity to cells; • Permeation of cellular and nuclear membranes • Efficiency of deliver; and • Mechanisable.ImmunologyNorwood’s Immunology Project is aimed at: (a) Rebuilding the immune system by triggering the regrowth of the human thymus gland to induce the production of new white blood cells (T-cells) to treat life-threateneing diseases. (b) Growing a completely new, fully-functional thymus from stem cells. Potential therapeutic areas include: • Cancer; Viral infections, Auto-immune diseases; and Vaccinations and transplantation (both organ, bone marrow and stem cells).

Profile:

Novachem Proprietary Limited

ACN 16 005 116 521

Contact: Phone: Email: Internet: Address:

Dr David Waluka, Manager +61 3 9826 4400 Fax: +61 3 9826 8422

sales@novachem.com.au www.novachem.com.au
50 Garden Street South Yarra, VIC, 3141 Australia Novachem is an Australian supplier of consumables for research in the chemical, physical and biological sciences, specialising in stable isotopes and standards for environmental analysis. Among its product range are deuterated solvents, NMR tubes, labelled compounds, stable isotopes, certified reference materials, environmental standards, reagents for molecular biology, media for affinity chromatography, and synthetic peptides. Novachem sources these and other lines from a worldwide supplier network, and is known for providing hard-to-find chemicals. Suppliers include Cambridge Isotope Laboratories, AccuStandard, Dr. Ehrenstorfer GmbH, Resource Technology Corporation, Promochem, Wako Pure Chemical Industries, and Millipore. Novachem was incorporated in 1975. For five years it engaged in the development, manufacture and marketing of formulated consumer and industrial products. In 1980, the company underwent a radical transformation to become a specialist supplier of consumables for research in the chemical, physical and biological sciences. These include supplies for use in wide variety of fields, such as nuclear magnetic resonance; radiolabelling applications; forensic toxicology; biochemistry, molecular biology and immunology; peptide synthesis; and environmental analysis. ACN 80 004 377 780 Nufarm Limited

Profile:

Contact: ASX: Phone: Email: Internet: Address:

Dr Mike Dalling, Group General Manager, R&D NUF +61 3 9282 1000 Fax: +61 3 9282 1001

corporate.information@au.nufarm.com www.nufarm.com
103-105 Pipe Road Laverton North, VIC, 3026 Australia Nufarm is a science-based company involved in the manufacture and supply of agricultural, industrial and specialty chemicals. The company has production and marketing operations throughout Australasia, Asia, Europe and North America. Nufarm is a public company with its primary listing on the Australian Stock Exchange (NUF). Nufarm is a global leader in the supply of phenoxy herbicides (2,4-D, MCPA) and has a significant position in a range of other agricultural chemicals. Through its ag-chemical operations, Nufarm has proprietary technology relating to manufacturing and formulation of products. The company has entered into strategic alliances with a number of major ag-chemical companies, including Monsanto, Novartis, DuPont, Dow AgroSciences, and Aventis. These alliances involve joint marketing rights to particular products, R&D collaborations and manufacturing joint ventures. The company also has a strategic position in biotechnology via its activities relating to the genetic improvement of plants, through its subsidiary, Florigene [see separate entry]. Nufarm is also a major shareholder in Nugrain, a joint venture involving Wesfarmers and Australia's major grain handling organisations, which is introducing quality control systems for the introduction of biotech enhanced crops into Australia [see separate entry]. The company has increased spending on R&D - mainly associated with the Australian biotechnology program of the recently acquired Florigene business- and incurred higher costs associated with market development and expansion activity, particularly in North America.

Profile:

Nugrain Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Barry Cox, General Manager +61 3 9282 1184 Fax: +61 3 9282 1148

ACN 31 085 901 604

barry.cox@nugrain.com.au www.nufarm.com
103-105 Pipe Road Laverton North, VIC, 3026 Australia Nugrain Pty Ltd was established in 1999, as a joint venture involving Nufarm Limited, a sciencebased company involved in the manufacture and supply of agricultural, industrial and specialty chemicals; Australia's three largest grain handling companies - GrainCorp (incorporating VicGrain), AusBulk (formerly SACBH) and CBH; and Wesfarmers Landmark, a leading Australian agribusiness. The mission of the company is the responsible delivery of conventionally bred and genetically modified plant varieties to Australian farmers, end customers and consumers. Nugrain aims to foster the Australian grain industry's use of new plant breeding technology. The company plans to achieve this through direct participation in the accelerated development and release of proprietary conventionally bred and genetically manipulated plant varieties, which possess attributes important to the grower, processor and consumer. Nugrain aims to assist in the development of this technology throughout Australia via the implementation of accredited quality assurance programs for the management of new technologies and products, and regular participation in scientific debate to promote the uptake of new plant varieties and their successful utilisation by farmer, end user and consumer. [See separate profile for Nufarm Limited]. ACN 23 081 455 094 Nutrasense Australia Pty Ltd

Profile:

Contact: Phone: Email: Internet: Address:

Mr Alistair Cumming, Managing Director +61 3 5973 4888 Fax: +61 3 5973 4188

info@nutrasense-australia.com www.arkopharma.com
Unit 30, 1140 Nepean Highway Mornington, VIC, 3931 Australia Postal Address: PO Box 324 Mt Eliza, VIC, 3931 Australia

Profile:

Nutrasense Australia Pty Ltd, formed in 1998, is now part of the Arkopharma Laboratories nutraceuticals group, based in Europe. Nutrasense Australia has its head office based on Victoria's Mornington Peninsula. Currently, Nutrasense Australia manufactures and markets a range of arthritis and osteoarthritis treatments, including ARTHRO-AID™ Capsules, for temporary relief from painful flare ups in the hand, knee, ankle or hip joints, back, or any other localised area of the body; and ARTHRO-AID DIRECT™ Arthritis Cream, using the Fusome™ delivery system for enhanced transfer of nutrients through the dermal layer. ARTHRO-AID DIRECT contains glucosamine, a vital, naturally occurring building block of normal cartilage, and shark cartilage, a naturally occurring source of glycosaminoglycans. Now, as part of the Arkopharma group, Nutrasense Australia will be expanding its product range. It is through Arkopharma’s mission to provide a comprehensive approach to health and well-being that Nutrasense Australia aims to grow and become a leader in the field of complementary medicine. New products of natural origin are planned for a range of conditions, including menopause, weight control, headache and stress, and skin disorders. Products recently launched in Australia include Phyto Soya (for menopause) based on soy bean, and Exolise (slimming) based on green tea extract, AR25® Catechol.

Nutrihealth Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Paul Raff, Commercial Manager +61 3 9931 1118 Fax: +61 3 9369 4922

ACN 85 091 021 813

paul.raff@nutrihealth.com.au www.nutrihealth.com (under construction)
10 Ives Road Altona North, VIC, 3025 Australia Nutrihealth Pty Ltd's primary business is the marketing of seed and a range of products derived from the processing of a specialised strain of canola called Monola® Oil (Monola). Nutrihealth has exclusive rights to Monola through an agreement with Ag-Seed Research Pty Ltd. In terms of the end product, Monola enjoys superior characteristics in both health (has the lowest level of saturated fats of all commonly used frying oils) and stability in the frying process (equal to palm oil and tallow) over all commonly used soft oils. Canola is one of the major success stories for field production in Australia with approximately 1.9 million tones produced per annum. Canada produces approximately 6 times the volume of Australia and has developed a similar product to Monola, namely, Canadian Low Linolenic canola. The demand for this product is well established and growing in the Asian markets. Monola is currently achieving a more efficient yield profile against standard canola than the Canadian variety. In terms of end user demand, estimates by the respective Councils in both Australia and Canada show that Monola and the Canadian Low Linolenic varieties can reach one-third of the production of standard canola over the next 10 years. ACN 72 007 064 066 Nutrition Care Pharmaceuticals Pty Ltd

Profile:

Contact: Phone: Email: Internet: Address:

Dr Ian Brighthope, Managing Director +61 3 9769 0811 Fax: +61 3 9769 0822

webmaster@nutritioncare.com.au www.nutritioncare.com.au
25-27 Keysborough Avenue Keysborough, VIC, 3173 Australia Nutrition Care Pharmaceuticals Pty Ltd specialises in nutrition and environmental medicine, and its products are used extensively by the healing professions. They are specialists in plant extractions and preparations, and also use essential fatty acids and oils to create professional supplements. The Nutrition Care product range is exclusive to practitioners and available by professional prescription only. Nutrition Care products are designed to fulfil a number of aims, such as the prevention of specific diseases or complications; detoxification; stimulation of regeneration and repair processes; and functional improvements in the individual (eg IQ or sports performance). Ongoing research is conducted by and for Nutrition Care to spearhead better products. Nutrition Care has a state-of-the-art TGA-licensed manufacturing facility. The company is innovative and is involved in the design and implementation of clinical studies, with a particular emphasis on the use of trace elements in various formulations to influence the process of inflammation and carcinogenesis. Nutrition Care was one of the first Australian companies to recognise and clinically develop probiotics for human health maintenance and various disease conditions. Nutrition Care is very active in expanding its export markets and relationships with international companies. It has had significant growth into the Asian-Pacific marketplace and some minor penetration into Europe and the Americas. Nutrition Care uses low-allergy excipents in all formulations. The company sources its raw materials internationally, and wherever possible, Australian ingredients are used, especially with respect to organically grown herbs. Most formulations are free from added sugars, salt, yeast, starches, gluten, wheat, corn, cereals, dairy products, preservatives, artificial colours and flavours. Through a START grant funded project with Monash University, Nutrition Care developed a grape seed extract rich in OPC (oligomeric proanthocyanidins).

Profile:

O'Shea and Associates

ACN 007 196 376

Contact: Phone: Email: Address:

Ms Anne O'Shea, Principal Consultant +61 3 9576 1500 Fax: +61 3 9576 1955

oshea@bigpond.net.au
Level 2 61 Station St Malvern, VIC, 3144 Australia O'Shea and Associates provides clinical trial management, including protocol preparation and submission to Ethics Committees (CTX/CTN). The firm also reviews and compiles registration dossiers, including bibliographic submissions and preparation of clinical/technical reports. Other services include strategic planning in clinical research, regulatory affairs, pharmacoeconomics and new business development. Medical information services including preparation of product information, consumer medicine information and literature reviews ACN 34 081 236 875 Ocean Wave Seafoods Pty Ltd Mr Peter Rankin, Managing Director +61 3 5282 5350 Fax: +61 3 5282 5354

Profile:

Contact: Phone: Email: Address:

peterrankin@msn.com.au
295 Dandos Road Lara, VIC, 3212 Australia Postal Address: PO Box 190 Lara, VIC, 3212 Australia

Profile:

Ocean Wave Seafoods Pty. Ltd. is engaged in abalone, shellfish and finfish aquaculture production, and also aquaculture development consultancy. The company operates a multispecies hatchery, nursery and grow-out facilities at Lara, near Geelong, Victoria. Consultancy services are offered in the fields of aquaculture technology, animal husbandry and hatchery production and aquaculture business development and management.

Oncomab Ltd
Contact: Phone: Email: Internet: Address: Mr Marcus Clark, CEO (03) 9854 5700 Fax: (03) 9854 5777

ACN 101 431 814

enquires@primabiomed.com.au www.primabiomed.com.au
Unit 7 79-83 High Street Kew, VIC, 3101 Australia Development of anti-cancer antibodies as diagnostics and therapeutics

Profile:

Optiscan Imaging Limited
Contact: ASX: Phone: Email: Internet: Address: Mr Matthew Barnett, CEO OIL +61 3 9538 3333 Fax: +61 3 9562 7742

ACN 81 077 771 987

info@optiscan.com www.optiscan.com
15 - 17 Normanby Road Notting Hill, VIC, 3168 Australia Postal Address: PO Box 1066 Mount Waverley MDC, VIC, 3149 Australia

Profile:

Optiscan Imaging Limited is using its patented platform technology to develop a miniaturised flexible microscope for assisting diagnosis - internally in the gastrointestinal tract and the cervix, and externally for detection of skin cancer and determining the severity of burns. The microscope, technically a confocal endomicroscope, combines optical fibre and laser technologies to provide clear high-magnification images of living tissue cells. Digital images of cells appear in real time on a computer screen and can be sent via the Internet to pathologists in diagnostic centres. With the initial development of the platform technology virtually complete, Optiscan is now researching different applications of the technology. The company has made positive headway with its skin cancer trials, being conducted in Queensland, and has widened its clinical trials to include applications in gastroenterology. The gastroenterology development is being accelerated by Optiscan’s collaboration with Japanese endoscope manufacturer Pentax, with a view to Pentax including confocal microscopy as part of their product offering in the future. Optiscan recently received notification from the US Food and Drug Administration (FDA) that its miniaturised handheld microscope, the Optiscan Stratum, has been cleared for sale in the US market. Optiscan Imaging Limited was formed in 1994, listed on the Australian Stock Exchange in August 1997, and was given a further boost in June 1998 with an R & D Start grant from the Federal Government. The Melbourne company already markets a system for research applications, and has also granted non-exclusive licences to the world's six largest microscope manufacturers for certain other applications of the confocal microscope. ACN 24 004 145 868 Orica Limited Mr James Fazzino, Investor and analyst enquiries ORI +61 3 9665 7111 Fax: +61 3 9665 7937

Contact: ASX: Phone: Email: Internet: Address:

companyinfo@orica.com hung.nguyen@orica.com www.orica.com.au
1 Nicholson Street Melbourne, VIC, 3000 Australia Postal Address: GPO Box 4311 Melbourne, VIC, 3001 Australia

Profile:

Orica Limited is a publicly owned chemical company listed on the Australian Stock Exchange (ORI). Orica employs around 9000 staff across approximately 30 countries. The company's core business includes the manufacture and supply of commercial explosives and mining chemicals; agricultural chemicals and fertilisers; industrial and speciality chemicals including products for water care; and paints and paint preparation products. Subsidiary company Orica Australia Pty Ltd has an interest in pesticide bioremediation, and received a Commonwealth Government Biotechnology Innovation Fund grant in September 2001 of $250,000 for "Enzymatic Bioremediation of Pesticides". If successful, the project will result in the fast-tracked commercialisation of a range of formulated enzyme products capable of degrading major organochlorine, organophosphate, carbamate and pyrethroid pesticides. The major outcomes will be a significant reduction in pesticide levels in broadacre run-off and effluent generated from rinsing food produce and pesticide spray equipment.

Orphan Australia Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Gennaro D'Alessandro, Manager - New Products +61 3 9769 5744 Fax: +61 3 9769 5944

ACN 11 067 189 342

info@orphan.com.au www.orphan.com.au
48 Kangan Drive Berwick, VIC, 3806 Australia Orphan Australia is a privately owned pharmaceutical company based in Melbourne, providing niche products to Australia, New Zealand and selected South East Asian countries. Orphan Australia specializes in the development, marketing and distribution of 'orphan drugs' - typically used by specialists to treat serious and/or life threatening disorders where current therapy is either unavailable or inadequate, and which affect relatively small patient populations. Among recent advances achieved by the company in Australia are: - Orphan Australia's treatment for kidney stones (UROCIT®-K, potassium citrate) tablets accepted for release - agreement for future distribution with United Therapeutics Corporation (USA) for a subcutaneous prostacyclin therapy for the treatment of late-stage pulmonary hypertension, UT-15 (with the pending name of Uniprost) - Ursofalk (ursodeoxycholic acid) now available on the Pharmaceutical Benefits Scheme (PBS) for Primary Biliary Cirrhosis (licensed from Dr Falk Pharma GmbH) - ReVia (naltrexone HCI) now available Authority Listed on the PBS for use within a comprehensive treatment programme for alcohol dependence (licensed from Du Pont Pharmaceuticals) Orphan Australia is part of an international network of orphan pharmaceutical companies, and began operations in 1995. The company actively seeks new licensing opportunities with international companies. ACN 85 000 160 403 Ortho-Clinical Diagnostics Mr Cameron Ridley, National Sales Manager +61 3 8540 0400 Fax: +61 3 8540 0440

Profile:

Contact: Phone: Email: Internet: Address:

cridley@ocdau.jnj.com; bconnors@ocdau.jnj.com www.orthoclinical.com
31 Hardner Road Mt Waverley, VIC, 3149 Australia Ortho-Clinical Diagnostics, a Johnson & Johnson company, provides high-value diagnostic products and services for the global health care community. For more than half a century, the company has been committed to providing accurate, timely, and cost-effective solutions for screening, diagnosing, monitoring and confirming diseases. Ortho-Clinical Diagnostics combines ongoing investment in technological innovation and product quality with a focus on customer service and support. The company’s patented MicroSlide™ and enhanced chemiluminescence technologies have transformed the way that clinical laboratories perform testing. Ortho-Clinical Diagnostics is headquartered in Raritan, New Jersey, while the Australian headquarters is in Melbourne. Ortho Clinical Diagnostics supports research in Australian laboratories on the use of products in certain clinical conditions or as part of pre-market evaluation. The company maintains a leadership position in two major market segments: transfusion medicine and clinical laboratories. In transfusion medicine, Ortho-Clinical Diagnostics has developed and commercialised instrument systems and reagents that screen blood for AIDS and hepatitis, aimed at ensuring the safety of the world's blood supply. For blood typing, Ortho-Clinical Diagnostics supplies instrumentation and reagent systems. For the clinical laboratory, Ortho-Clinical Diagnostics has patented MicroSlide™ technology and systems for use in stat and routine random-access in-vitro diagnostic testing. The company offers basic metabolites, classical chemistries, special chemistries, proteins, toxicology and therapeutic drug monitoring tests. Immunodiagnostics include enhanced chemiluminescence technology and systems offering immunoassay testing capabilities across menu categories of thyroid function, reproductive endocrinology, cardiology, anemia, metabolism, oncology and infectious diseases.

Profile:

Oxoid Australia Pty Limited

ACN 79005422659

Contact: Phone: Email: Internet: Address:

Mr Greg Ashworth, Sales and Marketing Manager +61 3 9458 1311 Fax: +61 3 9458 4759

info@oxoid.com.au www.oxoid.com.au
104 Northern Road West Heidelberg, Vic, 3081 Australia Postal Address: PO Box 220 West Heidelberg, Vic, 3081 Australia

Profile:

Oxoid is one of the world's leading manufacturers and distributors of microbiological culture media and other diagnostic products. The corporate headquarters in Basingstoke, Hampshire is the main production and administrative site, supported by a network of wholly owned sales and distribution companies in Europe, North and South America and Australia. The Oxoid range of products is used in clinical and industrial laboratories to isolate and identify the bacteria or other organisms causing disease or spoilage.

Pacific Medical Pty Ltd
Contact: Phone: Email: Internet: Address: Mr William Crothers, Chief Executive Officer +61 3 8416 0333 Fax: +61 3 8416 0355

support@pacificmedical.com.au www.pacificmedical.com.au
Level 1, 263 Mary Street Richmond, VIC, 3121 Australia Pacific Medical Pty Ltd was established in 1989 in Victoria to market and distribute the Laryngeal Mask Airway (LMA) throughout Australasia and the Asia-Pacific region. Since that time the product range has expanded to now include orthopaedic, ear/nose/throat and head & neck products, plus additional airway management products. The head office is in Melbourne and there are two regional offices in Singapore and Korea. These three locations also service New Zealand, Indonesia, Malaysia, Philippines, Papua New Guinea, China, Japan, Taiwan, Vietnam, Laos and Cambodia. Pacific Medical also distributes an extensive range of ear/nose/throat and head & neck products, including Atos laryngectomy, rhinology and otology products; Boston Medical surgical and respiratory products; the Mucosal Atomization Device (MAD™); artificial larynxes; Passy-Muir tracheostomy and ventilator speaking valves; and Tracoe tracheostomy tubes. As well, Pacific Medical distributes Orthofix orthopaedic products and USBiomaterials PerioGlas® bone graft particulate.

Profile:

Panvax Limited
Contact: Phone: Email: Internet: Address: Mr Marcus Clark, CEO +61 3 9287 0637 Fax: +61 3 9287 0639

ACN 23 100 033 583

enquiries@primabiomed.com.au www.primabiomed.com.au
Suite 2 1233 High Street Armadale, VIC, 3143 Australia Panvax Limited was formed in March 2002 to further develop and commercialise the DCtag technology that was discovered by scientists at the Austin Research Institute (ARI). The ARI has demonstrated that this technology can enhance immune responses to vaccines in experimental animals and that these responses will protect those animals from disease. The technology at mid2002 is being evaluated in small and large animal models to confirm the preliminary data and to prepare for clinical evaluation of the technology. DCtag has potential for applications in the control of infectious diseases and cancer. Panvax’s business strategy focuses on strengthening the underlying technology and commercialising the outcomes through a combination of product development for specific disease applications, and technology licensing to increase the penetration of the technology into the market. ACN 84 096 155 243 Pargenex Pharmaceuticals Pty Ltd Dr Tom Cocks, Director and Chief Scientist +61 3 8344 5678 Fax: +61 3 8344 8328

Profile:

Contact: Phone: Email: Internet: Address:

t.cocks@pharmacology.unimelb.edu.au www.pargenex.com (under construction)
Level 9 Medical Building University of Melbourne, VIC, 3010 Australia Pargenex Pharmaceuticals Pty Ltd has been formed to develop new drugs for the treatment of inflammatory diseases, in particular asthma and arthritis. The patented technology involves novel ways of activating long-lasting and naturally occurring anti-inflammatory mechanisms in the body by safe and selective compounds that stimulate barrier cell protease-activated receptors (PARs). As their name indicates, PARs are activated by enzymes usually serine proteases like thrombin (PAR1, PAR3 and PAR4) and trypsin (PAR2). They can, however, be activated by unique synthetic peptides. PAR2 is the main target for Pargenex, as these receptors have been discovered to constitute the sensory arm on airways epithelial cells of a powerful bronchoprotective mechanism, analogous to the cytoprotective and most likely anti-ulcer role for PAR2 in the stomach and intestine. Also, high levels of PAR2 expression are observed on synovial cells lining joints, indicating that a similar protective system operates there too. Pargenex has now found trypsin to be synthesised and released in a regulated manner from airways epithelium in response to inflammatory stimuli. Pargenex has new data concerning structural requirements for active PAR2activating peptides. This has already generated unique peptides and will help in the design of small molecule activators of PAR2. Pargenex will operate initially out of The University of Melbourne and will eventually relocate to Bio21. The company aims to make safe and effective new drugs for asthma, arthritis and possibly other important inflammatory diseases and seeks partnerships with synergistic people and organisations.

Profile:

Perseverance Corporation Limited
Contact: ASX: Phone: Email: Internet: Address: Mr Chris Roberts, Director PSV +61 3 5439 7244 Fax: +61 3 5439 7281

ACN 13 010 650 049

chrisr@perseverance.com.au www.perseverance.com.au
Fosterville Gold Mine McCormicks Road Fosterville, VIC, 3557 Australia Perseverance Corporation Limited is a public company which first listed on the Australian Stock Exchange in 1987. Perseverance has more than 1,200 shareholders. The largest single shareholder is a Scottish based company, Palmaris Capital plc, but more than half the shareholders are Victorian, with many coming from regional Victoria. Perseverance Corporation Limited is Victoria’s second largest gold producer, and has produced more than 385,000 ounces valued at over A$210 million at a long term average gold price of $550/oz. From the perspective of biotechnology, Perseverance has an interest in treating refractory gold sulphide deposits with biological oxidation. Perseverance has now completed preparatory test work and assessed competing technologies, selecting the most suitable for these deposits. Sulphide ore which underlies the oxide mineralisation, and requires a different treatment process, is planned to be treated through a bacterial oxidation plant using Goldfields Limited’s BIOX® process. In the deeper sulphide zone, the gold occurs as fine grains contained within the sulphide minerals, arsenopyrite and pyrite. Gold from the sulphide zone is difficult to recover in high yield using the traditional cyanidation process, without the prior breakdown by oxidation of the sulphide minerals to release the gold grains. The Fosterville Sulphides Project (FSP) will establish a process plant to oxidise this ore, using naturally occurring bacteria, enabling the subsequent recovery of gold by cyanidation techniques. A contract has been entered into with Minsaco, a subsidiary of the large South African miner, Goldfields Limited, to permit Perseverance to utilise the BIOX® process.

Profile:

Peter MacCallum Cancer Centre
Contact: Phone: Email: Internet: Address: Mr Jerry de la Harpe, General Manager (Research) +61 3 9656 3723 Fax: +61 3 9656 1414

j.delaharpe@pmci.unimelb.edu.au www.petermac.org or www.pmci.unimelb.edu.au
St. Andrews Place East Melbourne, VIC, 3002 Australia Postal Address: Locked Bag 1 A’Beckett Street Victoria, 8006 Australia

Profile:

Peter MacCallum Cancer Centre is a specialist oncology centre, and Australia’s only comprehensive cancer centre. The Cancer Institute Board was established by an Act of Parliament in March 1949 with two major objectives: to consolidate Victoria’s radiotherapy services and to continue research into cancer and allied diseases. The Cancer Institute Board commenced its activities in one room of the former Queen Victoria Hospital in Melbourne. From this modest beginning the Cancer Institute/Peter MacCallum Hospital has grown to become an internationally recognised cancer research and treatment centre. In 1990 approval was given to move Peter Mac to our present site in East Melbourne, in close proximity to a number of the city’s major hospitals (public and private) and on the fringe of the business district, as well as within five minutes by car to The University of Melbourne, with which the Institute has a strong affiliation. The Institute’s Chief Executive Officer is Dr David Hillis and the Director of Research is Associate Professor David Bowtell. The Centre has a long-standing history as a research body and is the largest cancer research team in Australia, comprising some 240 research and support staff and 77 PhD and higher degree students, located across 25 laboratories and organised into 6 programmes. Allowing for the specialist clinical connections on the site, the Centre's Research Division is uniquely placed to translate biological discoveries from the bench to the bedside, the essence of modern translational research.

PharmAction Manufacturing Pty Limited
Contact: Phone: Email: Internet: Address:

ACN 78 076 755 354

Mr David Lyon, Sales and Marketing Manager, Business Development Manager +61 3 9278 7555 Fax: +61 3 9369 6730

davidl@pharmaction.com.au www.pharmaction.com.au
73-83 Cherry Lane Laverton North, VIC, 3026 Australia PharmAction Manufacturing is a contract pharmaceutical manufacturer operating in purpose designed facilities in Melbourne, Australia. In addition to the provision of contracting services, PharmAction has a range of innovative, over the counter (OTC) products and complementary and alternate medicines that are available to licence. All activities and manufacturing are consistent with the international standards of Good Manufacturing Practice (GMP), the Medical Device Standards (ISO9002) and Good Clinical Practice, as appropriate. The company offers a comprehensive range of services to the pharmaceutical and health industries. These include: (1) Contract manufacturing and packaging to a world class standard: PharmAction has a TGA licence to manufacture sterile, or pack non-sterile, therapeutic goods and complementary and alternate medicines for human use. (2) A complete range of technical services to manufacturing and packaging: PharmAction has a primary responsibility to ensure that all aspects of new and changed products are successfully transferred to operations from PharmAction Product Development or, as a contract manufacturer, from other pharmaceutical companies. The Technical Services/Quality Assurance Group performs the full service quality control and quality assurance function for PharmAction. (3) Product development: This involves the formulation, process development, and stability testing of drug products from pre-formulation to marketing, including the development, validation and registration of all formulations and processes and their transfer to manufacture. It also involves analytical development, which supports the pharmaceutical development and manufacturing activities, including the selection, development and validation of methods for drug products. Other services include clinical trials, formulation, pilot batch manufacture, and stability testing to support registration of products. ACN 67 099 439 371 Pharmasafe Pty Ltd

Profile:

Contact: Phone: Email: Internet: Address:

Mr Richard Li, Director +61 3 9629 6615 Fax: +61 3 9614 1946

richard.li@sino.com.au www.sino.com.au
Level 3 43-51 Queen Street Melbourne, VIC, 3000 Australia Pharmasafe Pty Ltd was launched in early 2002 to commercialise Chinese natural product based medicines for several major diseases, including hepatitis B and arthritis. Pharmasafe holds the intellectual property rights, and is responsible for manufacture or licensing the manufacture, and for marketing and distribution of the medications throughout Australia and internationally. Professor Tzi Chiang Lin will hold a 60% stake in Pharmasafe, with other 40% held by ASX-listed investment service company Sino Securities International Limited (SSI). Professor Lin has been a practitioner and researcher of Chinese medicine for close to 30 years. SSI will be providing its investment banking services to Pharmasafe, and a related ASX-listed company, GoConnect Limited, will handle promotion, marketing and distribution on the internet.

Profile:

Pharmion Pty Limited
Contact: Phone: Ms Jennifer Antonino, Sales & Marketing Director, Australia & New Zealand +61 3 9869 8000 Fax: +61 3 9869 8099

ACN 87 097 066 512

Email: Internet: Address:

jmcdonnell@pharmion.com www.pharmion.com
Level 1 476 St Kilda Road Melbourne, VIC, 3004 Australia Pharmion Pty Limited is the Melbourne-based, Australian subsidiary of the US parent, Pharmion Corporation, which is a global pharmaceutical company. Pharmion's aim is to provide specialised products in an ethical manner, initially in the haematology and oncology areas, focusing on serious unmet needs. To date, two haematology products have been licensed. Clinical trial and registration activity has commenced on a global and local scale for these products. Further products are currently under investigation for in-licence, clinical development and registration. Pharmion has a well-developed global regulatory group, an innovative information technology team and highly specialised sales and medical marketing support and utilises these core strengths to bring improved patient care. ACN 098 823 235 Phytogene Pty Ltd

Profile:

Contact: Phone: Email: Address:

Prof German Spangenberg, +61 3 9479 3851 Fax: +61 3 9479 3851

german.spangenberg@nre.vic.gov.au
Plant Biotechnology Centre Latrobe University Bundoora, VIC, 3083 Australia Phytogene Pty Ltd is a "spin-off" company wholly owned by Agriculture Victoria Services Pty Ltd, part of the Victorian Department of Natural Resources and Environment (NRE). It was established in 2001 with the assistance of a Federal Government Biotechnology Innovation Fund Grant. Phytogene has developed a method for the manipulation of senescence in plant species using gene technology. The technology has a wide range of potential applications including the increased shelf life of leaves, fruit, flowers and tubers; reduced perishability of horticultural crops; and increased carbon fixation in senescence retarded leaves leading to enhanced yields, enhanced biomass production in forage plants and enhanced seed production. The company’s focus over the ensuing two-year period will be to obtain full patent protection and establish the proof of concept in a wide range of plant species.

Profile:

Planreal Australasia
Contact: Phone: Email: Internet: Address: Dr Bruce Anderson, Manager +61 (0)419 305 342 Fax: +61 3 9331 5501 australasia@planreal.com, bnanderson@planreal.com

ACN 57 313 611 787

www.planreal.com
25 Garden Avenue Keilor, VIC, 3036 Australia Planreal AG was founded in 1977 in Lucerne, Switzerland, and provides value-adding services into the property acquisition, divestment and redevelopment sector throughout Europe. Planreal also offers specialist environmental biotechnology and microbiology services for the bioremediation and restoration of contaminated land and groundwater, with an emphasis on costeffective microbiological methods. Planreal uses bioremediation methods and expertise developed over several years by an interdisciplinary international team of scientists, engineers and consultants from Australia, the United Kingdom, Germany and France in addition to the core capabilities provided from the head office in Switzerland. Key tools in the assessment and monitoring processes include lux-based bacterial biosensors, radiolabelled substrate mineralization, respirometry and biogeochemical parameter analysis and tracking. Planreal has undertaken feasibility studies and full-scale soil and groundwater bioremediation projects at several contaminated sites in Europe, and has recently extended operations to North America, Brazil and Australia. Many of the project sites have been impacted with organic hydrocarbon and chlorinated solvent contamination, and some have additional impacts from mineral oils, pesticides and heavy metals. A key feature in all projects is the use of environmental microbiology and biotechnology tools for the development of a cost-effective strategy to restore and add value to industrial land, and to minimize future economic and legal liabilities whilst minimizing risks to human health and the environment.

Profile:

Plant Biotechnology Centre - Department of Natural Resources and Environment
Contact: Phone: Email: Internet: Address: Prof German Spangenberg, Institute Director +61 3 9479 2995 Fax: +61 3 9479 3618

German.Spangenberg@nre.vic.gov.au www.nre.vic.gov.au
Agriculture Victoria, DPI c/La Trobe University Bundoora, VIC, 3083 Australia The Plant Biotechnology Centre is a Research Institute of Agriculture Victoria, a business of the Victorian Department of Natural Resources and Environment. The Institute, conveniently located at the Bundoora campus of La Trobe University, has over 60 staff and postgraduate research students and a strong research base with skills in plant biotechnology and associated biosciences. The Institute is focused on the development and deployment of genomics, transgenic and molecular marker technologies for plant improvement, and is world-leader in pasture plant biotechnology. The main Institute services are: a) strategic research in plant gene technology, plant molecular marker technology and plant genomics; b) transfer of new plant biotechnologies and products to commercialization; and c) training in plant biotechnology at postgraduate level.

Profile:

Plant Cell Biology Research Centre

Contact: Phone: Email: Internet: Address:

Prof Tony Bacic, Director +61 3 8344 5041 Fax: +61 3 9347 1071

abacic@unimelb.edu.au www.botany.unimelb.edu.au
Plant Cell Biology Research Centre, School of Botany, University of Melbourne Melbourne, VIC, 3010 Australia The Centre, within the School of Botany, was established by Professor Adrienne E. Clarke in 1982 with Special Research Centre funding from the Australian Research Council. The current Director is Professor Tony Bacic and the Deputy Director is Dr Ed Newbigin. Over the past twenty years the Centre has established an international reputation in the area of plant biotechnology and molecular and cellular biology, particularly relating to the basis of cell-cell recognition during fertilisation in higher plants and the structure, function and biosynthesis of cell surfaces (cell walls) and secretions of both land plants and marine red algae. Some of the discoveries from the basic research program have led to the establishment of a startup company, Hexima Ltd. Current research programs are focussed on agriculture, food industry and fundamental science. Agriculture work through a joint functional genomics initiative on the "Growth and end-use quality of cereals" with the Department of Plant Science at the University of Adelaide (Professor Geoff Fincher and Peter Langridge) and the GRDC. Food industry initiatives are carried out through the CRC for Bioproducts. Fundamental aspects of plant growth and development are also studied, including the role of arabinogalactan-proteins and selfincompatibility in flowering plants. The Centre now has 10 postdoctoral fellows and 23 postgraduate students.

Profile:

Plantic Technologies Limited
Contact: Phone: Email: Internet: Address: Mr David MacInnes, Managing Director & Chief Executive Officer +61 3 9691 5907 Fax: +61 3 9691 5901

ACN 71 097 524 975

davidm@plantic.com.au www.plantic.com.au
Unit 2 Angliss Park Estate 227-331 Fitzgerald Road Laverton, VIC, 3026 Australia Plantic Technologies Limited has an exclusive worldwide licence to commercialise technology that uses biodegradable starch based polymers as an alternative to conventional petrochemical-based plastic packaging. This environmentally friendly technology has been developed by the Australian Government supported Cooperative Research Centre for International Food Manufacture and Packaging Science. TSL Group Limited [see separate entry] was instrumental in maximising the benefits of this start-up for the CRC through preparation of business plans, establishing infrastructure and raising venture capital.

Profile:

PlantTech Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Bruce Walker, National Production and Cultivation Manager +61 3 9641 2400 Fax: +61 3 9641 2410

ACN 22 099 431 884

bwalker@planttech.com.au www.planttech.com.au
Level 10 600 Bourke St Melbourne, VIC, 3000 Australia PlantTech Pty Ltd commercialises technology in agriculture. It specialises in the commercialisation of seed and seed-related products. The company was formed in early 2002 through the merging of Paramount Seeds and Grainco Australia Seeds and the subsequent acquisition of Seed Grain Biotechnology Australia Pty Ltd. PlantTech is a joint venture between Elders Limited and Grainco Australia Limited. PlantTech provides an efficient pathway to market for technology transfer to agriculture. The organisation is structured to provide Research and Development companies with an end-to-end service, including manufacturing and production, sales and marketing, and royalty collection and adminstration. PlantTech has regional offices in Western Australia, South Australia, Victoria, New South Wales and Queensland, with its head office based in Melbourne. ACN 43 077 675 373 PPD Australia Pty Limited Ms Lesley Gerrard, Clinical Operations Manager +61 3 9804 5211 Fax: +61 3 9804 5233

Profile:

Contact: Phone: Email: Internet: Address:

Lesley.Gerrard@australia.ppdi.com www.ppddevelopment.com
Suite 1, Level 4 Illoura Plaza 424 St Kilda Road Melbourne, VIC, 3004 Australia PPD Australia Pty Limited is part of PPD Development, the clinical research (CRO) operating subsidiary of PPD, Inc. With a global infrastructure of dedicated project teams, cross-functional therapeutic units and innovative technologies, PPD Development works with a worldwide commitment to quality, to deliver strategic solutions for preclinical programs, Phase I-IV clinical development and market support. With more than 4,600 professionals in 47 offices and 21 countries in the key and emerging markets in Europe, the Americas, the Middle East, Africa, Asia and the Pacific Rim, PPD Development provides local experts with well-established networks. PPD Development expertise crosses a wide range of therapeutic arenas with extensive experience in antiviral/anti-infective, central nervous system, gastrointestinal, respiratory, cardiovascular, endocrinology, oncology, critical care and women’s health. These teams work closely with clients across program management, regulatory and clinical trial management. In addition, seamless communications between clients and PPD Development are supported by online resources, and rigorous team training on project protocols to promote a consistent level of quality, providing clients strategic solutions for a decided advantage.

Profile:

Prana Biotechnology Ltd
Contact: ASX: Phone: Email: Internet: Address: Mr Dennis Cahill, Laboratory Manager PBT +61 3 9690 7892 Fax: +61 3 9824 8161

ACN 37 080 699 065

aquick@pranabio.com; gkempler@pranabio.com www.pranabio.com
Level 1 100 Dorcas Street South Melbourne, VIC, 3205 Australia Prana Biotechnology Ltd, a Melbourne company which listed on the ASX in March 2000, is developing therapeutic drugs for age-related diseases. Prana researchers believe their lead compound PBT-1 has the potential to treat Alzheimer's Disease. PBT-1 can dissolve protein deposits (amyloid plaques) in brain tissue believed to be related to the cause of Alzheimer's Disease. The key research has been done over the past 20 years by University of Melbourne scientists Professor Colin Masters, Associate Professor Ashley Bush (based mainly at Harvard Medical School in the USA) and their colleagues. This work, which focuses particularly on the involvement of certain metals in the disease process, forms the basis of Prana's intellectual property portfolio. A key Phase II human clinical trial testing PBT-1 in Alzheimer's Disease was completed in April 2002, with successful results being reported in Geneva at the 7th International Springfield Symposium on Advances in Alzheimers Therapy. Prana has established a medicinal chemistry laboratory at the University of Melbourne. Prana's platform technology is applicable to other age-related and degenerative disorders, including cataracts, involuntary repetitive muscle movement (such as that caused by prolonged treatment with drugs used to treat schizophrenia), Parkinson's disease, and motor neuron disease (Lou Gehrig's disease), as well as prion-related conditions such as Creutzfeldt-Jakob disease and mad cow disease.

Profile:

Premier Bionics Limited
Contact: ASX: Phone: Email: Internet: Address: Mr Martin Soust, Executive Director and Chief Executive Officer PBI +61 3 9594 5473 Fax: +61 3 9594 6330

ACN 67 099 084 143

enquiries@premierbionics.com.au; martin@premierbionics.com.au www.premierbionics.com.au
C/- The Ritchie Centre, Level 5, Monash Medical Centre 246 Clayton Road Clayton, VIC, 3168 Australia Premier Bionics Limited has been established to invest in and commercialise late stage 'R' and early stage 'D' projects in the medical devices and diagnostics markets. To achieve this, it will seek to identify and invest in high quality Australian R&D projects, as measured by a range of criteria including market potential, strength of intellectual property, experienced management team, and potential for significant commercial returns. The company will focus its efforts on ensuring optimal commercial outcomes through disciplined ‘hands on’ management of R&D projects and staged financing based on achievement of technical and commercial milestones. By bringing together its extensive scientific, commercial and project management expertise residing in its Board, management and Scientific Advisory Panel, it will build value and maximise the commercial potential of its investments. It will also implement commercialisation and exit strategies from an early stage of development. Premier Bionics expects that many of its investments will be based on technology developed in Australian research institutes and universities. To maintain continuity of the R&D programs the company will also secure the involvement of key founders, scientists and inventors through appropriate incentive structures. Premier Bionics’ first investee company is Pulmosonix Pty Ltd, a company developing medical devices utilizing proprietary technology based on acoustics, and targeting specific human respiratory disorders [see separate entry].

Profile:

Prima Biomed Ltd
Contact: ASX: Phone: Email: Internet: Address: Mr Marcus Clark, Chief Executive Officer PRR +61 3 9854 5700 Fax: +61 3 9854 5777

ACN 90 009 237 889

enquiries@primabiomed.com.au www.primabiomed.com.au
Unit 7, 79-83 High Street Kew, VIC, 3101 Australia Prima Biomed Ltd was formed in mid-2001 when Prima Resources Limited switched its focus from mining to biomedical research and development. Prima focuses on the commercialisation of biomedical research and has negotiated first rights to commercialise all technologies arising from Melbourne’s Austin Research Institute (ARI), with the exception of Xeno Trans. This work will initially be pursued through three project companies owned jointly by Prima Biomed (65%) and others (35%): Arthron Limited, Cancer Vac Limited and Panvax Limited [see separate entries]. Prima provides R&D funding and its experienced management team. Arthron aims to develop pharmaceuticals to treat inflammatory autoimmune diseases, including rheumatoid arthritis and a bleeding disorder, immune thrombocytopenia purpura (ITP). The strategy is to block certain receptors, found on most inflammatory white blood cells, and that are involved in key inflammatory pathways. The objective is to develop compounds to control autoimmune disease by blocking the receptors, thereby inhibiting the release of inflammatory chemicals. Cancer Vac is developing a therapeutic process for treating solid tumours. Research has indicated that stimulation of cells "ex vivo" (temporarily removed from the patient) may generate potent immune responses that will eliminate, arrest or retard the growth of tumours. The cell type of interest is the dendritic cell. Reintroduction of primed dendritic cells into the body may lead to the eradication of tumours through killing of tumour cells by cytotoxic T cells. Panvax is developing platform technology to enhance immune responses to vaccines and other immunotherapies. Through the DCtag technology, Panvax has discovered a mechanism for targeting antigens to dendritic cells and subsequently enhancing both B and T cell immune responses. This discovery is being evaluated in animal models prior to preparation for testing in human clinical trials.

Profile:

Prince Henry’s Institute of Medical Research
Contact: Phone: Email: Internet: Address: Prof Evan Simpson, Director +61 3 9594 4372 Fax: +61 3 9594 6125

evan.simpson@med.monash.edu.au www.med.monash.edu.au/phimr
Level 4, Block E, Monash Medical Centre 246 Clayton Rd Clayton, VIC, 3168 Australia Postal Address: PO Box 5152 Clayton, Victoria, 3168 Australia

Profile:

Prince Henry’s Institute began as the Medical Research Centre in 1960 at Prince Henry’s Hospital, Melbourne, Australia. In 1990, the Institute moved to the Monash Health Research Precinct that includes the Monash Medical Centre and Monash University Faculty of Medicine and the Monash Institute of Reproduction and Development. The Institute has developed world-standard research and clinical programs in the field of endocrinology (the investigation of the production and function of hormones). Research at the Institute has made substantial internationally recognised contributions to new knowledge in the fields of ovarian, uterine and breast cancer, reproductive physiology and medicine of the male and female. It is one of a few major research institutes that combine basic research with patient care. The World Health Organization has recognised the work and status of the Institute by designating it a WHO Collaborating Centre for Research in Human Reproduction - one of only two in Australia.

ProBio International Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Laith Reynolds, Executive Chairman +61 3 9909 7050 Fax: +61 3 9909 7052

ACN 17 096 204 741

info@probioinc.com www.probioinc.com
Suite 213, Level 2 530 Little Collins Street Melbourne, VIC, 3000 Australia ProBio licenses and develops technologies and intellectual property (IP) in animal reproduction and modification, cell therapies, genomics and associated technologies for use in agriculture and medicine. ProBio’s goal is to enable and ease the ready flow of knowledge, rights and rewards within life sciences worldwide. ProBio has a significant portfolio of technologies and IP in focused disciplines and sectors, and a sophisticated understanding of associated sciences, markets and commercialisation. In additional to in- and out-licensing, ProBio is well placed within the Life Sciences industry to provide standardized procedures for the identification, valuation, patenting and marketing of scientific and medical IP. The company develops business models and plans for IP marketing for universities, research laboratories and commercial enterprises, enabling researchers and organisations to better benefit from their research efforts and to provide a standardised method of licensing and managing biotech IP on their behalf. Uniquely, ProBio also manages the rights to technological improvements generated by the licensees. ProBio is a participant in the new Cooperative Research Centre (CRC) for Innovative Dairy Products, in alliance with six other participants. Approved in Oct 2001, the CRC is funded in part by the Commonwealth Government of Australia.

Profile:

Process Design and Fabrication Proprietary Limited
Contact: Phone: Email: Internet: Address: Mr Pat Scrimizzi, Business Development Manager +61 3 9551 3490 Fax: +61 3 9551 3590

ACN 52 004 565 137

pat.scrimizzi@pdf.com.au www.pdf.com.au
100 Fairbank Road Clayton, VIC, 3169 Australia Postal Address: PO Box 1452 Clayton, VIC, 3169 Australia

Profile:

Process Design and Fabrication Proprietary Limited (Pdf) is an engineering and project management group with offices in Melbourne, Sydney and Perth. A significant supplier of customised process and manufacturing systems throughout Australia and South East Asia for over 40 years, Pdf has considerable experience in the integration of process technology and holds a client list containing many high-profile pharmaceutical companies such as GlaxoSmithKline, Schering-Plough, Novogen Industries and Merck Sharp & Dohme. Pdf specialises in the design, construction and project management of process facilities, plant and equipment for a range of industries, including pharmaceutical, chemical, food & beverage, and manufacturing, pilot plants, pilot plant scale up and laboratory facilities. Pdf also provides feasibility studies and masterplanning services. Pdf can provide assistance with FDA & TGA approvals and validation protocols and qualifications including design, installation, operation and process validation. Pdf will provide training, commissioning and ongoing support to operations and maintenance. Projects range in scope from skid-mounted packages, to large scale "turnkey" plants involving civil and building works, infrastructure, process plant and equipment, process simulation, clean room design, LV and HV power system design, instrument and control systems, services, Hazard and Operability (HAZOP) studies, hazardous area installation design and dossier preparation and Dangerous Goods Regulations audits. Pdf was acquired in 1999 by Lycopodium Pty Ltd, a Perth-based engineering consultancy with extensive Australian and international experience. Lycopodium further strengthens Pdf’s project development expertise with tried and proven systems in the areas of procurement and cost control, and project and construction management procedures. The combined organisations employ over 200 personnel to support Australian and international engineering projects.

ProPharma CRO Pty Ltd
Contact: ASX: Phone: Email: Internet: Address: Mr Peter Fursdon, Office Head and Head of Data Management NASDAQ listed (PPD Inc) +61 3 9830 4394 Fax: +61 3 9830 0146

ACN 66 098 739 532

pfursdon@propharmacro.com www.ppdi.com
Suite 202 991 Whitehorse Road Box Hill, VIC, 3128 Australia Postal Address: PO Box 217 Canterbury, VIC, 3126 Australia

Profile:

ProPharma CRO Pty Ltd is a wholly owned subsidiary of PPD Inc. The division provides clinical data management services in support of clinical trials being conducted in Australia and Asia. It acts as the data management hub for PPD Development’s Asian region and works closely with PPD Development’s clinical groups which are based in Melbourne, Singapore, Hong Kong, Taiwan, China, India and Thailand. It also specialises in stand alone data management contracts, particularly smaller, proof of concept, Phase I/II and Phase IV studies. Staff are very experienced and the division is fully integrated into PPD Development’s global data management network. It provides processing using ICH GCP compliant systems and to international standard SOPs (Standard Operating Procedures).

Prostate Diagnostics Pty Ltd
Contact: Phone: Email: Address: Prof Gail Risbridger, Chief Scientific Officer +61 3 9594 7118

ACN 090 899 120

Gail.risbridger@med.monash.edu.au
27-31 Wright Street Clayton, VIC, 3168 Australia Postal Address: Monash Institute of Reproduction and Development Monash Medical Centre 246 Clayton Road Clayton, VIC, 3168 Australia

Profile:

Prostate Diagnostics Pty Ltd has developed novel diagnostic techniques capable of distinguishing aggressive and slow growing prostate tumours.

Pulmosonix Pty. Ltd
Contact: Phone: Email: Internet: Address: Dr Martin Soust, CEO +61 3 9594 5473 Fax: +61 3 9594 6330

ACN 92 096 917 127

pbinfo@premierbionics.com.au www.premierbionics.com.au
C/- The Ritchie Centre, Level 5 Monash Medical Centre 246 Clayton Road Clayton, VIC, 3168 Australia Pulmosonix is a newly formed company developing platform technology based on the transmission of audible sound through biological tissues. The company has received funding from Premier Bionics Limited to further develop two specific applications of this technology: (1) a monitor that will continuously and non-invasively record the inflation of the lungs in humans; and (2) a device that will non-invasively monitor the patency of the upper airways. The first device will have valuable application in an intensive care setting, while the second device has potential uses in clinical sleep laboratories in the diagnosis of obstructive apnea and in the control of respiratory support devices.

Profile:

QIAGEN Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Duncan Jones, Managing Director +61 3 9489 3666 Fax: +61 3 9489 3888

ACN 75 072 382 944

qiagenaustralia@ozemail.com.au www.qiagen.com
17 Austin Street Fairfield, VIC, 3078 Australia Postal Address: PO Box 25 Clifton Hill, VIC, 3068 Australia

Profile:

QIAGEN believes it is the world’s leading provider of innovative enabling technologies and products for separating and purifying nucleic acids (DNA and RNA). Since 1986, the company has developed and marketed a broad range of proprietary products for the academic and industrial research markets. More recently, increased understanding of nucleic acids’ structure and function and the development of innovative technologies such as the polymerase chain reaction (PCR) have rapidly expanded nucleic acid use in developing commercial markets. These markets include genomics, DNA sequencing for gene-based drug screening, nucleic acid based molecular diagnostics for genetic and infectious diseases, genetic vaccination, and gene therapy. With the growing need for nucleic acid purification technologies in these markets, QIAGEN believes it is in a strong position for continued growth and success in the future.

QNA International Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Graham Thurston, General Manager +61 3 9479 3762 Fax: +61 3 9479 3764

info@qna-international.com www.qna-international.com
Suite 13, TEC Building, Latrobe R&D Park 2 Park Drive Bundoora, VIC, 3083 Australia Postal Address: PO Box 2001 East Ivanhoe, VIC, 3079 Australia

Profile:

QNA International Pty Ltd (QNA) was established in 1996 to create opportunities for enterprises to commercialise and or export their technology and products. Using its expertise, experience and international network, QNA has successfully assisted a number of clients in the introduction of their product or technology into international markets, resulting in sales and collaborative marketing as well as R&D assistance.

R P Scherer Holdings Pty Ltd
Contact: Phone: Email: Internet: Address: Mrs Ronda Jacobs, General Manager +61 3 9586 1222 Fax: +61 3 9586 1200

ACN 61 007 219 990

ronda.jacobs@rpscherer.com www.rpscherer.com
217 -221 Governor Road Braeside, VIC, 3195 Australia Postal Address: PO Box 805 Mordialloc, VIC, 3195 Australia

Profile:

Originally an American based company, R P Scherer has been operating in Victoria for over 40 years and became R P Scherer Holdings Pty Ltd in 1989. As part of Cardinal Health, Inc.’s Pharmaceutical Technology and Services group, R P Scherer offers broadbased experience, unique and proprietary technologies and specialised services. While the company provides innovative drug delivery solutions for a full range of therapeutic products, R P Scherer is predominantly a TGA-licensed contract manufacturer of soft capsules, tablets, hard shell capsules, liquids and creams for the complementary healthcare (health and nutritional) area. They also produce many over-the-counter (OTC) and prescription products for a large number of companies, with more than a dozen of the top 100 drug products sold using R P Scherer technologies. R P Scherer also has a large export market with approximately 40% of all goods they manufacture being exported. In addition to contract manufacturing, R P Scherer provides a full complement of services including: research, analytical and process development; stability testing; packaging; production of clinical trial materials; assistance with regulatory affairs; and commercial manufacturing capabilities. R P Scherer is also a licensed manufacturer of veterinary products and some food items.

RareCellect Ltd
Contact: Phone: Email: Internet: Address: Mr Ian Smith, Secretary +61 3 9417 5711 Fax: +61 3 9417 2987

ACN 14 096 135 947

info@gtg.com.au www.gtg.com.au
60 - 66 Hanover Street Fitzroy, VIC, 3065 Australia Postal Address: PO Box 115 Fitzroy, VIC, 3065 Australia

Profile:

A member of the ASX-listed Genetic Technologies Limited group (GTG), RareCellect Ltd is one of two recently formed GTG companies branching out into major new biotechnology areas. RareCellect revolutionises testing for disease in unborn babies. RareCellect is pursuing the development of a new procedure called RareCellect™, based on the company’s proprietary foetal cell recovery technology. The technology is based on the discovery that a very small number of foetal cells exist in a mother's blood stream and these foetal cells can survive in the mother's circulation for many years. The RareCellect process uses genetic markers to differentiate between the mother’s blood cells and those originating from the foetus. A high-speed cell sorter separates the foetal cells, which can then be tested for abnormalities. The RareCellect process will be a major step forward in foetal testing as it is non-invasive and so it is safer, cheaper, easier and may be done earlier in the pregnancy.

Ratek Instruments Pty. Ltd.
Contact: Phone: Email: Internet: Address: Mr Ray Cutting, Managing Director +61 3 9887 2161 Fax: +61 3 9887 2163 mail@ratek.com.au, ray@ratek.com.au

www.ratek.com.au
60 Wadhurst Drive Boronia, VIC, 3155 Australia Postal Address: PO Box 4431 Knox City, VIC, 3152 Australia

Profile:

Since 1979, Ratek Instruments has grown to become one of Australia's leading manufacturers of laboratory equipment for use in the industrial, scientific and medical research fields. Operating from a modern self-contained factory in Boronia, Melbourne, all equipment is designed and produced in house. Components and materials used are almost entirely from local suppliers. Ratek Instruments manufactures thermoregulators, coolers, dry block heaters, mixers and shakers, incubators and waterbaths. The company also has the capacity to tailor equipment to customer specifications.

Regional Laboratory Services
Contact: Phone: Email: Address: Dr David Paynter, Principal Scientist +61 3 5762 7502 Fax: +61 3 5762 7287

rls@benalla.net.au
Samaria Road Benalla, VIC, 3672 Australia Postal Address: PO Box 805 Benalla, VIC, 3672 Australia

Profile:

Regional Laboratory Services is a privately owned laboratory providing diagnostic services in animal health, environmental and agricultural testing. Clients include private individuals, industry, and Government bodies. The laboratory has NATA (National Association of Testing Authorities) accreditation for veterinary biochemistry, haematology and toxicology.

Rhodia Australia Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Leonard Lane, Manager – Dairy Applications +61 3 9541 1000 Fax: +61 3 9548 8458

ACN 72 003 502 485

leonard.lane@ap.rhodia.com www.food.us.rhodia.com
352 Ferntree Gully Road Notting Hill, VIC, 3168 Australia Postal Address: PO Box 1544 Clayton South, VIC, 3169 Australia

Profile:

Rhodia Australia, based at Notting Hill Victoria, is the Australian arm of a major multinational speciality chemical company. Some might recognise the name Rhone Poulenc, which is where Rhodia has its origins. Formed approximately three years ago after the merger of Rhone Poulenc and Hoechst (now called Aventis), Rhodia became the new entity for the speciality chemicals division. So although new in name, Rhodia has had a long association with local industry. The Food Ingredients Division services all areas of the industry, supplying hydrocolloids and stabiliser systems, cheese and yoghurt cultures, probiotics, bioprotectants, speciality meat phosphates and baking phosphates, and flavourings such as vanillin and ethyl vanillin. The local team is supported by global resources and technical centres based in Europe, America and Asia enabling the company to respond to the varied needs and requests from Australian customers.

Rio Tinto Limited
Contact: ASX: Phone: Email: Internet: Address: Dr Bruce Kelley, General Manager, Technology Development RIO +61 3 9242 3111 Fax: +61 3 9242 3222

ACN 96 004 458 404

bruce.kelley@riotinto.com www.riotinto.com
Technical Services 1 Research Avenue Bundoora, VIC, 3083 Australia Rio Tinto Technical Services (TS) is a unique resource of mining industry professionals providing assistance to Rio Tinto's head office and its operations. Over 150 technical specialists are located in Melbourne and other cities in Australia, the UK and USA. A key area of work is monitoring and improving the environmental performance of the Group. The TS Development wing does this by linking an external research program with projects at RT sites, to transfer innovative technologies to the company's operations. One example of this is in the development and implementation of environmental biotechnologies for mining and industrial land contamination, and treatment of waste streams. Rio Tinto's scientists and engineers have more than 12 years' experience in this area, with successful field scale projects in Australia, New Zealand, Europe and the USA. Site projects have ranged from initial assessments, process evaluation (treatability) studies, technical and economic evaluations of remedial options, and preparation of detailed engineering designs, to supervision of construction, on site commissioning and operations, and finally validation of successful clean-ups. Processes used successfully include landfarming, composting, biopiles, in situ bioremediation (bioventing and biosparging) and natural attenuation. Contaminants treated include petroleum hydrocarbons (fuels, oils and solvents), polyaromatic hydrocarbons, chlorinated solvents, cyanide, sulphate, and metals and metalloids (manganese, copper, zinc, uranium and selenium). Rio Tinto head office: Tel: +61 3 9283 3333; Fax: +61 3 9283 3707; 33rd Floor, 55 Collins Street, Melbourne VIC 3000, Australia

Profile:

RMIT Drug Discovery Technologies
Contact: Phone: Email: Internet: Address: Ms Edna Yeo, RDDT Manager +61 3 9925 7194 Fax: +61 3 9925 7664

ACN 49 781 030 034

rddt@rmit.edu.au www.rddt.com.au
Bundoora West Campus Building 223 Level 2 Bundoora, VICTORIA, 3083 Australia Postal Address: PO Box 71 Bundoora West Campus Australia

Profile:

As one of the few drug discovery centres in Australia, RMIT Drug Discovery Technologies was established in year 2003 to develop and provide preclinical toxicology and pharmacology services to the biotechnology and pharmaceutical industries in Australia. Compounds generated by the biotechnology and pharmaceutical industries require early testing and screening to minimize longterm development costs. Inadequate toxicity data often leads to: costly development of unfavourable compounds, drug withdrawals during clinical trials or after licensing, therapeutic failure and toxicity in clinical use, or mortality. This would directly benefit the consumers in the long run with much more affordable drugs and less therapeutic side effects.RMIT Drug Discovery Technologies is also a research centre with an objective of developing intellectual property in drug discovery and development technologies. Currently RMIT Drug Discovery Technologiesis in collaboration with Victorian Partnership for Advanced Computing, Department of Computer Science (RMIT) and Department of Chemistry (La Trobe University) developing high technology in silico toxicology evaluations (Computational Prediction of Drug Toxicity). RMIT Drug Discovery Technologies plays an important role in University education by developing undergraduate and postgraduate programs with specific drug development technologies and quality management standards as well as the opportunities for work placements.RMIT Drug Discovery Technologies Team is managed by Ms Edna Yeo for more information please email RMIT Drug Discovery

Technologies@rmit.edu.au

Rutherglen Research Institute - Department of Natural Resources and Environment
Contact: Phone: Email: Internet: Address: Dr Garrick MacDonald, Institute Director +61 2 6030 4500 Fax: +61 2 6030 4600

garry.mcdonald@nre.vic.gov.au www.nre.vic.gov.au
Chiltern Valley Road Rutherglen, VIC, 3685 Australia Postal Address: RMB 1145 Chiltern Valley Road Rutherglen, Victoria, 3685 Australia

Profile:

DNRE-Rutherglen is a major Research Institute that is situated in a delightful rural landscape, surrounded by an 870-hectare research farm with sheep, cattle, grain crops, wine grapes and a 400-head beef cattle feedlot. It is located 25 minutes west of the Albury-Wodonga growth centre in the renowned Rutherglen wine-producing region. The Institute has been well regarded for its innovative work in cropping and lamb production and natural resource protection, and is now embracing a new lead role in DNRE for the development of dryland agricultural ecosystems that enhance the environment. The Institute has 66 staff, including 11 PhD holders, organised into 3 research sections: Environmental Services, Plants in Agroecosystems and Food and Wine Production Systems. Within these sections research is arranged into scientific programs including water and the environment, soil resource management, alternative perennial plants (native and exotic), balanced nutrient cycling, drivers of change in land use, and sustainable food and wine production. The Institute's major customers and stakeholders include the State Government, Catchment Management Authorities, Murray-Darling Basin Commission, Land and Water Australia, the Grains Research and Development Corporation, Meat and Livestock Australia, Grape and Wine Research and Development Corporation, CRC for Plant-Based Solutions to Dryland Salinity, CRC for Viticulture, ACIAR and numerous corporate agribusinesses. ACN 68 685 634 275 S 2 F Pty Ltd

Contact: Phone: Email: Internet: Address:

Ms Kirsty Hibbins, Business Development Manager +61 3 8862 8918 Fax: +61 3 8862 8998

kirhib@s2f.com.au; andkin@s2f.com.au www.s2f.com.au
2 Domville Avenue Hawthorn, VIC, 3122 Australia S 2 F Pty Ltd (S2F) is a specialist consulting organisation dedicated to the delivery of project services to the laboratory, pharmaceutical and high technology industries. S2F offers its clients an integrated multi-disciplined team of project managers, architects, servicers and process engineers with the experience and knowledge to provide a comprehensive facility design and delivery service. S2F has the capacity to manage all aspects of specialist laboratory projects from the feasibility study through master planning, cost planning, design and documentation through to construction management, commissioning and validation. S2F has experience in all facets of specialist laboratory facilities, including all levels of PC (BSL) labs, as well as specialist facilities such as spectrometry and magnetic resonance imaging (MRI) suites, specific pathogen-free (SPF) animal houses, and phenomics facilities, to the requirements of regulatory authorities such as the Therapeutic Goods Administration (TGA), the Food and Drug Administration, Eudralex, and the Gene Technology Regulator (OGTR). With offices in Sydney, Melbourne, Brisbane, Philadelphia and Shanghai, S2F has the capability to serve its clients throughout Australia, Asia and the US.

Profile:

S G E International Pty. Ltd.
Contact: Phone: Email: Internet: Address: Mr Reno Cerra, Business Development Manager +61 3 9837 4200 Fax: +61 3 9874 5672

rcerra@sge.com www.sge.com.au
7 Argent Place Ringwood, VIC, 3134 Australia Postal Address: PO Box 437 Ringwood, VIC, 3134 Australia

Profile:

S G E International Pty. Ltd. (SGE) began in 1966 as Scientific Glass Engineering, in a tiny garage at the backyard of a house in Melbourne, Australia. Today, SGE has two modern facilities engaged in developing and manufacturing chromatography and analytical products. SGE has grown substantially, with 250 employees by April 2002, and a distribution and support network in nine countries, including worldwide distribution partners. SGE started solely as a syringe manufacturer, but now manufactures a vast array of products for chromatography and mass spectroscopy. These products include GC capillary columns, GC/MS accessories, HPLC columns, HPLC accessories, and GC retrofit instrumentation. SGE provides the biotechnology industry with micro syringe arrays and micro fluidic handling equipment. SGE is an ISO-accredited company. The major instrument manufacturers in these fields all rely on and incorporate SGE-manufactured components in their systems. The company is heavily committed to research and development, with 11 R&D employees involved in more than 20 in-house research projects. SGE strongly pursues environmentally sustainable activities. Many years ago SGE purchased a substantial grazing landholding in the Otway Ranges in the South Eastern part of Australia, and converted it to a Eucalyptus Blue Gum plantation that is now nearing maturity. SGE has produced many times more trees specifically for paper production than the whole organisation has consumed.

Sartorius Australia Pty. Ltd.
Contact: Phone: Email: Internet: Address: Mr Michael Godfrey, Business Development Manager +61 3 9590 8800 Fax: +61 3 9590 8828

ACN 29 007 161 462

sartaus@sartorius.com.au www.sartorius.com
Unit 17 104 Ferntree Gully Road Oakleigh, VIC, 3166 Australia Postal Address: PO Box 8004 East Oakleigh, VIC, 3166 Australia

Profile:

Sartorius Australia is a leading supplier of equipment and consumables to the biotechnology and pharmaceutical industries. The Sartorius Group comprises Sartorius Separation Technology (membrane filtration, sterile filtration, crossflow filtration, ion-exchange membranes and full validation services), BBraun Biotech (bioreactors, fermentors and laboratory equipment) and Vivascience (proteomics, ultrafiltration and cell culture equipment and consumables). Sartorius Australia is the only internationally recognised bioreactor and fermentor supplier that operates directly in Australia. The parent company is based in Goettingen in Germany and has a long history as a driver and innovator in filtration and separation technology. Sartorius Australia was formed in 1991 to meet the needs of the Australasian market. The company has rapidly expanded and is now recognised as a competent and able supplier of knowledge and expertise. The company specialises in process development and has invested in the development of its staff as a valuable resource to give Sartorius Australia and customers a unique competitive advantage.

Saurin Technologies Pty. Ltd.
Contact: Phone: Email: Internet: Address: Mr Rakesh Aggarwal, Managing Director +61 3 9646 6771 Fax: +61 3 9646 8779

ACN 88 091 106 946

sales@saurin.com.au www.saurin.com.au
6 Westside Avenue Port Melbourne, VIC, 3207 Australia Specialising in plant and equipment for the food and pharmaceuticals industries, the Saurin Group of companies has three independent divisions. Saurin Technologies Pty. Ltd. provides solutions for the food processing industry. The Research & Development Division develops pilot plant, and is involved in major R&D projects. Longwarry Food Park Pty. Ltd. (operating from the former Bonlac Foods Longwarry site) provides contract spray drying and offers manufacturing facilities to food manufacturers to enable a quick route to market. Current R&D projects include the development of a novel twin fluid nozzle for spray drying, to improve the high pressure equipment currently required. Saurin has already brought the first true in-line mixer to market. With CSIRO, Saurin is developing pulse combination technology for spray drying. Saurin has exclusive worldwide rights to this technology. Saurin is also developing micro-encapsulation equipment for probiotics in collaboration with the School of Food Sciences, University of Western Sydney. Other R&D projects are being undertaken with Monash University. Saurin’s technologies comprise mixing, dehydration, process improvement, and pilot plant design and manufacture. Saurin can design and manufacture a wide range of process equipment, or upgrade existing plant. Saurin can simulate a client’s manufacturing processes, design or supply equipment, or upgrade processes on a turnkey basis. The Mini equipment range is ideal for laboratory product testing. The Maxi range is for small production-scale operations. Saurin exports to USA, UK and Bangladesh. Exports include high-grade equipment used for blood purification and pharmaceutical production. Saurin earned commendation as Emerging Exporter in the 2002 Governor of Victoria Export Awards.

Profile:

Schumacher Pharmaceuticals Pty. Ltd.
Contact: Phone: Email: Address: Dr Monty Rudov, Joint Managing Director +61 3 9654 8791 Fax: +61 3 9650 1205

ACN 30 004 547 602

cwaves@bigpond.com
252 Collins Street Melbourne, VIC, 3000 Australia Schumacher Pharmaceuticals Pty. Ltd. has developed a number of herbal-based products based on the healing properties of Secale cereale, more commonly known as rye. While the nutritional properties of the rye grain have been known for centuries, the healing effects of the extract made from the juvenile rye grass are only more recently beginning to be investigated. It is the extract from rye grass, harvested when its nutritional properties are at their peak, that is the active agent in the product originally developed by the founders of the firm, the Schumacher brothers. The products based on the rye grass extract demonstrate profound healing properties in the human body, effected primarily through their effects upon the immune system. These effects appear to be mediated by particular phytoestrogens and lignans present in the rye extract, which regulate the human immune system, hence the application of the term 'immunomodulator'. Laboratory experiments have defined a number of molecules in the rye extract, all of which have demonstrated immunological effects. For example, several isoflavones (a subgroup of phytoestrogens) are present, one of whose effects is to arrest cell growth. The actions of such molecules might provide a clue to the mechanisms underlying the remarkable results of cancer trials, in which the cell growth in culture of five different cancer lines was significantly inhibited. Significantly, this inhibition was not mediated by cytotoxic activity, and some intervention in DNA, RNA or protein synthesis is suggested.

Profile:

Science Traveller International
Contact: Phone: Email: Internet: Address: Mr John Douglass, MD +613 5441 4898

ACN 006937864

info@scitrav.com http://www.scitrav.com/wwater
125 Mollison Street P.O.Box 107 Bendigo, VIC, 3550 Australia Postal Address: Box107 Australia

Profile:

Science Traveller International (STI) is an international software company with offices in USA and Australia. Since 1988, our company has been developing high technology and scientific products across a wide range of disciplines for multi-national clients. Our scientific software is used in over 60% of laboratories around the world.We also produce a range of software products for laboratory instrumentation, environmental monitoring and wastewater applications.

Scientec Research Pty. Ltd.
Contact: Email: Address: Dr Michael O’Donoghue, Chief Executive Officer and Principal Scientist Fax: +61 3 9844 2076

ACN 32 058 744 371

scientec@labyrinth.net.au
71 Yarra Street Warrandyte, VIC, 3113 Australia Scientec Research Pty Ltd is a 100% privately owned Australian scientific research and development company formed in February 1993. Scientec’s principal area of activity has been the development of its own technologies for controlled release drug delivery. In addition, Scientec Research provides contract research and development services to a number of Australian academic and industrial groups. The principal areas of service provision have been in development of (i) controlled release drug delivery systems; (ii) drug formulations; and (iii) manufacture processes and associated equipment.

Profile:

Scientex Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Joseph Simonetti, Director +61 3 9877 0500 Fax: +61 3 9894 3699

ACN 18 006 697 310

info@scientex.com.au www.scientex.com.au
4/109 Whitehorse Road Blackburn, VIC, 3130 Australia Postal Address: PO Box 1378 Doncaster East, VIC, 3109 Australia

Profile:

Scientex Pty Ltd is exclusive distributor for a range of analytical instruments and products from specialist manufacturers with respected brands: Polymer Laboratories (PL) specializes in resins for chromatography and for synthesis. PL offers a range of high quality products for solid phase synthesis and solution phase synthesis, for low volume and scale up production. Instruments include evaporative light scattering detector and high temperature GPC systems. Precision Detectors offers dynamic light scattering (also known as photon correlation spectroscopy) for determination of Rh. Molecular weight (Mw) may be determined using Raleigh light scattering or differential viscometry (DV) as relatively inexpensive alternatives to mass spectrometry. Viscotek holds the international patent for the four capillary bridge viscometer. The need to separate particles has been enhanced with the Postnova field flow fractionation (FFF) techniques. Traditional methods have included size exclusion chromatography (SEC) and ultracentrifugation. FFF offers an elegant fast alternative to both these techniques. Picometrics manufactures a range of laser induced fluorescence detectors (LIF) for ultra low detection of naturally fluorescence species or those with fluorescence tags and suit HPLC, micro HPLC and CE. Analytical techniques include: Setaram and Rubotherm- thermal analysis, Bohlin- rheometers, Anter- thermo-physical testing, Testometric-universal test machines. Specialist applications are represented by the TLC/FID Iatroscan from Iatron, NIR chemical imaging from Spectral Dimensions, particle size from PL, electronic aroma sensing from Smartnose and chiral detection from PDR-Chiral.

ScimaR
Contact: Phone: Email: Address: Mr Bud Thompson +61 3 9842 3386 Fax: +61 3 9842 3407

ACN 93 449 422 808

scimar@bigpond.net.au
4 Ruskin Close Templestowe, VIC, 3106 Australia ScimaR is a niche distributor focused on the life sciences market. Products distributed are in the areas of cell & molecular biology, nucleic acid research, monoclonal antibody production/purification, yeast genetics, clinical chemistry raw materials and research biochemicals.

Profile:

Scitech Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Con Sapounas, Managing Director/Director of Sales +61 3 9480 4999 Fax: +61 3 9416 9959

cons@scitech.com.au www.scitech.com.au
155 Plenty Road Preston, VIC, 3072 Australia Postal Address: PO Box 1625 Preston, VIC, 3072 Australia

Profile:

Established in 1989, Scitech has grown to become one of Australia's leading suppliers of image capture analysis and data acquisition products. Scitech offers innovative and leading edge technology, service, and expertise. Specialities include machine vision, digital imaging, microscopy, data acquisition, and high-speed cameras. Products used in the Life Sciences sector include a wide range of digital and video cameras, frame grabbers, imaging software, gel documentation, microscope accessories, lighting, motorized stages, and data acquisition and phase imaging products. Products include the Media Cybernetics range of image analysis and 3D visualisation software, gel documentation and analysis software, and the Array Pro Analyser for microarray data analysis. Scitech offers the largest range of specialist digital cameras in Australia: from 1.4 to 12 million pixels; and from low light to high speed (1000 frames per sec). Customers include CSIRO, universities, major hospitals, the Defence Science and Technology Organisation (DSTO), leading manufacturers, and microscope suppliers. Scitech is a member of the Scientific Suppliers Association and the Australian Society for Biochemistry and Molecular Biology (ASBMB).

SDA Biotech Pty Ltd
Contact: Phone: Email: Internet: Address: Ms Paris Brooke, Managing Director +61 3 9629 9917 Fax: +61 3 9629 9099

ACN 22 061 715 384

info@sdabiotech.com.au www.sdabiotech.com.au
Level 8 460 Collins Street Melbourne, VIC, 3000 Australia SDA Biotech Pty Ltd is a team of strategists, communicators and educators assisting biotechnology awareness and commercialisation. SDA Biotech provides strategic communication advice to maximise potential, build value and enhance visibility and credibility. The company assists national and international clients in effective management of their communication across all sectors, to strengthen commercial positioning in the market. Its role is as the communication core for corporate, financial, business, government, media and scientific communities. SDA Biotech provides counsel to shareholders, opinion leaders, analysts, investors, industry collaborators, journalists, healthcare providers and consumers.

Profile:

SeerPharma Pty Ltd
Contact: Phone: Email: Internet: Address: Mrs Sue Cox, Office Manager +61 3 9897 1990 Fax: +61 3 9897 1984

ACN 28 096 346 173

sue.cox@seerpharma.com www.seerpharma.com.au
Suite 3, Level 1 818 Whitehorse Road Box Hill, VIC, 3128 Australia SeerPharma Pty Ltd is the product of a merger of Pharma Systems International and Seer Solutions, two Australian consultancies specialising in Quality Assurance, good manufacturing practice (GMP) compliance and information technology in the pharmaceutical, medical devices and biologicals industries. Pharma Systems was started in 1989 to provide professional products and services in GMP Compliance, Quality Assurance and Training. Seer Solutions was formed in 1994 to provide innovative computer systems to satisfy the pharmaceutical regulatory requirements and to bridge the communication gap between information technology and pharmaceutical specialists. The two companies worked together for some time prior to their merger in 2001. The merged company is better able to remain current with international trends. It aims to grow both nationally and internationally. SeerPharma’s head office is in Melbourne, and the company has other offices in Sydney, the UK, and Singapore.

Profile:

Servier Laboratories (Aust.) Pty. Ltd.
Contact: Phone: Email: Internet: Address: Mr Barry Young, Managing Director +61 3 8823 7333 Fax: +61 3 9822 7517

ACN 54 004 838 500

barry.young@au.netgrs.com www.servier.com
8 Cato Street Hawthorn, VIC, 3122 Australia Servier Laboratories (Aust.) Pty. Ltd. (Servier Australia) is the local affiliate of a privately owned Paris-based parent company. Servier is a research-based manufacturer of human pharmaceutical products – the main areas of focus being cardiovascular and metabolic diseases. Servier Australia distributes this range of products. Australia is designated an International Centre for Therapeutic Research within the group. Preclinical, Phase II and Phase III research and development work is undertaken in Australia on behalf of the parent company.

Profile:

Shimadzu Australia Manufacturing Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Brian Godden, Manufacturing Manager +61 3 9767 4488 Fax: +61 3 9793 7733

briang@sam.shimadzu.co.jp www.shimadzu.com.au
7 Monterey Road Dandenong, VIC, 3175 Australia Melbourne-based Shimadzu Australia Manufacturing Pty Ltd (SAM) is part of the Shimadzu Group, one of the world’s largest manufacturers of analytical instrumentation. SAM’s facility at Dandenong is one of the Group’s major manufacturing plants. Shimadzu combines its worldwide pool of dedicated expertise to design, manufacture and market its solutions-based product range, which includes: HPLC - high performance liquid chromatography systems, including the fully integrated LC-2010 high throughput HPLC system - LC-MS - mass spectrometry detection for liquid chromatography - GC - gas chromatograph range, including fast GC - GC-MS - gas chromatograph/mass spectrometers - UV-visible, fluorescence, FTIR and atomic absorption spectrophotometers, - Total organic carbon and thermal analyzers, and the Shimadzu Biotech range of instrumentation specifically designed for the life science/biotechnology industries. Shimadzu emphasises innovative thinking, painstaking design and development, meticulous manufacture and stringent testing, to ensure that its products meet the toughest international standards of excellence. SAM and sister companies Shimadzu Medical Systems and Shimadzu Scientific Instruments now employ over 200 people in Australia and New Zealand. The Group’s parent company, Shimadzu Corporation, is based in Tokyo, Japan. Shimadzu Corporation has ISO-9001 certification and SAM has ISO-9002. SAM has manufactured approximately 50 different types of high-tech instruments, including analytical instruments, medical equipment, environmental measuring instruments, and testing machines. Annual turnover is in excess of A$50 million and production continues to expand. Staffing levels have been steadily increasing and over 150 people are now employed. Most of the instruments produced are exported to Japan, USA, Europe and Asia. The same instruments are provided to the Australasian market through sister companies in Australia and New Zealand.

Profile:

Sigma Pharmaceuticals Pty Ltd
Contact: Phone: Email: Internet: Address: Ms Louise Leone, Executive Assistant to CEO +61 3 9839 2800 Fax: +61 3 9839 2801

ACN 88 004 118 594

louise.leone@signet.com.au www.sigmaco.com.au
96 Merrindale Drive Croydon, VIC, 3136 Australia Postal Address: Locked Bag 268 Croydon, VIC, 3136 Australia

Profile:

The Sigma Group of companies (ASX SIG) is engaged in the manufacture and wholesale distribution of pharmaceutical and allied healthcare products in Australia. It is the largest Australian contract manufacturer for Australian and international pharmaceutical companies and the leading Australian antibiotic manufacturer, with other core business being the manufacture and marketing of company branded products and brand acquisition and development. Since it began manufacturing in 1942 in Victoria, the group's manufacturing subsidiary, Sigma Pharmaceuticals Pty Ltd, has become one of the largest Australian-owned pharmaceutical manufacturers, and has developed a wide range of quality Australian over-the-counter and prescription products through in-house development, acquisition and licensing agreements. Sigma is also a significant contract manufacturer, producing pharmaceutical products for a number of domestic and international pharmaceutical companies. It has the ability to manufacture liquids, creams, ointments, tablets, capsules, lozenges, injectibles and other sterile products. It has now established itself as an international contract manufacturer, having been awarded a major 7-year supply contract in Japan, and others with several pharmaceutical multinationals, increasing contract turnover to A$150 million. Other recent initiatives have included the purchase of Aventis’ Baulkham Hills (NSW) plant, together with a minimum 7-year manufacturing contract; the purchase of the branded products range from Glaxo Wellcome Hong Kong; increased market share in both the prescription and OTC markets in Australia; and a more recent acquisition of a number of branded pharmaceuticals from Wyeth Australasia.

Silbase Scientific Services Pty. Ltd.
Contact: Phone: Email: Address: Mr Ian Smith, Director +61 3 9417 2400 Fax: +61 3 9416 3808

ACN 22 080 724 027

silbase@genetype.com.au
60-66 Hanover St Fitzroy, VIC, 3065 Australia Postal Address: PO Box 115 Fitzroy, VIC, 3065 Australia

Profile:

Silbase Scientific Services Pty. Ltd. is part of the ASX-listed Melbourne-based group Genetic Technologies Limited (GTG). The company carries out DNA paternity testing and minor forensic work. Largely sourcing referrals from New South Wales for analysis at the Victorian headquarters of GTG, Silbase Scientific Services has been has been operating as a specialist parentage testing laboratory since 1986. Silbase is accredited by the National Association of Testing Authorities (NATA) and is thereby authorised to perform parentage testing under the Family Law Act. Only reports from an accredited lab can be used in family law proceedings. These reports are also accepted by the Registry of Births, Deaths and Marriages, and the Department of Immigration. Silbase offers parentage testing, DNA analysis, and testing for forensic investigation, immigration matters, family reunions, estate-kinship disputes, and twins and sibship analysis. [See separate entry for Genetic Technologies Limited].

Silliker Microtech Pty. Ltd.
Contact: Phone: Email: Internet: Address: Mr Stephen Jay, Director +61 3 9877 8222 Fax: +61 3 9877 8444

ACN 94 006 462 335

sales@sillikermicrotech.com www.sillikermicrotech.com
20 King Street Blackburn, VIC, 3130 Australia Silliker Microtech offers consulting and laboratory analysis in industrial microbiology and chemistry and related areas. Major areas of expertise include the food, pharmaceutical, medical device, antimicrobial, preservation, cosmetic, toiletry, and water industries. Specific consulting experience encompasses Hazard Analysis and Critical Control Point (HACCP), factory hygiene, food safety plans and management, food shelf life studies, good manufacturing practice (GMP), good laboratory practice (GLP), sterilisation validation, product stability studies and laboratory method validation. Established in 1985 and known as Microtech Laboratories until October 2001, the company in June 2000 joined the Silliker Group, based in Illinois, USA. Silliker comprises a worldwide network of 29 laboratories and technical consultancy teams providing industrial microbiology and chemistry analytical services, technical consulting and auditing, product stability assessment, applied research, and staff training for the food industry. Food Safety Solutions is now also part of Silliker Microtech, and its expanded food safety consulting team operates from both Melbourne and Sydney. The food industry is one of the company’s largest markets. Silliker Microtech employs approximately 110 personnel nationally and services a wide range of industries. It will maintain its broad ranging accreditation with Australian regulatory authorities NATA, TGA and NRA. Silliker Microtech has offices and laboratories in Melbourne and at a new site in Regents Park, Sydney, and all Australian states and international areas are serviced.

Profile:

Simons GeneType Diagnostics Pty. Ltd.
Contact: Phone: Email: Address: Mr Ian Smith, Director +61 3 9417 5711 Fax: +61 3 9416 4076

ACN 13 007 279 736

ians@genetype.com.au
60-66 Hanover Street Fitzroy, VIC, 3065 Australia Postal Address: PO Box 115 Fitzroy, VIC, 3065 Australia

Profile:

Simons GeneType Diagnostics Pty Ltd is part of the ASX-listed Melbourne based group Genetic Technologies Limited (GTG) [see separate entry]. Simons GeneType specialises in DNA parentage, individuality, and forensic laboratory analysis. The Company was formed in 1989 and is accredited by the National Association of Testing Authorities (NATA) to perform parentage testing under the Family Law Act. Only reports from an accredited laboratory can be used in family law proceedings. These reports can also be accepted by the Registry of Births, Deaths and Marriages. Some of the laboratory's more publicly known activities include the acquittal of Lindy Chamberlain, the identification of the person responsible for the bombing of the Turkish consulate in South Yarra, Victoria, and the identification of crew members lost from the yacht "Great Expectations".

Solagran Limited
Contact: ASX: Phone: Email: Internet: Address: Dr Vagif Soultanov, Chairman SLA.AX +61 3 9820 2699 Fax: +61 3 9820 3155

ACN 085 675 323

info@solagran.com www.solagran.com and www.lazure.com.au
Level 11 492 St Kilda Road Melbourne, VIC, 3004 Australia Solagran Limited, based in Melbourne, owns all the intellectual property pertaining to technology for manufacture and applications of products collectively known as Bioeffectives®. Bioeffectives® are natural biologically active substances obtained via specialized technology which allows their isolation as balanced, synergistic complexes with predefined therapeutic properties. Bioeffectives are the results of over 72 years of fundamental research and clinical trials undertaken in Russia and NIS countries, and have a wide range of applications in the prevention and treatment of illness. For example, Bioeffective® R, a member of the polyprenols group, has shown extremely promising results in Level I and II hepatitis, HIV and multiple sclerosis clinical trials. Other Bioeffectives are marketed for their antimicrobial, tissue-regenerative, wound and burn healing, anti-inflammatory and immunomodulating properties. Solagran is currently seeking regulatory approval for several Bioeffectives® from the Therapeutic Goods Administration. Solagran’s extraction technology can be tuned to virtually any plant or tree source, including local Australian species.

Profile:

St. Vincent’s Institute of Medical Research
Contact: Phone: Email: Internet: Address: Prof Thomas Kay, Director +61 3 9288 2480 Fax: +61 3 9416 2676

svimr@medstv.unimelb.edu.au www.svimr.unimelb.edu.au
9 Princes Street Fitzroy, VIC, 3065 Australia Postal Address: 41 Victoria Parade Fitzroy, Victoria, 3065 Australia

Profile:

St. Vincent’s Institute of Medical Research was established in 1957, initially through a bequest from the late John Holt. It is an independent health and medical research institute affiliated with the University of Melbourne and St. Vincent’s Hospital. The current Director is Professor T.J. Martin AO FRS. The Institute, which has a Faculty of 14 laboratory heads and a total staff of 100, including 10 post graduate research students, regularly hosts visiting international students and scientists. Staffing and research support is funded by peer-reviewed grants from national and international bodies, Trusts, charities and donations, and industry collaborations, with infrastructure support from the State government.

Starpharma Pooled Development Limited
Contact: ASX: Phone: Email: Internet: Address: Dr John Raff, Chief Executive Officer SPL +61 3 8532 2704 Fax: +61 3 9510 5955

ACN 20 078 532 180

john.raff@starpharma.com www.starpharma.com
Level 1, Old Baker Building Prahran, VIC, 3081 Australia Postal Address: PO Box 6535 St Kilda Road Central, VIC, 8008 Australia

Profile:

Starpharma is an Australian-owned Research and Development group consisting of 4 subsidiary companies operating under a parent funding entity set up as a Pooled Development Fund (PDF). It was established to commercialise novel polyvalent compound technology discovered at the Biomolecular Research Institute in Melbourne, Australia, to which Starpharma has acquired exclusive world-wide rights. The technology is protected by broad patents and comprises a class of high molecular weight, branch-like chemicals (dendrimers) and other polyvalent compounds with demonstrated activity against a broad range of viruses and other human diseases for which current therapies are inadequate. To fund new research opportunities and to exploit the wide range of activity shown by the polyvalent compounds, Starpharma Pooled Development Fund raised additional capital through a public float on the Australian Stock Exchange (ASX) in September 2000. Starpharma has been concentrating its resources to date on developing two priority programs to the point of showing efficacy in humans (phase II clinical trials), prior to licensing to a major pharmaceutical company. In March 2001, it was reported that one of these projects, the sexually transmitted disease (STD) prevention project, has advanced to full preclinical development. The company also announced that it has been issued with a key patent for its biotechnology and has obtained further funding from the US based National Institutes of Health (NIH). The second of the priority projects, an anticancer application (Angiogenesis Inhibitor Program) is currently in the preclinical development phase. The platform technology has further demonstrated a broad range of activity in a number of other disease applications. Starpharma’s polyvalent compounds have shown potential as drugs active against toxins, HIV and AIDS related viruses, hepatitis B virus infection and related liver cancer, malaria, respiratory viruses, and exotic viral diseases.

Stem Cell Sciences Limited
Contact: Phone: Email: Internet: Address: Dr Peter Mountford, Chief Executive Officer +61 3 9804 5505 Fax: +61 3 9804 5520

ACN 93 063 293 130

peter.mountford@stemcellsciences.com.au www.stemcellsciences.com.au
Level 1 28 Riddell Parade Elsternwick, VIC, 3185 Australia Stem Cell Sciences Ltd (SCS) was established in 1994 to realize the potential of Embryonic Stem (ES) cells in human medicine. ES cells retain the ability to form all cell types found in the body even following extensive growth in culture. Stem Cell Sciences, in an exclusive alliance a recognised world-leading institute in ES cell research, the Centre for Genome Research (CGR, Edinburgh University), has developed proprietary ES cell-based technologies to provide an unlimited supply of highly purified cells including neurons, heart and blood cells for immediate application in the company's cell-based gene and drug screening business and future application in human cell-based gene and tissue therapies. Stem Cell Sciences' patented technologies enable the growth and selection of stem cells and their application in new drug discovery. In the future, the Company aims to develop cellbased therapies for currently incurable diseases such as Parkinson's disease and diabetes. Stem Cell Sciences' discovery platform has attracted equity investments and research and licensing agreements with international biopharmaceutical companies including GlaxoSmithKline, Hoechst Marion Rousell, BioTransplant Inc., Genentech Inc., and Aventis. In March 2001, Stem Cell Sciences announced the creation of a wholly-owned UK subsidiary, Stem Cell Sciences (UK) Ltd, and will continue to expand its Australian operations. Stem Cell Sciences is seeking to accelerate the growth of its business through venture capital investment.

Profile:

Sun 2000 Pty. Ltd.
Contact: Phone: Email: Internet: Address: Miss Debbie Monet, National Sales and Marketing Manager +61 3 9550 1598 Fax: +61 3 9545 1033

ACN 41 080 045 316

monet@sun2000.com.au www.sun2000.com.au
490 Wellington Road Mulgrave, VIC, 3170 Australia Sun 2000 Pty. Ltd. established its "Sun 2000" natural product purfication and cosmetic business in 1998. Based on holistic health care principals, Sun 2000 has pioneered a range of herbal skin care and body care products designed to protect and nourish the skin. Sun 2000 has also added a unique product range with the first UV (Encapsulations) products. Sun 2000 recognised the need for a highly active herbal skin care range as a natural alternative to other products. The product range incorporates the latest innovative technology, encapsulation in a beeswax emollient. Encapsulation is a unique process where the chemicals are locked-in to a natural substance to prevent the absorption of impurities and active ingredients into the skin. Active ingredients like octyl methoxycinnamate and zinc oxide are "locked in", blocking the chemicals from the skin interaction, which can adversely affect the condition and function of the skin. The encapsulation process enables the ingredients to be transported in a natural emollient derived from beeswax, thus providing a protective film over the skin that allows certain herbal ingredients to absorb fully into the underlying tissue. Monne International Pty. Ltd. is the parent company of Sun 2000 Pty. Ltd. Both are based in Melbourne, Australia and Sun 2000's product range is 100% Australian developed and manufactured. Sun 2000 distributes nationally throughout department stores, and selected pharmacies, health food stores, beauty salons, hairdressers and sporting outlets, and exports into five countries: Germany, Hong Kong, Iceland, South Africa and the United Kingdom.

Profile:

Swinburne Centre for Biomedical Instrumentation
Contact: Phone: Email: Address: Dr Andrew Wood, Director +61 3 9214 8867 Fax: +61 3 9819 0856

andrewwood@swin.edu.au
Swinburne University School of Biophysical Science and Electrical Engineering Hawthorn, VIC, 3122 Australia Postal Address: PO Box 218 Mail 31 Hawthorn, Victoria, 3122 Australia

Profile:

It provides a focus for research and consulting activities related to medical & physiological instrumentation. The centre draws on the strengths in biophysics, psychophysiology and instrumentation within the School. It acts as an umbrella organisation to coordinate instrumentation aspects of other centres within Swinburne.

Syngene Ltd.
Contact: Phone: Email: Internet: Address: Mr Graeme Kaufman, Managing Director +61 3 9826 0399 Fax: +61 3 9824 0083

ACN 78 006 161 753

graeme.kaufman@circadian.com.au www.circadian.com.au/syngene.htm
Level 1 10 Wallace Avenue Toorak, VIC, 3142 Australia Postal Address: PO Box 23 Toorak, VIC, 3142 Australia

Profile:

Syngene Ltd. holds DNA-based diagnostic patents which underpin a technique to locate gene expression precisely within tissues, already being used in research, with potential for diagnostic applications. Syngene’s patent in the USA expires in 2014. In the research applications of its diagnostic patent, Syngene has granted a non-exclusive worldwide licence to Roche Diagnostics in respect of its diagnostic technology, and additional projects and potential collaborations are being evaluated. Several diagnostic companies are seeking to develop genetically-based diagnostics for application to human disease prognosis as a result of the increasing knowledge of the connections between genes and disease. Syngene has also established a research project to develop new delivery technologies for oligonucleotides. Syngene’s major sharehoders are Circadian Technologies Limited (42%) [see separate entry], Howard Florey Institute of Experimental Physiology (20%), and Casthree Pty Ltd (an entity controlled by Consolidated Press Holdings Limited) which subscribed for a 20% interest in February 2000.

Syngenta Seeds
Contact: Phone: Email: Address: Mr Peter Gerner, Managing Director (03) 9706 3033

steve.lonie@syngenta.com
36 Newson Street Keysborough, VIC, 3173 Australia Postal Address: Locked Bag 1335 Dandenong South, Victoria, 3164 Australia

Profile:

The Gribbles Group Limited
Contact: ASX: Phone: Email: Internet: Address: Mr Wallace Cameron, Group Managing Director GGL +61 3 9538 6777 Fax: +61 3 9538 6765

ACN 66 091 000 225

liaison@gribbles.com.au www.gribbles.com.au
1868 Dandenong Road Clayton, VIC, 3168 Australia Postal Address: Private Bag 4444 Clayton, VIC, 3169 Australia

Profile:

The Gribbles Group is a medical, scientific and technical testing company. It is a leading provider of high-quality diagnostic and analytical information services, in Australia and overseas. Beginning in 1936, with the first private medical laboratory in South Australia, Gribbles has grown to encompass human and veterinary pathology, analytical and environmental testing, radiology, medical and day surgery centres. The group employs over 1500 staff in Australia and over 400 internationally. In Australia, Gribbles operates over 35 laboratories and 175 pathology collection centres providing testing services to over 2.5 million patients and organisations; while the international businesses have grown rapidly since 1996 and now operate in Malaysia, Indonesia, Brunei, New Zealand. Gribbles has recently commenced a joint venture in India. The Malaysian organisation has grown to be the largest private pathology provider in Malaysia, while in India plans are for 27 laboratories and 270 collection centres over the next 3 years. Recent acquisitions in Australia include GM laboratories and AMDEL, which will significantly strengthen Gribbles' position in provision of environmental and analytical testing. The Gribbles Group is committed to growth through excellence and innovation. It is an organisation with an increasingly international focus, while remaining strongly Australian in its core philosophies and business approach.

Thermo Trace Ltd
Contact: Phone: Email: Internet: Address: Mr Tony Bigum, CEO +61 3 9790 4100 Fax: +61 3 9790 4155

ACN 47 002 634 442

trace@thermotrace.com.au www.thermotrace.com.au
189-199 Browns Road Noble Park, VIC, 3174 Australia Postal Address: PO Box 700 Noble Park, VIC, 3174 Australia

Profile:

Thermo Trace Ltd (formerly Trace Scientific) was established in 1983 and consolidated operations in Melbourne in early 1999. Thermo Trace manufactures and markets globally diagnostic reagents for automated instrument platforms; innovative speciality diagnostic tests; and cell and tissue culture products. Thermo Trace also sells a range of associated analytical instruments. Thermo Trace's patented stabilisation technology (Dynamic Stabilisation Technology) has helped the firm capture business with global diagnostic players and has facilitated the uptake of Trace diagnostic reagents throughout the world. Thermo Trace manufactures premium grade cell, tissue and organ media, media components, media supplements and ancillary products. Trace Foetal Bovine Serum and related blood products for cell and tissue culture are made from Australian or New Zealand sourced raw material. Each product is traceable through the collection facility to the farm and herd of origin. The products are manufactured in ISO 9001 accredited facilities to the relevant regulatory guidelines (USFDA, USDA, NRA or TGA). Many of these guidelines have been, or are being, harmonized with Emark guidelines and therefore comply with European requirements. Thermo Trace Ltd is a business unit of Thermo Electron Corporation, based in Massachusetts USA.

Thorgard Pharmaceuticals (Aust.) Pty Ltd
Contact: Phone: Email: Internet: Address: Mr Joseph Vella, Chief Executive Officer and Managing Director +61 3 9670 7966 Fax: +61 3 9670 7933

ACN 23 098 254 516

josephv@thorgard.com.au www.Thorgard.com.au
Level 2, 250 Queens Street Melbourne, VIC, 3000 Australia Thorgard Pharmaceuticals (Aust.) Pty Ltd is an Australian owned pharmaceutical company with overseas alliances that has been performing extensive research and development work in the area of generic conjugated estrogens that are derived from pregnant mares' urine (PMU). These generic conjugated estrogens are used in the women’s health industry (hormone replacement therapy) and in the areas of osteoporosis and ischaemic heart diseases. Thorgard's R & D involves the internationally patented inventions that relate to the collection systems used on the pregnant mares to collect uncontaminated urine. Thorgard has also developed estrogen extraction essays that are used for commercial purposes. Additionally, Thorgard has set up commercial natural estrogen collection farms (NECS) in Australia to collect the pregnant mares' urine which is then sold (in gel or powder form) to other major pharmaceutical companies around the world.

Profile:

Tridan Limited
Contact: Phone: Email: Address: Dr Richard Thwaites, Business Manager, CRC for Biopropducts +61 3 9396 8749 Fax: +61 3 9396 8729

ACN 006 785 217

rthwaites@albright.com.au
295 Whitehall Street Yarraville, VIC, 3013 Australia Postal Address: PO Box 20 Yarraville, VIC, 3013 Australia

Profile:

In 1994, Albright & Wilson (Australia) Ltd, a large chemical manufacturer, formed a partnership with Tridan Limited, a small R&D investment company, to establish a state-of-the-art biotechnology fermentation scale-up facility at Yarraville, and together with the University of Melbourne and Food Science Australia, became major participants in what has now become the CRC for Bioproducts. The three participants have an equal share in the intellectual property. The CRC for Bioproducts has a focus on developing commercially valuable materials produced by plants and other living organisms - such as natural colours, nutraceuticals including the active components in herbal remedies, pharmaceutical intermediates, and biopolymers. It aims to establish new industries based on these novel bioproducts and bioprocesses, and also use the skills developed by the Centre to improve the efficiency and profitability of existing industries involved in the production and use of bioproducts. The research program has three facets: cell culture and fermentation of novel plant cell lines; extraction of novel and useful compounds from agricultural waste, seaweed and other biomass sources; and applied physico-chemical studies of macromolecules in solutions and gels, relevant to products in a range of industries. The resources of the Centre include a pilot scale fermentation facility (up to 10,000 litres) used primarily for production of materials from plant cells, laboratories equipped for functional testing of biopolymers and food ingredients, and state-of-the-art facilities for carbohydrate chemistry and plant molecular biology.

TSL Group Limited
Contact: Phone: Email: Address: Mr Ross Dobinson, Managing Director +61 3 3 9691 5900 Fax: +61 3 9691 5901

info@tslgroup.com.au
Level 34 360 Collins Street Melbourne, Vic, 3000 Australia TSL Group Limited (TSL) is the leading provider of expert commercial advisory services to Australia's life sciences sector. Our primary focus is on optimising the commercial value of intellectual property generated from Australia's strong scientific research base. At the same time we aim to build significant value for investors. We have a well-informed understanding of the research, development and innovation environment. A key strength is our extensive national and international networks within the scientific and commercial arenas developed over 20 years. TSL has a proven track record in identifying promising technologies and structuring these effectively to achieve successful commercial outcomes. We have the expertise to assist companies and research organisations with all stages of their development, from seed to maturity. We also advise investors in the life sciences sector on strategies to reduce risk and maximise returns.

Profile:

UCB Pharma (a division of UCB Australia Pty Ltd)
Contact: Phone: Email: Internet: Address: Mr Grant Fraser +61 3 9303 0600 Fax: +61 3 9303 0689

ACN 48 005 799 208

Grant.Fraser@UCB-Group.com www.ucb-group.com
19 Potter Street Craigieburn, VIC, 3064 Australia Postal Address: PO Box 341 Craigieburn, VIC, 3064 Australia

Profile:

The UCB Group, headquartered in Belgium, is a multinational pharmaceutical and chemical group. Formed under the name of Union Chimique Belge in 1928, the Group has its origins in the 18th century. The business areas of the Group are currently centered around three industrial fields : the Pharma Sector, the Chemical Sector and the Film Sector. Globally, each sector has a decentralised organisation, with profit centres by type of market or activity. UCB is a Group which currently comprises the parent company, UCB SA, together with about one hundred and forty subsidiaries and associated companies, mainly in Western Europe but also in the Americas and Asia, in countries with rapid growth. UCB also covers the world through its agents, distributors and licensees and its products are sold in virtually every country. The Group employs more than 8,000 people, of whom around half are in the Pharma Sector. UCB Pharma is a research and development pharmaceutical company. The Melbourne office of UCB Pharma is responsible for business development and the marketing activities supporting key products in the therapeutic areas of the Central Nervous System, and Allergy. The major products of UCB Pharma are Zyrtec® (cetirizine), Nootropil® (piracetam) and Keppra® (levetiracetam).

Uniseed Pty Limited
Contact: Phone: Email: Internet: Address: Mr Gareth Dando, Chief Executive Officer +61 3 9362 5804 Fax: +61 3 9347 5888

ACN 63 094 466 752

enquiries@uniseed.com www.uniseed.com
215 Grattan Street Parkville, VIC, 3052 Australia Uniseed Pty Limited is a pre-seed and seed stage venture capital fund designed to bridge the gap between the research in Australian universities and the commercial venture capital and investment community. Uniseed has twin headquarters, in Melbourne, Victoria and Brisbane, Queensland. It was established in 2000 as a joint venture between the commercial arms of the University of Queensland and the University of Melbourne, with initial funding of A$20 million. It primarily invests in opportunities connected with these universities and their affiliated institutions. Over half of Uniseed’s investments to date have been in the biotechnology, bioscience and biomedical area. As of November 2002, investments included six Victorian companies profiled in this Directory – Hatchtech Pty Limited, Chirogen Pty Ltd, Cryptopharma Pty Ltd, Pargenex Pharmaceuticals Pty Ltd, Calibre Biotechnology Pty Limited and Hepitope Pty Ltd – as well as 10 interstate companies.

Profile:

Valley Seeds Proprietary Limited
Contact: Phone: Email: Internet: Address: Mr Donald Coles, Managing Director +61 3 5797 6203 Fax: +61 3 5797 6307

ACN 68 004 950 396

dcoles@valleyseeds.com www.valleyseeds.com
295 Maroondah Link Highway Alexandra, VIC, 3714 Australia Alexandra-based company Valley Seeds Proprietary Limited specializes in breeding grasses that have drought tolerance, winter growth and other desirable traits, for forage, pasture, turf and lawn use. The company supplies the Australian market, in part through its strategic alliance with Yates Limited, and exports widely, including to major South American markets through Uruguay-based partner Fadisol SA. (Valley Seeds has formed a spin-off, Access Genetics - see separate entry). Since 1993, Valley Seeds has been working with researchers from the University of Melbourne in an innovative genetics project to eliminate the misery caused by grass pollen. Asthma and allergies are frequently triggered by plant pollen, particularly grass pollen. The Melbourne team, led by Dr. Prem Lata Bhalla and Professor Mohan Bir Singh, isolated the genes in grass pollen that cause asthma and hay fever, and worked out how to switch off the allergy-causing genes in ryegrass and other grasses. Valley Seeds will be incorporating the allergy-free characteristic into new varieties of grasses whose pollen does not cause asthma and hay fever. The company expects that the major benefit from the introduction of these genetically modified varieties will be to the end-consumer and the general public. ACN 67 004 559 540 Varian Australia Pty Ltd

Profile:

Contact: Phone: Email: Internet: Address:

Mr Philip Binns, Marketing Manager +61 3 9566 1101 Fax: +61 3 9566 1196

philip.binns@varianinc.com www.varianinc.com
679 Springvale Road Mulgrave, VIC, 3170 Australia Varian Australia Pty Ltd is the Australian research, manufacturing and marketing arm of US-based Varian, Inc., a major supplier of scientific instruments, vacuum technologies, and contract manufacturing. Varian Australia's 4-hectare manufacturing plant at Mulgrave employs around 400 people, and exports over A$100 million in scientific instruments to over 60 countries worldwide. The main instruments manufactured in Victoria are targeted towards applications in biotechnology, health, pharmaceutical, environmental and material science industries. Specifically, these instruments include UV-Vis spectrophotometers for molecular studies, and atomic absorption, inductively coupled plasma and mass spectrometry for the study of elemental species in most substances. Varian, Inc. (Nasdaq: VARI) is a world leader in providing key tools and technologies that enable advances in the life sciences and health care, semiconductor processing, and telecommunications industries. Varian serves life science, health care, chemical, environmental, and industrial customers, totalling more than 20,000 customers annually, and global sales in 2000 were US$749 million, 12% accounted for by the Asia-Pacific region. The company manufactures in 13 locations on three continents; operates sales and service offices in North America, Europe, and the Pacific Rim; and employs some 4,100 people. It is organized into three segments: Scientific Instruments, Vacuum Technologies, and Electronics Manufacturing. Although Varian, Inc. was formed in 1999, it has a rich technological heritage dating back more than 50 years, and was spun off from Varian Associates, Inc., a pioneering Silicon Valley company. Among many other innovations, Varian was the first to commercialize the NMR spectrometer. The VacIon pump, invented by Varian for producing ultra-high vacuum environments, paved the way for many important endeavours, including semiconductor manufacturing and space science research.

Profile:

Victoria Institute of Biotechnology
Contact: Phone: Email: Internet: Address: Prof Mark Hogarth, Chief Executive Officer +61 3 9287 0666 Fax: +61 3 9287 0601

pm.hogarth@ari.unimelb.edu.au www.ari.unimelb.edu.au/vib
Victoria University Hoppers Lane Werribee, VIC, 3030 Australia The VIB will be established as a world-class R&D and business for discovery, structure based rational design and development of novel therapeutics and drugs. A facility for work at each step of the drug development pathway; the development of an integrated facility for structure-based design of new therapies and drugs. This will help create the depth, critical mass and coordination of Victorian capability so essential to value adding to Australian discoveries and their accelerated entry into international clinical trails. It will use leading edge technologies to develop therapeutics for the treatment of both human and animal diseases. It will enable researchers from academe and small and large companies to use information from their own sources or from the various Genome Projects (Human, Animal and Parasite) to generate new therapeutic candidates. VIB’s intention is to become a key research participant locally and an essential asset holder by occupying a vital technical and expertise niche in Victoria’s overall bioscience infrastructure. It will be part of wider consortia nationally and internationally, dedicated to developing human skills and in efficient use of resources in advancing these technologies and in developing new therapies. The VIB will thus provide expertise to, and draw expertise from, wider State-based consortia of R&D enterprises and so directly addresses both perceived gaps i.e. integrated therapy/drug discovery and design and (ii) development of all pre-clinical expertise, thereby strongly leveraging off Victoria’s unique and long-standing basic biomedical R&D excellence.

Profile:

Victoria University of Technology
Contact: Phone: Email: Internet: Address: Dr Paul Chambers, Senior Lecturer, School of Life Sciences +61 3 9216 8271 Fax: +61 3 9216 8284

paul.chambers@vu.edu.au www.vu.edu.au
School of Life Sciences Werribee Campus Victoria University of Technology Werribee, VIC, 3030 Australia Postal Address: School of Life Sciences Werribee Campus Victoria University of Technology PO Box 14428 Melbourne, Victoria, 8001 Australia

Profile:

Biotechnology activities at Victoria University of Technology are conducted primarily by the School of Life Sciences and Technology in the Faculty of engineering and Science. The School is involved in biotechnology education, training and research programs offering BSc degrees in biotechnology, and Nutrition and Food Science. We also offer Honours, Masters and Doctorate degrees by research. Biotechnology research activities are coordinated primarily through the School of Life Sciences. Biotechnology research is conducted in gene discovery, microbial and enzyme technologies, forensic molecular biology, bioremediation, cancer genetics, yeast biotechnology, food science and technology and animal technologies relating to fertility and productivity. ACN 36 004 188 863 Victorian Chemical Company Proprietary Limited

Contact: Phone: Email: Internet: Address:

Dr Bob Killick, Managing Director +61 3 9429 8277 Fax: +61 3 9429 6404

bobkillick@vicchem.com www.vicchem.com
37 Appleton Street Richmond, VIC, 3121 Australia Postal Address: PO Box 71 Richmond, VIC, 3121 Australia

Profile:

The Victorian Chemical Company is a manufacturer and marketer of specialty agricultural and industrial oleo-chemicals. Established in 1933 near the centre of Melbourne, Australia, the company has built a world-wide reputation for the design and production of customised products. In the early years, Victorian Chemicals concentrated on serving the textile and tanning industries that were booming in the inner city. The company's first agricultural product ( Voullaire's™ EE-MULS-OYLE™ ) was developed during the late 1930s in conjunction with local grape growers and the CSIRO to dry grapes to sultanas. Voullaire's is now the leading product for drying grapes in Australia and is used in several other countries under the Victoria™ brand. In 1983, the company was purchased by the Killick family, and shortly after several other agricultural products were developed including bloat control products for cattle and insecticidal spray oils for horticulture. During the 1990s, development work focused on adjuvants for broadacre applications. HASTEN is the key product to be commercialised from this work that is now distributed in many countries. HASTEN is based on ethyl oleate and improves the effectiveness of herbicides. Other products include sulfonated esters and oils, fatty esters and emulsifying esters, speciality wetting agents, fatty alkanolamides, textile lubricants, degreasers, chemical intermediates, and speciality blends. Victorian Chemicals manufactures their range of oleo-chemicals according to the international quality standard ISO 9002. Victorian Chemicals remains committed to the development of new innovative products, and is exploring the development of technology in areas such as plant growth hormonal regulation.

Victorian Infectious Diseases Reference Laboratory
Contact: Phone: Email: Internet: Address: Dr Michael Catton, Medical Director +61 3 9342 2600 Fax: +61 3 9342 2660

ACN 73 802 706 972

vidrl@mh.org.au www.vidrl.org.au
10 Wreckyn Street North Melbourne, VIC, 3051 Australia Postal Address: Locked Bag 815 Carlton South, VIC, 3053 Australia

Profile:

The Victorian Infectious Diseases Reference Laboratory (VIDRL) is Victoria’s largest public health reference laboratory, with core expertise in virology and mycobacteriology. Key activities are: (i) Providing laboratory capacity for infectious diseases outbreak investigations by the Department of Human Services, Victoria. (ii) Undertaking reference laboratory testing, disease surveillance, applied research and test development, maintaining reference collections and providing expert advice in major program areas. The major program areas are: - Victorian HIV Reference Laboratory (State Reference Laboratory) - Mycobacterium Reference Laboratory - Vaccine Preventable and Related Diseases - Viral Gastroenteritis - Respiratory Pathogens - Blood-Borne Viruses and Sexually Transmitted Infections (iii) Providing diagnostic pathology services for the Melbourne Sexual Health Centre. VIDRL holds three Australian national designations, namely the National Poliovirus Reference Laboratory, the National Measles Reference Laboratory, and the National High Security Quarantine Laboratory (NHSQL). VIDRL holds World Health Organisation (WHO) Collaborating Centre designations in Virus Reference and Research and in Biosafety in Microbiology. VIDRL is a WHO Regional Poliovirus Reference Laboratory and the WHO Regional Measles Reference Laboratory for the Western Pacific Region. VIDRL is also a WHO National Influenza Centre. VIDRL undertakes a diverse range of research projects. These include studies on the mechanism of antiviral drug resistance, transmission of hepatitis B and C viruses, the role of enteric pathogens in disease outbreaks and molecular aspects of Mycobacterium tuberculosis. Investigations of the epidemiology of infectious agents of public health significance, and the development of potential new laboratory technology are also important areas of study. Research is undertaken in all program areas, but blood borne viruses are of particular interest.

Victorian Institute for Dryland Agriculture
Contact: Phone: Email: Internet: Address: Dr Chris Korte, Acting Institute Director VIDA +61 3 5362 2111 Fax: +61 3 5362 2187

chris.korte@nre.vic.gov.au www.nre.vic.gov.au/vida
Natimuk Road Horsham, VIC, 3400 Australia Postal Address: Private Bag 260 Natimuk Road Horsham, Victoria, 3401 Australia

Profile:

The core activity of VIDA is breeding of broad acre cereal (wheat, barley), pulse (field peas, chickpeas and lentils) and oilseed (Brassica napus and Brassica juncea) crops. The ‘traditional’ breeding programs are now supported by biotechnologies to increase the rate of genetic gain in yield, agronomic properties and end-use characteristics, and enhance the competitiveness of Victoria’s crop improvement program. The Institute has a molecular marker laboratory which leads Australia in the implementation of markers in wheat, barley and pulse breeding; houses the Australian Temperate Field Crops Collection (ATFCC), the Australian genetic resource centre for pulses and oilseeds; routinely uses doubled haploids for cereal and oilseed improvement; has unique facilities (glasshouses, field nurseries to enable growth of two generations of crops per year) to fast-track the release of new varieties to meet the needs of industry; and has a grain quality research program which leads Australia in the use of NIR technology to predict grain quality for all crops. VIDA’s Mallee Research Station, located in the central Victorian Mallee, is a second campus of the Institute. The Station is well equipped to evaluate crops for adaptation to low rainfall environments, in conjunction with national and international research programs. Developing crops with genetic attributes to perform in cropping systems of the marginal environments in Southern Australia is an essential role of the Institute.

Victorian Institute of Animal Science
Contact: Phone: Email: Internet: Address: Dr Chris Langford, Director +61 3 9217 4200 Fax: +61 3 9217 4299

Chris.Langford@nre.vic.gov.au www.nre.vic.gov.au/agvic/vias
475 Mickleham Rd Attwood, VIC, 3049 Australia The Victorian Institute of Animal Science (VIAS) is the leading animal research institute of the Department of Natural Resources and Environment's Agriculture Victoria. VIAS is located across three campuses: Attwood, Werribee and Frankston. The staff of the Victorian Institute of Animal Science are committed to the delivery of quality animal science services and innovative products and solutions to our customers, in support of industry competitiveness, product safety and the environment The Victorian Institute of Animal Science has research activities that cover animal production, animal health and biological science. With an international reputation it has always been at the forefront of technological innovation. VIAS is building on its core capabilities in areas such as molecular biology, DNA analysis, genomics, transgenics and many other strategic areas. This enhanced capacity builds on existing strengths in diagnostic technologies, quantitative genetics and animal physiology. VIAS plays a key role in the education of the science leaders of the future through its post graduate research programs, there being about 40 students at any one time. VIAS also boasts a modern conference facility comprising a 150 seat theatre and meeting rooms only a few minutes drive from Melbourne's Tullamarine airport.

Profile:

Viralstar Ltd
Contact: Phone: Address: Dr John Raff, CEO (03) 8532 2700 Fax: (03) 9510 5955 Level 1 Old Baker Building Prahan, VIC, 3181 Australia

ACN 083 205 421

Profile:

Viralstar Limited has agreed to provide research funding for further development of the Technology in the field of antiviral therapeutics. Viralstar may become involved in the commercialisation process of this area of the Technology.

Virax Holdings Limited
Contact: ASX: Phone: Email: Internet: Address: Mr David Beames, Chief Executive Officer VHL +61 3 9854 6230 Fax: +61 3 9853 5134

ACN 56 006 569 106

virax@virax.com.au www.virax.com.au/html/home.html
Suite 220, Kew Junction Tower 89 High Street Kew, VIC, 3101 Australia Virax Holdings Limited is a publicly listed (ASX:VHL) early stage biopharmaceutical company focusing on the development of immunotherapeutics for the treatment of autoimmune disorders, HIV/AIDS, cancers and infectious diseases. Virax has established a specialised Good Manufacturing Practice (GMP) manufacturing facility for vaccines and delivery vectors. Virax is developing vaccines using their platform technology, Co-X-Gene™, which derives from innovative work at the John Curtin School of Medical Research and CSIRO Livestock Industries in Geelong. The initial target for these vaccines is to treat people already infected with HIV with candidate vaccine VIR201, the Phase I/IIa trial having commenced. Virax has received an AusIndustry R&D Start Grant in respect of this trial. A program to develop a prostate cancer immunotherapeutic has commenced in collaboration with Royal Adelaide Hospital. Future applications of Co-X-Gene™ include therapeutic or preventative vaccines against other cancer targets, infectious and autoimmune diseases. Virax is also a key member of an Australian consortium that will receive A$27m from the US National Institutes of Health (NIH) to accelerate development of vaccines to prevent infection by HIV/AIDS. Other Victoria-based members are the University of Melbourne and CSIRO Livestock Industries, with the project being managed by the Institute of Drug Technology Australia Limited [see separate entry]. The team will fast track the development and testing of a ‘prime and boost’ vaccine, designed to stimulate the body to make special white blood cells to find and destroy any newly HIV-infected cells. The prime vaccine will be DNA based, while the boost vaccine will be based on fowlpox virus utilising Virax technology.

Profile:

Viridans Pty. Ltd.
Contact: Phone: Email: Internet: Address: Ms Wendy Opie, Executive Director +61 3 9596 8592 Fax: +61 3 9596 8612

ACN 054 535 929

viridans@bigpond.com www.viridans.com.au
Suite 4 614 Hawthorn Road Brighton East, VIC, 3187 Australia Viridans Pty Ltd is a privately owned company which specialises in biocomputing - software platforms concerning ecological and biological databases. The databases are created for use by local government, universities and ecological consultants, and provide information such as a guide to various flora and fauna, where certain species can be found, and whether they are endangered or not. Specific databases have been created for use in government departments such as the Department of Natural Resources and Environment in Victoria, and the Department for Environment and Heritage in South Australia. Viridans professional Flora and Fauna Database software is used in Australia on some of the country's largest biological databases, such as the Victorian Flora Information System, which contains approximately 1.5 million plant records; the Victorian Fauna Display System which contains more than 2.1 million records of zoological data; and the South Australian Flora and Fauna Database (SAFFD), which contains over 550,000 records of botanical and zoological data. In addition, Viridans software is used to maintain smaller databases such as the Victorian Butterfly Information System (VBIS), the Mallee Parks Grazing Monitoring System (MPGMS), the Ballarat Regional Flora Information System (BALFIS), and the Mallee Mandatory Monitoring database. The Viridans public access CD-Rom products are subsets of larger, more complex professional biological databases. These systems are designed specifically for the storage, retrieval, analysis and display of taxonomic and geographic flora and fauna data.

Profile:

Vision BioSystems Limited
Contact: Phone: Email: Internet: Address: Dr Owen Wright, Sales Director +61 3 9211 7400 Fax: +61 3 9265 8401

ACN 72 008 582 401

owen.wright@vision-bio.com www.vision-bio.com
495 Blackburn Road Mount Waverley, VIC, 3149 Australia Postal Address: Private Bag 18 Mount Waverley, VIC, 3149 Australia

Profile:

Vision BioSystems, a wholly owned subsidiary of the publicly owned company Vision Systems Limited [see separate entry], is a global supplier of a range of automated biomedical instruments known for their quality and innovation excellence. Vision BioSystems has been manufacturing innovative, quality proven laboratory instruments for in excess of 16 years. Its products cover a range of segments including histopathology, haemotology, clinical diagnosis and electron microscopy. For histopathology, the tissue preparation products manufactured by Vision BioSystems are world leaders. For haemotology, automated blood smear preparation and staining delivers key sample preparation steps. Toward a better understanding of the link between genes and diseases, a number of instrument systems are in development. Vision Systems acquired the monoclonal antibody company Novocastra Laboratories Ltd (UK) in mid 2002 and sells these products through Vision BioSystems.

Vision Systems Limited
Contact: ASX: Phone: Email: Internet: Address: Dr Owen Wright, Sales Director VSL +61 3 9211 7000 Fax: +61 3 9211 7001

ACN 45 008 582 401

duncan.jones@vision-bio.com www.vsl.com.au
495 Blackburn Road Mount Waverley, VIC, 3149 Australia Vision Systems Ltd is a technology based manufacturing and services company which markets high value products, contract engineering and technology based services worldwide. Vision Systems Ltd is listed on the Australian Stock Exchange and employs over 600 people at Feb 2002. The company has grown tenfold over the last five years and continues to achieve annual growth rates in excess of 25%. The Vision Systems Group manufactures a range of high value products, including video-based surveillance and security systems under the ADPRO® brand, fire protection systems based around aspirated smoke detection (which achieves high sensitivity and very early fire detection) sold under the VESDA® brand, and automated laboratory instruments for the histopathology, haematology and clinical chemistry markets through their subsidiary company, Vision BioSystems (formerly Vision Instruments) [see separate entry]. The objective of the company is to continue to grow international sales in key markets with innovative products and services driven by ongoing investment in the company's technology base. In 2002-03, Vision Systems will be releasing two second generation biomedical instruments - an immunohistochemistry stainer, and an in-situ hybridisation stainer. Other projects are in development. ACN 35 003 190 421 Vita Life Sciences Limited

Profile:

Contact: ASX: Phone: Email: Internet: Address:

Mr Mark Greenwood, Managing Director VLS +61 3 9867 2713 Fax: +61 3 9867 5437

enquiries@vitalifesciences.com.au www.vitalifesciences.com
Level 5 432 St Kilda Road Melbourne, VIC, 3004 Australia Vita Life Sciences, listed on the Australian Stock Exchange (ASX), is a pharmaceutical and healthcare company focusing on two market segments: 1. Vita Medical - research and development, innovation, and distribution of proprietary medical and healthcare equipment in nuclear medicine, specialising in the areas of lung diagnostics and cardiac stress testing; and 2. Vita Health - development, manufacture and distribution of prescription and over-the-counter medicines, as well as complementary and alternative medicines, dietary supplements and health foods. The company has also recently formed ViMed Bio Sciences Pty Ltd to develop novel imaging technologies. Vita Medical’s main product, Technegas, has a market share of 78% and 30% respectively in its key markets of Australasia and Europe. Technegas is used for diagnosis of various lung diseases. Vita Medical commenced operations in 1976 to develop and manufacture medical and health care equipment for nuclear medicine. Vita Medical’s manufacturing plant for Technegas equipment is adjacent to Australia’s major nuclear research establishment near Sydney. Expanded applications of the technetium-based biomedical technology include an encapsulation technology to deliver an ultrafine radio-pharmaceutical for medical applications. Potential applications extend to other isotopes for diagnostic/therapeutic products. Further projects include PVDS for delivery of Technegas for patients with breathing difficulties; and ThromboTrace for diagnosis of Deep Vein Thrombosis. Vita Health, with origins in Singapore in 1947, has more than 545 registered products, many developed and formulated at its Sydney laboratory, and exports to over 30 countries.

Profile:

Vital Life Sciences
Contact: Phone: Email: Internet: Address: Dr Andrew Vizard, Chairman +61 3 9605 5900 Fax: +61 3 9605 5999

ACN 86 085 968 341

info@vitalcapital.com www.vitalcapital.com/key_invesments/tocovite/index.htm
C/- Mr S Friedmann, Vital Capital Limited, Level 2 90 William St Melbourne, VIC, 3000 Australia Tocovite is developing products for the dietary and health care markets. Among these is a process to produce water-soluble forms of fat-soluble nutrients - initially vitamin E, and potentially other natural and synthetic compounds. The objective is increasing the compatibility of vitamin E and other nutrients, such as coenzyme Q10 and vitamin K1, as additives to everyday food, drinks, and water-based cosmetics. Water-soluble nutrients are more easily absorbed and used by the human body. Tocovite plans to market and distribute water-soluble vitamin E as a natural cosmetic emulsifier. Tocovite is also developing a method of extracting tocotrienols from palm oil distillate. These vitamin E precursors are themselves a valuable source of antioxidants, and can delay the onset of certain chronic and degenerative diseases. Tocotrienols have not previously been commercially extractable in sufficient quantities, and Tocovite's process should provide cost-effective supplies for the first time. Other projects being researched include methods of extracting natural vitamin E from palm oil. This promises to yield a 'natural' and premium product at a low cost. Tocovite’s technology is also applicable to a large number of pharmaceutical drugs, and fourteen patents have been lodged. The company has identified eight classes of drugs for its first round of research into changing the properties of selected compounds, with the view to improving their transdermal, intravenous and oral delivery, as well as their systemic transport and bioavailability. Tocovite is in the process of splitting into two companies to better commercialise its technology. Vital Capital will retain its equity in each company. Australian-based Vital Health Sciences will develop applications for personal care, human nutrition and animal nutrition. US-based Vital Biosciences will focus on the development and commercialisation of pharmaceutical applications.

Profile:

Vitapharm Research Pty. Ltd.
Contact: Phone: Email: Internet: Address: Mr Peter Wilson, Business Development Manager International +61 3 9764 1555 Fax: +61 3 9764 1554

ACN 48 082 174 918

bizdev@vitapharm.com.au www.vitalbiotech.com
20 Kingsley Close Rowville, VIC, 3178 Australia Vitapharm Research is a member of the Vital Biotech Group which has a proven profitable track record in developing, manufacturing and distributing pharmaceutical products. Vitapharm is responsible for the new down-stream, value-adding technology development and early stage concepts of biological formulations that offer patient friendly delivery of effective, yet affordable, products. Commercialisation occurs through Vital Biotech with its extensive marketing network, regulatory approval expertise and manufacturing and distributing capability in China (PRC). In a strategy to be close to this commercial activity, the organisation was the first Australian biotechnology company to list successfully on the Hong Kong Stock Exchange. The PSD platform technology developed by Vitapharm replaces freeze drying of biologicals to yield room temperature stabilised products for non-injection delivery. It can be applied to proteins, enzymes, vaccines, probiotics and potentially, many other biopharmaceutical products. Vitapharm has established a unique business model in the pharmaceutical/ biotechnology industry where Australian technology is combined with the Chinese market to efficiently create and commercialise biopharmaceuticals with low risk, low cost and immediate returns. Pharmaceutical and biotechnology companies can partner with Vitapharm Research to incorporate their new and existing biologicals into the PSD platform technology and gain quick and easy access to the fast and growing Chinese market. Using this approach, Vitapharm Research grows with its international partners achieving technological and commercialisation advantages with: - low production cost through freeze-drying replacement - commercially viable and patient friendly delivery systems - non-refrigerated stable biological products - extended patent protection - expanded product clinical indications - differentiation from competitor/generic products - access to the PRC market

Profile:

Walter and Eliza Hall Institute of Medical Research
Contact: Phone: Email: Internet: Address: Mr Brad Allan, Community Relations Manager +61 3 9345 2345 Fax: +61 3 9345 2329

allan@wehi.edu.au www.wehi.edu.au
1G Royal Parade Parkville, VIC, 3050 Australia The Walter and Eliza Hall Institute is Melbourne's - and Australia's - oldest and most respected medical research institute. It resides at the hub of one of the world's great biomedical research precincts, the 'Parkville strip', just north of the city's centre. A great tradition of excellence, honed over an eighty year history, has secured for the Hall Institute an outstanding international reputation. Indeed, it is one of an elite group of medical research centres acknowledged around the world as the powerhouses of 20th century medical research. Key discoveries emerging from the Institute include colony-stimulating factors, SOCS proteins and novel genes regulating apoptosis. Founded in 1915, using funds from a trust established by Walter Hall, grazier and miner and his wife Eliza, the Institute is now an innovative organisation of over 500 people, housed in an ultramodern building, with close links to the neighbouring Royal Melbourne Hospital and University of Melbourne. The Hall Institute attracts some of the best and brightest young biomedical researchers from around Australia and overseas. Institute staff are at the cutting edge of their research fields, many in constant demand as invited speakers at international research conferences. Its graduates are held in high regard at home and abroad; many go on to postdoctoral studies in leading overseas centres such as the Whitehead Institute; Harvard Medical School; the University of California at Berkeley; the Medical Research Institute at Mill Hill; Imperial Cancer Research Fund; and the European Molecular Biology Laboratory. Institute researchers seek to understand the basic mechanisms of disease, motivated by the knowledge that exposing the underlying genetic and molecular processes will lead to the new therapies, drugs and vaccines needed for longer, healthier lives. The principal focus of the Institute remains the blood cell system and its diseases, but there are growing programs in development and neurobiology, genetic susceptibility to disease; and bioinformatics. The Institute's pioneering exploration of the immune system continues apace, alongside vigorous investigations of auto-immune disorders, particularly insulin-dependent diabetes and arthritis. Exciting discoveries being made about two major parasitic diseases, malaria and leishmaniasis, are aiding the search for protective vaccines and new drugs. The identification of mutations that cause cancer remains a key objective, with a particular emphasis on those responsible for chromosome translocation in leukemia and lymphoma, those that lead to breast cancer and those that perturb cell survival and cell cycling. Aided by the node of Australian Genome Research Facility recently established within the Hall Institute, great progress is being made in looking for genes that make people susceptible to diabetes, the eye disease glaucoma and the brittle-bone disorder osteoporosis. Cancer - and malaria - susceptibility genes are also being sought. The research laboratories are organised as eight divisions/groups: Cancer and Haematology; Molecular Genetics of Cancer; Immunology; Autoimmunity and Transplantation; Infection and Immunity; Development and Neurobiology; Genetics and Bioinformatics; and Structural Biology.

Profile:

Whatman Asia Pacific
Contact: Phone: Email: Internet: Address: Mr John Sestanovich, Area Sales Manager 03 9787 7830 Fax: 03 9787 7092

john.sestanovich@whatman.com www.whatman.com
PO Box 1245 Mornington, Vic, 3931 Australia Postal Address: PO Box 1245 Mornington, Vic, 3931 Australia

Profile:

Whatman Asia pacific is a global company with operations in Europe , North America and Asia, and sales in more than 140 countries world wide. We specialise in separations technology to provide the latest in laboratory filtration and processing, microplates for high throughput screening applications, media for the manufacture of medical and diagnostic devices, as well as range of products employing our patented FTA technology for the collection, transport, purification and archiving of DNA from a wide variety of biological sources, all at room temperature. Whatman continues to innovate to the meet the needs of life science.

Wilkore Pty. Ltd.
Contact: Phone: Email: Internet: Address: Mr Michael Wilkinson, Managing Director +61 3 9764 2033 Fax: +61 3 9763 9867

ACN 13 668 230 908

michaelwilkinson@wilkore.com.au www.caribbeanpark.com
1 Dalmore Drive Caribbean Park Scoresby, VIC, 3179 Australia Wilkore is a design and construction company based in Melbourne, Australia, specialising in the pharmaceutical and bioscience industries. Wilkore's expertise is in the provision of a broad range of design, management and construction skills to facilitate the construction of new buildings and the refurbishment of existing ones. Over the past 15 years, Wilkore has established a reputation for building large, high-quality industrial, commercial and pharmaceutical projects. Wilkore's direct fields of expertise include design and construction, project planning, quality assurance, commissioning and validation, cost management, and contract management for pharmaceutical and biotechnology projects. Among Wilkore’s recent projects was the design and construction of major new manufacturing facilities and a new head office/warehouse complex for the Institute of Drug Technology Australia Limited [see separate Directory entry]. Some of Wilkore’s other clients include Sigma, Amrad, Becton Dickinson and Arrow Phamaceuticals. Wilkore is also an integral partner in the business and technology precinct at the 490-acre Caribbean Park, situated at the demographic centre of Melbourne. At the core of Caribbean Park is the proposed MiniFAB project which brings together biotechnology, nanotechnology and microtechnology in an open-access incubator and prototyping facility.

Profile:

Xeno Trans Limited
Contact: Phone: Email: Internet: Address: Prof Ian McKenzie, Chief Executive Officer +61 3 9287 0681 Fax: +61 3 9287 0601

ACN 74 097 283 166

i.mckenzie@ari.unimelb.edu.au www.ari.unimelb.edu.au
359 Brunswick Road Brunswick, VIC, 3056 Australia Xeno Trans Limited, formed in mid-2001 as a spin-off of the Austin Research Institute, is creating transgenic pigs whose kidneys will not be rejected by a transplant recipient. The Austin research group that developed the technology successfully implanted a kidney into a baboon in South Africa during 2001, with rejection held off for 30 days. The company is, at mid-2002, seeking $2 million a year for three years to develop a second batch of transgenic pigs suitable for transplant into baboons. The use of animal organs (such as pig) for human organ transplantation is known as xenotransplantation. The demand for such organs is caused by a chronic shortage of organ donors. In the USA alone, around 40,000 patients per year fail to receive transplanted organs. Xeno Trans has an especially interesting target - the particular sugar on the surfaces of pig organ cells which stimulates the immune system of the human to generate a massive response leading to organ rejection. The Austin Research Institute characterised and patented the crucial gene responsible for the sugar to blame. This gene codes for a enzyme (a specific galactosyl transferase) which catalyses the key step in assembling the sugar. Knocking out the gene so it cannot function is one strategy being used to breed pigs which make organs suitable for transplantation into a human. The organs, not displaying the offending sugar, are more likely to survive rejection.

Profile:

XRT Limited
Contact: Phone: Email: Internet: Address: Mr Grant Dow, Managing Director +61 3 8545 2000 Fax: +61 3 8545 2050

ACN 25 076 348 000

info@xrt.com.au www.xrt.com.au
86 Peters Avenue Melbourne, VIC, 3170 Australia XRT Limited (XRT) is a leader in the field of x-ray phase contrast imaging. The images have visual and data content superior to those produced using existing technology, and the technology delivers contrast and resolution not previously available from commercial x-ray instruments. Formed in 1996 to capture the commercial potential of patented discoveries made by researchers at the CSIRO, XRT acquired the technology and is now commercialising on the basis of its strong intellectual property position. Prior to the CSIRO's scientific work, the basic principles underlying conventional x-ray technology had not changed significantly since their inception 105 years ago. The standard x-ray radiograph in use today only records the fraction of x-rays which pass through an object. Phase contrast imaging differs in that it not only measures the absorption but also the interference caused by refraction of the x-ray wave after passing through an object. The applications of the technology are very diverse. Structures not discernable with the older technology may be seen in exceptional detail. It also offers new approaches for the development of computer chip products, quality control in manufacturing, inspection of aircraft components, and in the study of biology, pathology, minerals and other complex structures. A key investor is BioTech Capital Limited, which for a A$4-million investment, holds 20% of the company at the start of June 2001.

Profile:

Yakult Australia Pty. Ltd.
Contact: Phone: Email: Internet: Address: Mr Greg Jerram, Manager of Personnel and Public Relations +61 3 9793 2045 Fax: +61 3 9793 2468

ACN 97 055 486 443

info@yakult.com.au www.yakult.com.au
10 Monterey Road Dandenong, VIC, 3175 Australia Yakult, the fermented milk drink, has been manufactured in Australia since 1994. However, it has a long and interesting history overseas that spans over 60 years. Yakult has been available in Japan since it was developed by Dr Minora Shirota, a medical practitioner in Japan in 1935. Dr Shirota founded the Yakult Honsha Company in Japan in 1955. Since then, the number and type of products manufactured by Yakult has increased. Yakult is now available in a total of 24 countries world-wide. The emphasis for the distribution of the product remains based upon the company’s philosophy of assisting all peoples of the world to better health through the promotion of sound health practices, and effective use of probiotics. Yakult Australia Pty. Ltd. is a wholly-owned subsidiary of an international company, Yakult Honsha, and was incorporated in 1992. The Yakult factory, which is located in Dandenong, Victoria, was built in 1993. Production and marketing commenced in January 1994 and Yakult was officially launched in Melbourne on 1 February 1994. Yakult is produced in a technologically advanced manufacturing plant with an on-site biotechnology laboratory and modern office complex. The multi-million dollar plant will be the only plant in Australia, and has the capacity to supply all of the Australian market. Yakult has sales branch offices in all major states of Australia.

Profile:

Sign up to vote on this title
UsefulNot useful